



Management of type 2 diabetes, 2026. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

Melanie J. Davies^{1,2} · Vanita R. Aroda³ · Mandeep Bajaj⁴ · Nuha A. ElSayed^{5,6} · Francesco Giorgino⁷ · Jennifer Green⁸ · Rita R. Kalyani^{9,10} · Nisa M. Maruthur^{11,12} · Chantal Mathieu¹³ · Sylvia E. Rosas¹⁴ · Peter Rossing^{15,16} · Tommy Slater^{1,2} · Tsvetalina Tankova¹⁷ · Pinar Topsever¹⁸ · Apostolos Tsapas^{19,20} · John B. Buse²¹

Received: 3 June 2026 / Accepted: 30 July 2026

© American Diabetes Association and the European Association for the Study of Diabetes 2026

Abstract

The American Diabetes Association and the European Association for the Study of Diabetes convened a panel to update the consensus statement on the management of type 2 diabetes in non-pregnant adults, published since 2006 and last updated in 2022. The target audience is the multidisciplinary healthcare team providing diabetes care in the USA and Europe. A systematic examination of publications since 2022 informed new recommendations. This update has broadened the focus from the management of hyperglycaemia to the holistic management of type 2 diabetes and its risk of associated multiple long-term conditions. Fundamental aspects of diabetes care include promoting healthy lifestyle behaviours (healthy eating, 24 h physical behaviours including sleep, and avoiding tobacco and substance use), alongside the provision of psychological support and weight management interventions. For the management of people living with type 2 diabetes, earlier use, potentially from diagnosis, of sodium–glucose cotransporter 2 (SGLT2) inhibitors or/and glucagon-like peptide-1 (GLP-1)-based therapies to offer organ protection and improve long-term outcomes in type 2 diabetes is advocated. Furthermore, earlier combination use of SGLT2 inhibitors and GLP-1-based therapies should be considered in people with concomitant CVD, chronic kidney disease and heart failure. Finally, the ability to transform outcomes for people living with type 2 diabetes is within our grasp through the consistent, equitable and systematic implementation of strategies and therapies that are already available.

Keywords Cardiovascular disease · Chronic kidney disease · Consensus report · Glucose-lowering therapy · Holistic care · Lifestyle behaviours · Person-centred care · Social determinants of health · Type 2 diabetes mellitus · Weight management

Abbreviations

AHI Apnoea–hypopnoea index
AID Automated insulin delivery
AKI Acute kidney injury
ASCVD Atherosclerotic CVD

CGM Continuous glucose monitor
CKD Chronic kidney disease
CPAP Continuous positive airway pressure
CVOT Cardiovascular outcome trial
DKA Diabetic ketoacidosis
DPP-4 Dipeptidyl peptidase-4
DSMES Diabetes self-management education and support
ETD Estimated between-group difference
GIP Glucose-dependent insulintropic polypeptide
GLP-1 Glucagon-like peptide-1
GLP-1 RA GLP-1 receptor agonist
HFpEF Heart failure with preserved ejection fraction
HFrEF Heart failure with reduced ejection fraction
HHF Hospitalisation for heart failure
MACE Major adverse cardiovascular events

This article is being simultaneously published in *Diabetologia* (<https://doi.org/10.1007/s00125-026-06855-7>) and *Diabetes Care* (<https://doi.org/10.2337/dci26-0141>) by the European Association for the Study of Diabetes (EASD) and the American Diabetes Association (ADA).

This article underwent external peer review. Following this, the report was assessed for EASD by its Committee on Clinical Affairs and approved by its Executive Board, and for ADA by its Professional Practice Committee.

Extended author information available on the last page of the article

MALE	Major adverse limb events
MASH	Metabolic dysfunction-associated steatohepatitis
MASLD	Metabolic dysfunction-associated steatotic liver disease
MLTCs	Multiple long-term conditions
MNT	Medical nutrition therapy
MRA	Mineralocorticoid receptor antagonist
NAION	Non-arteritic anterior ischaemic optic neuropathy
OSA	Obstructive sleep apnoea
PAD	Peripheral arterial disease
SDOH	Social determinants of health
SGLT2	Sodium–glucose cotransporter 2
TIR	Time in range
TITR	Time in tight range
TTM	Transtheoretical model
TZD	Thiazolidinedione
UACR	Urine albumin: creatinine ratio

Introduction

Type 2 diabetes is a chronic complex disease, and management requires multifactorial behavioural and pharmacological treatments to prevent or delay complications and maintain quality of life (Fig. 1). This includes management of blood glucose levels, weight, cardiovascular and kidney disease risk factors, and associated multiple long-term conditions (MLTCs) and complications. This necessitates that care be delivered in an organised and structured way, such as described in the chronic care model, and includes a person-centred approach to enhance engagement in self-care activities, ideally delivered in a multidisciplinary setting. Careful consideration of clinical characteristics, social determinants of health (SDOH) and the preferences of people living with diabetes must inform individualisation of treatment goals and strategies, with consideration of the available therapeutic options to prevent or diminish the impact of MLTCs and complications.

Data sources, searches and study selection

This report follows the Accurate Consensus Reporting Document (ACCORD) principles [1]. The 16-member writing group was appointed by the EASD Committee on Clinical Affairs on behalf of the EASD Board and by the ADA's scientific leadership on behalf of its Board based on their clinical and research expertise in type 2 diabetes. The group included equal representation from both organisations across different clinical disciplines, and was co-chaired by Melanie Davies (EASD) and John

Buse (ADA). Two or four members of the writing group were assigned to be the primary authors of each section. These individuals had specific knowledge of the relevant area and were tasked with reviewing and summarising the available literature.

The group largely worked virtually, with regular recorded video conferences (April 2025–June 2026) and a 2 day face-to-face workshop in February 2026. The writing group accepted prior editions of this consensus report as a starting point [2, 3]. To identify newer evidence, a search was conducted on PubMed for RCTs, systematic reviews and meta-analyses published in English between 1 May 2022 and 31 December 2025. Eligible publications examined the efficacy or safety of pharmacological or non-pharmacological interventions in adults with type 2 diabetes. Reference lists in eligible reports were scanned to identify additional relevant articles. Additional references were identified by writing group members outside the PubMed search strategy by forward and backward citation chasing. Details of the keywords and the search strategy are available at <https://doi.org/10.17605/osf.io/pu93h>. Publications were grouped according to subject matter, and the writing group members reviewed this new evidence. Up-to-date meta-analyses evaluating the effects of therapeutic interventions across clinically important subgroup populations were assessed using relevant guidance [4, 5]. Evidence appraisal was informed by the Grading of Recommendations Assessment, Development and Evaluation (GRADE) guidelines on the formulation of clinical practice recommendations [6, 7]. Based on this evidence, writing group members collaboratively identified the topic areas and sections that needed to be updated in a non-anonymous setting. Topic areas and questions were posed to the full group by the chairs and other writing group members during meetings. Discussions were carried out in detail to clarify the meaning, resolve questions and bring forth new ideas. Consensus was sought through discussion among writing group members. Where consensus could not be achieved, final decisions were determined by majority vote. Qualitative meeting summaries were shared with writing group members and allowed reflection and the opportunity to air discussion points throughout the development of the report until consensus was reached. All writing group members collectively reviewed all sections to verify scientific rigour, language and utility to the intended readership. Each section, in turn, was revised and approved by the entire working group.

The draft consensus recommendations were presented for public comments at the ADA meeting in New Orleans in 2026, and the report was evaluated by external peer review, leading to subsequent revisions. Although evidence-based with stakeholder input, the recommendations presented herein reflect the values and preferences of the consensus

A HOLISTIC ANTICIPATORY INTEGRATED CARE APPROACH ADDRESSING TYPE 2 DIABETES AND ITS ASSOCIATED LONG-TERM CONDITIONS




Fig. 1 A holistic anticipatory integrated care approach addressing type 2 diabetes and its associated long-term conditions

group, acknowledging limitations in the evidence base. The dualities of interests of the authors were tracked throughout the development of this statement and are reported at the end of the article. The document was reviewed and approved by the ADA's Professional Practice Committee (PPC) and the EASD's Committee on Clinical Affairs (CCA).

The rationale, importance and context of type 2 diabetes treatment

Fundamental aspects of diabetes care include promoting healthy behaviours through medical nutrition therapy (MNT), 24 h physical behaviours (the five S's: standing; stepping; sweating; strengthening; and sleep) [2, 3] and psychological support, as well as weight management and tobacco/substance use disorder counselling as needed. This should be delivered in the context of diabetes self-management education and support (DSMES). The expanding number of interventions (from behavioural interventions to pharmacological interventions, devices, use of technology and surgery) and growing information about their benefits and risks provide more options for people with diabetes and providers but complicate decision-making [8]. This complexity is compounded by increased information from online sources and social media that can sometimes be incomplete or misleading [9–11].

In the last iteration of this consensus (2022), a focus on holistic care of the individual with diabetes was recommended and practical strategies addressed. People with type 2 diabetes often live with MLTCs and exhibit accelerated ageing, often driven by consequences of excess adiposity [12, 13]. The healthcare team should strive to achieve optimal outcomes with regard to cardiovascular, kidney, liver and pulmonary outcomes, physical function, wellbeing, cognitive outcomes and more. They should also address wider care needs associated with SDOH [14]. This effort must take a long view of optimising outcomes across the life course, accounting for the complex pathophysiology, dominantly driven by excess adiposity, underpinning type 2 diabetes [15] and seizing opportunities to achieve disease prevention, modification and remission, particularly through efforts to achieve 10–15% weight loss. A growing body of evidence identifies chronic low-grade inflammation as a mechanism behind type 2 diabetes and its associated cardio-kidney complications. Consequently, reducing residual inflammatory risk is increasingly recognised as a complementary therapeutic goal alongside optimisation of glucose levels, body weight and traditional cardiovascular risk factors, with the potential to modify disease progression and improve long-term outcomes [16, 17]. Interventions applied need to be reviewed and adjusted over time.

At diagnosis of type 2 diabetes and at regular intervals, alternative diagnoses such as type 1 diabetes, monogenic diabetes and hypercortisolism (among others) should be considered based on clinical context and in particular the response of individuals to treatment [18–22].

Attaining recommended glucose targets yields substantial and enduring reductions in the onset and progression of microvascular complications, and early intervention is essential. Recent recommendations suggest screening for type 2 diabetes in all adults aged ≥ 35 years and all adults with overweight or obesity at any age with any additional risk factor for diabetes to make the diagnosis early and afford the opportunity for treatment [23].

With regards to hyperglycaemia, the greatest absolute risk reduction for microvascular complications comes from improving very elevated glucose levels, and a more modest reduction results from near normalisation of plasma glucose levels. The impact of glucose management on macrovascular complications is less certain but is supported by multiple meta-analyses and epidemiological studies. Because the benefits of intensive glucose management emerge slowly while the harm can be immediate, people with longer life expectancy have more to gain from early intensive glycaemic management. A reasonable HbA_{1c} target for most non-pregnant adults with sufficient life expectancy to see microvascular benefits (generally ~ 10 years) is around 48–53 mmol/mol (6.5–7%) or lower [24]. A target of 48 mmol/mol (6.5%) or lower may be more appropriate for adults with type 2 diabetes who are managed with lifestyle/diet alone or in combination with medication that is not associated with hypoglycaemia, and for people with early-onset type 2 diabetes (diagnosis aged < 40 years) [25, 26]. Glucose monitoring can provide insight into the impact of lifestyle and medication management on blood glucose and symptoms, particularly when combined with education and support [27]. Continuous glucose monitoring (CGM) provides more information than blood glucose monitoring and can be useful for some people with type 2 diabetes [28]. Increasingly, CGM is viewed as an alternative method to assess and target glucose levels, with a general target of time in range (TIR) 3.9–10.0 mmol/l (70–180 mg/dl) $> 70\%$ [24]. Aiming for a lower target HbA_{1c} or more stringent CGM metrics, such as time in tight range (TITR) 3.9–7.8 mmol/l (70–140 mg/dl), may have value if these aims can be achieved safely. Less-stringent targets can be appropriate in individuals with limited life expectancy or advanced complications, or if other factors such as frailty are present [24].

Other targets are relevant to minimising risks of complications of diabetes, including those for BP and lipid management. Recent trials have demonstrated benefits of lower targets and more-intensive strategies in people with type 2 diabetes [29–32]. The recommended general BP goal is

<130/80 mmHg, though a systolic BP goal <120 mmHg should be encouraged in individuals with high cardiovascular or kidney risk [29]. For most people with type 2 diabetes aged >40 years, statin therapy is recommended. In those aged 20–39 years with type 2 diabetes and additional atherosclerotic CVD (ASCVD) risk factors, it may be reasonable to initiate statin therapy in addition to lifestyle therapy. For those with multiple CVD risk factors whose LDL-cholesterol remains ≥ 1.8 mmol/l (70 mg/dl) despite maximum tolerated statin therapy, it may be reasonable to add ezetimibe or a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor [29]. The European Society of Cardiology suggest a risk-based approach with a range of LDL-cholesterol target values. For example, in those at very high risk, a target LDL-cholesterol of <1.4 mmol/l (<55 mg/dl) is suggested [32].

Early diagnosis and intervention for diabetes MLTCs and complications afford best opportunities to slow progression. Thus, systematic screening for these should begin at the diagnosis of type 2 diabetes and should go beyond the traditional screening for microvascular complications (Fig. 1). Preventive-care paradigms should include a comprehensive medical evaluation, immunisation review, assessment of oral health habits, attention to bone health, screening and intervention for substance abuse, and assessing sexual health and adequacy of contraception [33]. Considering the increases in risk for specific cancers, such as colon, breast and endometrial cancer, in those living with obesity, specific attention should be paid to screening guidelines. Sex-specific factors beyond contraception should also be considered [34], including hypogonadism, erectile dysfunction and reduced fertility in men [35, 36], and menstrual cycle irregularities, polycystic ovary syndrome (PCOS), urinary stress incontinence and cardiometabolic risk across the reproductive life course in women [37, 38]. Regular (usually annual) assessment of diabetes complications, including a comprehensive eye and foot examination, the staging of chronic kidney disease (CKD), and the assessment of cardiovascular symptoms [29, 33, 39, 40], remains an essential part in diabetes care. More recent statements have recommended needs-based screening and assessment of heart failure [29], metabolic dysfunction-associated steatotic liver disease (MASLD) [33, 41] and psychological wellbeing [33].

The demonstrated broad benefits of both glucagon-like peptide-1 (GLP-1)-based therapies or/and sodium–glucose cotransporter 2 (SGLT2) inhibitors for high-risk individuals with ASCVD, heart failure, CKD, MASLD, obstructive sleep apnoea (OSA) and other obesity-related diseases and complications are largely independent of their glucose-lowering effects. In the present consensus report, ‘GLP-1-based’ therapies refer to both GLP-1 receptor agonists (GLP-1 RAs) and the dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) agonist tirzepatide. Though these treatments were initially introduced as glucose-lowering agents, they are now increasingly prescribed for other indications

and used for glycaemic and weight management and organ protection. As highly effective weight loss therapies have evolved, preservation of muscle mass and physical function are emerging as important considerations [42, 43].

There is increasing recognition of global threats to metabolic and mental health including lack of access to care, poverty, food and employment insecurity, deportation, discrimination, stigmatisation, disinformation, climate change, water and air quality, societal strife, and personal isolation and loneliness [44, 45]. The potential impact of these global issues is likely greater on people living with type 2 diabetes compared with the general population [44, 46]. Though beyond the scope of this consensus statement, the authors strongly endorse global collaboration to stem these trends.

The importance of the ‘principles of care’ as elucidated in the previous version of this consensus statement [2, 3] remains undiminished. For brevity, these critical issues are addressed in the section on ‘Putting it all together: strategies for implementation’, which encompasses communication between healthcare providers and people living with type 2 diabetes (language matters), DSMES, individualised approaches, treatment behaviours, persistence, weight reduction, use of diabetes technology and therapeutic inertia.

Therapeutic options: healthy lifestyle behaviours, weight management and pharmacotherapy for the treatment of type 2 diabetes

This section summarises the lifestyle and behavioural therapy, weight management interventions and pharmacotherapy that support the management of people with type 2 diabetes. Specific pharmacological treatment options are summarised in Table 1. Additional details are available in the previous ADA/EASD consensus report [2, 3] and the ADA’s 2026 ‘Standards of Care in Diabetes’ [47, 48].

MNT

MNT refers to a personalised dietary intervention [49]. This is integral to type 2 diabetes management, with evidence supporting its key role in improving glucose levels and reducing diabetes-related complications in individuals with and without obesity. Core dimensions of MNT include energy intake restriction and diet quality, with weight loss often being the primary objective.

Diet quality and eating patterns

There is no single ratio of carbohydrate, protein and fat intake that is optimal for every person with type 2 diabetes.

Table 1 Medications for lowering glucose: summary of characteristics

Medication	Efficacy	Hypoglycaemia [520]	Weight change [521]	Effects on cardiovascular outcomes		Effects on kidney outcomes		Effects on MASH outcomes	Route of administration	Cost	Clinical considerations
				Effect on MACE ^a	Heart failure ^a	Progression of CKD ^a	Dosing/use considerations ^b				
Metformin	High	No	Neutral (potential for modest loss)	Potential benefit	Neutral	Neutral	Contraindicated with eGFR <30 ml/min per 1.73 m²	Neutral	Oral	Low	- GI side effects common: to mitigate GI side effects, consider slow dose titration, extended-release formulations and administration with food - Potential for vitamin B₁₂ deficiency: monitor at regular intervals and replace as appropriate - DKA risk, rare in T2D: discontinue, evaluate and treat promptly if suspected; be aware of predisposing risk factors and clinical presentation (including euglycaemic DKA); discontinue before scheduled surgery (e.g. 3–4 days), during critical illness or during prolonged fasting to mitigate potential risk; reinitiate treatment again as early as possible according to physicians' recommendation - Increased risk of genital mycotic infections: mitigate risk with genital hygiene and avoid use in high-risk individuals - Necrotising fasciitis of the perineum (Fournier's gangrene), rare reports: institute prompt treatment if suspected - Attention to volume status, BP; adjust other volume-contracting agents as applicable
SGLT2 inhibitors	Intermediate to high	No	Loss (intermediate)	Benefit: canagliflozin, empagliflozin	Benefit: canagliflozin, dapagliflozin, empagliflozin, ertugliflozin	Benefit: canagliflozin, dapagliflozin, empagliflozin	- See labels for dose considerations for kidney function of individual agents - Glucose-lowering effect is lower for SGLT2 inhibitors at lower eGFR	Unknown	Oral	High	

Table 1 (continued)

Medication	Efficacy	Hypoglycaemia [520]	Weight change [521]	Effects on cardiovascular outcomes		Effects on kidney outcomes		Effects on MASH outcomes	Route of administration	Cost	Clinical considerations
				Effect on MACE ^a	Heart failure ^a	Progression of CKD ^a	Dosing/use considerations ^b				
GLP-1 RAs	High to very high	No	Loss (intermediate to very high)	Benefit: dulaglutide, liraglutide, semaglutide (s.c. and oral) Neutral: exenatide once-weekly, lixisenatide	Benefit: semaglutide (s.c.)	Benefit for kidney endpoints in CVOTs, driven by albuminuria outcomes: dulaglutide, liraglutide, semaglutide (s.c.) Benefit for CKD progression: semaglutide (s.c.)	- See labels for dose considerations for kidney function of individual agents - No dose adjustment for dulaglutide, liraglutide, semaglutide - Monitor kidney function when initiating or escalating doses in people with kidney impairment reporting severe adverse GI reactions	Benefit: semaglutide (s.c.)	s.c.; oral (semaglutide)	High	- Risk of thyroid C cell tumours in rodents; human relevance not determined (liraglutide, dulaglutide, exenatide extended-release, semaglutide) - Counsel individuals on potential for GI side effects and their typically temporary nature; provide guidance on dietary modifications to mitigate GI side effects [reduction in meal size, mindful eating practices (e.g. stop eating once full), decreasing intake of high-fat or spicy food]; consider slower dose titration for people experiencing GI challenges - Pancreatitis has been reported in post-marketing surveillance but causality has not been established; discontinue if pancreatitis is suspected - Evaluate for gallbladder disease if cholelithiasis or cholecystitis is suspected - Diabetic retinopathy: close monitoring of retinopathy in those at high risk (older individuals and duration of T2D >10 years) - NAION has been reported (very rare incidence) but causality has not been established: monitor for NAION during eye examinations - Impact on drug absorption: orally administered drug absorption may be impaired during dose titration

Table 1 (continued)

Medication	Efficacy	Hypoglycaemia [520]	Weight change [521]	Effects on cardiovascular outcomes		Effects on kidney outcomes		Effects on MASH outcomes	Route of administration	Cost	Clinical considerations
				Effect on MACE ^a	Heart failure ^a	Progression of CKD ^a	Dosing/use considerations ^b				
Dual GLP-1/GIP agonists	Very high	No	Loss (very high)	Benefit: tirzepatide	Benefit: tirzepatide	Benefit for kidney endpoints in CVOTs: tirzepatide	• See label for dose considerations for kidney function • No dose adjustment • Monitor kidney function when initiating or escalating doses in people with kidney impairment reporting severe adverse GI reactions	Potential benefit	s.c.	High	• Risk of thyroid C cell tumours in rodents but human relevance not determined • Counsel people on potential for GI side effects and their typically temporary nature; provide guidance on dietary modifications to mitigate GI side effects [reduction in meal size, mindful eating practices (e.g. stop eating once full), decreasing intake of high-fat or spicy food]; consider slower dose titration for people experiencing GI challenges • Pancreatitis has been reported in clinical trials but causality has not been established. Discontinue if pancreatitis is suspected • Evaluate for gallbladder disease if cholelithiasis or cholecystitis is suspected • Diabetic retinopathy: close monitoring of retinopathy in those at high risk (older individuals, duration of T2D > 10 years, established retinopathy) • Pancreatitis has been reported in clinical trials but causality has not been established. Discontinue if pancreatitis is suspected • Evaluate for gallbladder disease if cholelithiasis or cholecystitis is suspected • Diabetic retinopathy: close monitoring of retinopathy in those at high risk (older individuals, duration of T2D > 10 years, established retinopathy)
DPP-4 inhibitors	Intermediate	No	Neutral	Neutral	Neutral (potential risk, saxagliptin)	Neutral	• Dose adjustment required based on kidney function (sitagliptin, saxagliptin, alogliptin); can be used in kidney impairment • No dose adjustment required for linagliptin	Unknown	Oral	High	• Pancreatitis has been reported in clinical trials but causality has not been established. Discontinue if pancreatitis is suspected • Joint pain • Bullous pemphigoid (post-marketing): discontinue if suspected

Table 1 (continued)

Medication	Efficacy	Hypoglycaemia [520]	Weight change [521]	Effects on cardiovascular outcomes		Effects on kidney outcomes		Effects on MASH outcomes	Route of administration	Cost	Clinical considerations
				Effect on MACE ^a	Heart failure ^a	Progression of CKD ^a	Dosing/use considerations ^b				
TZDs	High	No	Gain	Potential benefit: pioglitazone	Increased risk	Neutral	• No dose adjustment required • Generally not recommended in kidney impairment due to potential for fluid retention	Potential benefit	Oral	Low	• Congestive heart failure (pioglitazone, rosiglitazone) • Fluid retention (oedema; heart failure) • Benefit in MASH • Risk of bone fractures • Weight gain: consider lower doses to mitigate weight gain and oedema • FDA Special Warning on increased risk of cardiovascular mortality based on studies of an older sulfonylurea (tolbutamide); glimepiride shown to be safe (see text) • Use with caution in people at risk for hypoglycaemia
Sulfonylureas (second-generation)	High	Yes	Gain	Neutral	Neutral	Neutral	• Glibenclamide (known as glyburide in the USA and Canada): generally not recommended in CKD • Glipizide and glimepiride: initiate conservatively to avoid hypoglycaemia	Unknown	Oral	Low	
Insulin (human insulin and analogues)	High to very high	Yes	Gain	Neutral	Neutral	Neutral	• Lower insulin doses required with a decrease in eGFR; titrate per clinical response	Unknown	s.c.; inhaled (human insulin) s.c. (analogues)	Low (s.c.) (human insulin) High (analogues)	• Injection site reactions • Higher risk of hypoglycaemia with human insulin (NPH or premixed formulations) vs analogues • Risk of hypoglycaemia and duration of activity increases with severity of impaired kidney function

^aMedications listed in alphabetical order^bFor agent-specific dosing recommendations, please refer to manufacturers' prescribing information

CV, cardiovascular; GI, gastrointestinal; TZD, type 2 diabetes

Instead, we recommend tailoring personalised eating patterns that emphasise foods with demonstrated health benefits, minimise foods shown to be harmful, and accommodate individual preferences with the goal of developing healthy dietary habits that are feasible and sustainable. Both the quality and the quantity of foods are crucially important (Fig. 2).

The Mediterranean diet has consistently demonstrated metabolic and cardiovascular benefits, along with improved glucose levels, even in the absence of substantial weight reduction [50–52]. This diet provides greater benefit than a low-fat diet for preserving kidney function in people with type 2 diabetes and obesity and for reducing cardiovascular events in people with CHD [53, 54]. Other diets have demonstrated short-term metabolic benefits but long-term safety and efficacy remain an area of question and interest [55].

Ketogenic diets encompass a broad range of nutritional interventions that vary both in the degree of carbohydrate restriction and in their energy composition. Ketogenic diets have shown some short-term benefits on glucose levels, insulin sensitivity and other metabolic outcomes, often preceding substantial weight loss. However, these diets should be balanced by the need to consider safety concerns and consider medication adjustment to mitigate both risk of hypoglycaemia and ketoacidosis risk, particularly with concomitant SGLT2 inhibitor use [50, 56, 57].

Dietary interventions providing different amounts of carbohydrates have been proposed as a means of achieving improved glycaemic management and weight loss in people living with type 2 diabetes. Low-carbohydrate diets have demonstrated beneficial effects on glucose management and body weight in people living with type 2 diabetes and overweight/obesity in the short term, decreasing the requirement for glucose-lowering medications [58–60].

There has been increasing interest in time-restricted eating and intermittent fasting strategies, such as alternate-day fasting or the 5:2 model in which weekly eating is normal for 5 days and daily energy intake is reduced to 2.09–2.51 MJ (500–600 kcal) on two non-consecutive days [61–65]. Intermittent fasting is relatively safe and effective in people with type 2 diabetes, though caution in the setting of specific glucose-lowering medications, such as insulin, is required. Such interventions can be challenging to sustain in the long-term, particularly prolonged fasting, and individual variability in response must be acknowledged [50]. A 5:2 intermittent fasting meal replacement strategy demonstrated greater HbA_{1c} reduction and weight loss over 16 weeks as compared with metformin or an SGLT2 inhibitor [66]. Time-restricted eating has been associated with greater weight loss compared with restriction of daily energy intake, with similar reduction in HbA_{1c} [67]. The long-term efficacy and safety of these approaches require further investigation.

A meta-analysis of 22 trials has demonstrated that both Mediterranean diet and intermittent fasting effectively improve glycaemic management, lipid profiles and anthropometric measurements in people with type 2 diabetes, with the former offering more consistent and sustainable long-term benefits [51]. A network meta-analysis of 42 RCTs, comprising 4809 people with type 2 diabetes, comparing ten dietary approaches, has demonstrated that ketogenic, Mediterranean, moderate-carbohydrate and low-glycaemic-index diets have promising effects for lowering HbA_{1c}, significantly related to weight loss [68].

Non-surgical energy restriction for weight loss


An overall healthy eating plan that results in an energy deficit, in conjunction with medications and/or metabolic surgery, supports glycaemic and weight management goals in adults with type 2 diabetes. Structured medical nutrition and lifestyle programmes may be considered for glycaemic benefit and can be adapted for specific cultural indications [2, 3]. Very-low-energy diets and formula meal replacement are highly effective for weight loss in the short term, with limited evidence on long-term sustainability [69]. They offer a method of achieving clinically meaningful weight loss and improvements in microvascular and macrovascular outcomes [70], particularly when access to medications is limited. The greatest improvements in outcomes are achieved through sustained weight loss and lifestyle change, rather than dietary composition itself.

The Diabetes Remission Clinical Trial (DiRECT) demonstrated that a structured low-energy diet, involving total diet replacement formula followed by stepped food reintroduction and behavioural support for weight-loss maintenance, delivered in primary care, resulted in type 2 diabetes remission in 46% of participants at 1 year [71, 72] and sustained remission at 2 years correlated with the extent of sustained weight loss. At 5 years, participants who continued to receive low-intensity support maintained a mean weight loss of 6.1 kg, with 13% (7% of the original intervention group) achieving type 2 diabetes remission [73]. Thus, long-term sustainability of remission with this approach remains challenging [73].

Intensive lifestyle intervention in the Look AHEAD trial led to broad improvements in health outcomes but no reductions in cardiovascular events [74]. However, in those with evidence of hyperglycaemia remission at a single point in time there was a 33% lower rate of CKD and 40% lower rate of composite CVD, with the greatest effect being seen in those with longer-term remission [75].

Several determinants of diabetes remission have been identified, including younger age, shorter diabetes duration, higher beta cell function, greater weight loss and greater energy deficit [76–78].

DIETARY PATTERNS AND METABOLIC EFFECTS IN PEOPLE LIVING WITH TYPE 2 DIABETES




MEDITERRANEAN DIET	
Mediterranean diet	- Sustainable long-term metabolic and CV benefits, even in the absence of substantial weight loss - Modulation of gut microbiota, improving insulin sensitivity, inflammation, oxidative status, overall metabolic health
LOW-ENERGY DIETS	
Low-energy diet (LED)	- Effective strategy for weight loss and glycaemic management in T2D with obesity - Can lead to T2D remission in the long term if implemented early in disease course (DIRECT 5-year follow-up), although prolonged remission is infrequent
Very-low-energy diet (VLED)	- VLED and formula meal replacement – highly effective approaches for weight management in T2D in the short term - VLED with total diet replacement induction phase – highly effective for T2D remission, with most of the evidence restricted to 1 year or less - Adherence challenges; of limited long-term sustainability; and may require medical supervision
INTERMITTENT FASTING STRATEGIES	
With focus on energy restriction: 5:2 fasting Alternate-day fasting (ADF)	5:2 intermittent fasting leveraging formula meal replacement over 12–16 weeks provides greater benefit for HbA_{1c}, weight reduction and other metabolic outcomes than oral glucose-lowering medications or lifestyle therapy
With focus on timing: Time-restricted eating (TRE)	- Beneficial effect on HbA_{1c}, body weight loss, lipids in the short term - More effective for weight loss than energy restriction, with similar reduction in HbA_{1c} - Adherence challenges, especially with prolonged fasting; individual variability in response
KETOGENIC DIETS	
Low-energy ketogenic diet (LEKD) Very-low-energy ketogenic diet (VLEKD)	- Significant improvement in blood glucose, HbA_{1c}, body weight, waist circumference, lipids vs non-ketogenic diets - Offers rapid metabolic benefits - Concerns over adherence and safety; may require medical support/supervision, particularly in patients on SGLT2 inhibitors
LOW-CARBOHYDRATE DIETS	
Low-carbohydrate diets (LCD)	- Beneficial effect on glucose management, insulin resistance, body weight, waist circumference, lipids, blood pressure vs control diets - Decreased requirement for glucose-lowering medications over the intermediate to long term - Low-carbohydrate breakfast – significantly lower glycaemic variability and higher TIR vs a low-fat breakfast

CV – Cardiovascular; SGLT2 – Sodium-glucose cotransporter 2; TEE – Total energy expenditure; TEI – Total energy intake; TIR – Time in range; T2D – Type 2 diabetes.

Fig. 2 Dietary patterns and metabolic effects in people living with type 2 diabetes

a 24 H PHYSICAL BEHAVIOURS (THE 5 S'S) IN TYPE 2 DIABETES MANAGEMENT



CBTi - Cognitive Behavioural Therapy for Insomnia; HIIT - High-intensity interval training.

* Evidence specific to established type 2 diabetes is limited; step targets are therefore inferred from population-level meta-analyses

§ Includes GLP-1 RA and the dual GLP-1/GIP agonist tirzepatide.

b THE 5 S'S: PRESCRIBING COMBINED 24 H BEHAVIOURS IN THOSE LIVING WITH TYPE 2 DIABETES

OVERVIEW:

- ① While general recommendations are for ≥150 min/week moderate-to-vigorous-intensity aerobic activity over ≥3 days, resistance exercise 2–3x/week, minimising sedentary time and progressing gradually based on tolerance, specific recommendations can be tailored to the individual

'24 h behaviours can be combined to match ability and preference, benefitting all people living with type 2 diabetes. When prescribing these behaviours, think of it like writing a medication prescription (e.g. who, what, dose and timing)'

WHAT?:

Behavioural components across the 24 h day

- Standing** – Time spent sitting or reclining with low energy expenditure
- Stepping** – All walking and step-based movement accumulated across the day
- Sweating** – Moderate-to-vigorous aerobic activity that increases heart rate and breathing
- Strengthening** – Activities that build or maintain muscle strength, power and physical function
- Sleeping** – Sleep, including its duration, quality and timing



WHO?: Applies to all, with examples of where additional tailoring may be beneficial

- Predominantly sedentary daily routines and/or difficulty standing for long periods (**Standing**)
- Very low habitual physical activity (**Stepping**) to increase cardiorespiratory fitness
- Low cardiorespiratory fitness (**Sweating**)
- Reduced muscle strength and/or impaired balance or stability, including frail older adults, those at risk of falls or individuals initiating GLP-1-based therapy[§] (**Strengthening**)
- Short sleep, insomnia, irregular schedules, OSA (**Sleeping**)

WHERE?: Everyday settings

- Home** – Standing breaks, short walks, sit-to-stand, floor-based exercises
- Gym** – Aerobic equipment, resistance machine, free weights
- Garden** – Digging, lifting, carrying
- Office** – Walking meetings, standing breaks, stairs
- Park** – Brisk walking, circuits, outdoor gym equipment
- Neighbourhood** – Walking to the local shops, post-meal walks, outdoor benches for sit-to-stands

HOW MUCH AND WHEN?:

Dose and timing – components can be combined and tailored

- Standing** – Minimise prolonged sitting and interrupt sitting time regularly across the day, particularly after meals
- Stepping** – Gradually increase steps from baseline by 500–1000/day, accumulated across the day. Indicative targets: ~6000–8000 steps/day (older adults) and ~8000–10,000 steps/day (younger adults)
- Sweating** – Work towards ≥150 min/week of moderate-to-vigorous activity or 75 min/week of vigorous/interval training, typically over 3–5 days per week, with no more than 2 consecutive days without activity
- Strengthening** – Include strengthening or functional activities targeting all major muscle groups on 2–3 days per week, progressed gradually and tailored to ability
- Sleeping** – Aim for ~7–8 hours per night of good-quality sleep with consistent timing

OSA - Obstructive Sleep Apnoea.

§ Includes GLP-1 RA and the dual GLP-1/GIP agonist tirzepatide.

Fig. 3 (a) Behaviours (the five S's) in type 2 diabetes management. (b) The five S's: prescribing combined 24 h behaviours in those living with type 2 diabetes

Dietary supplements

Numerous dietary supplements, including pre-/pro- and synbiotics, berberine, curcumin, fenugreek, okra, propolis and resveratrol, have been studied for their potential role in managing type 2 diabetes and its complications. The evidence of benefit is inconclusive [79–84]. Studies of vitamin D in type 2 diabetes have been completed, with very modest effects seen on HbA_{1c}. Current evidence does not support its use for glycaemic management [85–88].

Consensus recommendations

- An overall healthy eating plan that results in an energy deficit, in conjunction with medications and/or metabolic surgery as individually appropriate, should be considered to support glycaemic and weight management goals in adults with type 2 diabetes and overweight/obesity.
- MNT focused on identifying healthy dietary habits that are feasible and sustainable is recommended.
- Structured medical nutrition and lifestyle programmes should be adapted for specific cultural context.
- Consider offering intensive lifestyle therapy aiming for 10% or greater weight loss with the possibility of remission. Achieving remission of type 2 diabetes at any time may have long-term benefits.
- A Mediterranean dietary pattern should be preferentially considered in people with type 2 diabetes and established ASCVD, where feasible and acceptable to the individual.
- Specific dietary supplements are not recommended for glycaemic management in people with type 2 diabetes.

Physical activity behaviours

The management of type 2 diabetes is increasingly guided by a 24 h behavioural approach, in which the five S's (standing, stepping, sweating, strengthening and sleep) provide a practical, evidence-informed framework that brings together daily movement and rest patterns to support cardiometabolic health. This perspective emphasises that improvements in glucose levels, cardiovascular risk, functional capacity and cognitive health arise not only from structured exercise but also from the distribution of sedentary time, light movement and sleep across the day.

Embedding behavioural care within the five S's supports personalised recommendations that reflect real-world patterns of activity, rest and circadian rhythm, helping people living with type 2 diabetes to translate small, sustainable adjustment into meaningful cardiometabolic benefit. With growing evidence for 'lifestyle as medicine' in type 2 diabetes, this framework supports shared, person-centred decision-making across 24 h behaviours (Fig. 3).

Within this framework, structured exercise ('sweating') remains pivotal, with widespread benefits across physiological (e.g. fitness, adiposity and cardiovascular risk factors) and psychological (e.g. quality of life and depressive symptoms) markers of health [89, 90]. Meta-analyses of exercise training trials in people living with type 2 diabetes consistently demonstrate that regular moderate-to-vigorous aerobic activity produces clinically meaningful reductions in HbA_{1c} (~5–8 mmol/mol [~0.5–0.7%]) [91–93], with greater improvements observed at higher volumes of activity [94–96]. High-intensity interval training also improves HbA_{1c}, insulin sensitivity and fitness, supporting its role as a time-efficient modality, particularly when higher-volume training is impractical [92, 93, 95, 97].

Extending beyond aerobic modalities alone, evidence consistently shows that programmes combining aerobic and resistance exercise produce the largest overall improvements in HbA_{1c} (~8–10 mmol/mol [~0.7–0.9%]) and broader cardiometabolic health [91, 92, 98], with adjunctive flexibility, stability and mind-body modalities (e.g. yoga) supporting functional capacity and balance [89, 90]. Resistance exercise independently improves insulin sensitivity, HbA_{1c} (~4–5 mmol/mol [~0.4–0.5%]), preserves lean mass and supports functional capacity, reinforcing 'strengthening' as a core therapeutic lever in type 2 diabetes, particularly in phenotypes at risk of muscle loss [91, 92, 95, 98, 99]. This priority becomes even more pressing in the context of weight loss [12, 42, 100]. Recent body composition analyses from large pharmacotherapy trials, including SURMOUNT-1, indicate that approximately 25–40% of total weight loss achieved with GLP-1-based therapies reflects lean mass loss [101, 102], highlighting the importance of embedding both 'strengthening' and 'sweating' activities to preserve function and mitigate accelerated skeletal muscle ageing.

Beyond structured sessions, sedentary behaviour represents an independent, modifiable risk factor. Randomised crossover trials demonstrate that breaking up prolonged sitting with brief bouts of walking or simple resistance activities lowers postprandial glucose and insulin levels [103–105]. These findings are supported by recent systematic reviews and network meta-analysis, which identify

regular sitting interruptions, particularly involving light-intensity movement, as effective strategies for improving acute glucose and insulin regulation across the day [106–108].

‘Stepping’ behaviours provide an additional scalable target within the same 24 h behavioural framework. Evidence drawn predominantly from large population-based cohort studies and meta-analyses demonstrates a consistent dose–response association between daily step count and cardiometabolic outcomes, with each additional 500–1000 steps/day associated with lower all-cause mortality and cardiovascular events [109]. Step counts in the range of ~6000–10,000/day are associated with a clinically meaningful lower cardiometabolic risk [110–112] and, while diabetes-specific evidence remains more limited, these population-based findings support gradual progression in daily steps in people with type 2 diabetes.

Finally, ‘sleep’ completes the 24 h behavioural cycle. Both sleep quantity and quality show U-shaped or graded associations with HbA_{1c}, while observational evidence suggests that irregular sleep timing and later chronotype are associated with less-favourable metabolic profiles [113–118]. Clinical trials of behavioural sleep interventions, including cognitive behavioural therapy for insomnia, further indicate that improving sleep quantity and quality can lead to clinically meaningful reductions in HbA_{1c} [119]. Improvements in sleep quality and duration and reductions in HbA_{1c} can also be achieved through simple changes to sleep hygiene (e.g. consistent sleep schedule, limiting exposure to bright light and screens in the evenings, and avoiding consumption of caffeine in the afternoon and evening) [120]. Together, these findings support a personalised approach that considers sleep duration, quality and timing alongside other physical activity behaviours.

Consensus recommendations

- The five S’s (increasing standing, increasing stepping, incorporating sweating [aerobic] physical activity and strengthening [resistance exercise], and ensuring adequate quality, quantity and timing of sleep) are fundamental to glycaemic management and holistic care in type 2 diabetes.
- Counsel and support adults with type 2 diabetes to progressively increase physical activity volume and intensity beyond minimum thresholds when feasible and safe, given the dose-related benefits on glucose levels, cardiometabolic outcomes and overall wellbeing. It is important to consider the presence of MLTCs and frailty status.
- A combination of aerobic and resistance/strength activity, aiming for a minimum of 150 min/week of moderate-to-vigorous-intensity aerobic activity (or 75 min vigorous)

accumulated over ≥ 3 days per week, with sessions typically lasting ~30 min is recommended.

- Resistance exercise should be included 2–3 times per week, with intensity and progression adjusted according to individual tolerance and functional capacity, and in the context of individual MLTCs and frailty status.
- Resistance exercise should be encouraged during weight loss interventions to help preserve skeletal muscle mass and strength.
- Alongside regular structured exercise, reductions in sedentary time, increases in daily movement and optimisation of sleep should be recognised and supported.

Medications for lowering glucose

Cardio-kidney-protective glucose-lowering medications

SGLT2 inhibitors SGLT2 inhibitors are oral medications that reduce plasma glucose by enhancing urinary excretion of glucose. They have high glucose-lowering efficacy, with lower efficacy at lower eGFR. However, their scope of use has significantly expanded based on cardiovascular and kidney outcome studies [2, 3, 121]. Cardiovascular and kidney outcome trials have demonstrated their efficacy in the following outcomes:

- reducing the risk of composite major adverse cardiovascular events (MACE), cardiovascular death, myocardial infarction, hospitalisation for heart failure (HHF), and all-cause mortality in individuals with type 2 diabetes with an established/high risk of CVD
- improving kidney outcomes, including reducing the risk of significant loss of kidney function, development of kidney failure and kidney and cardiovascular mortality, in individuals with type 2 diabetes with established CKD.

This is discussed further in the section on ‘[Personalised approach to treatment based on individual characteristics and MLTCs](#)’ below. Evidence supporting their use is summarised in Table 1. Although the different SGLT2 inhibitors have not been compared in randomised studies, target trial emulation studies have suggested similar cardiovascular benefit [122].

Recent data have increased confidence in the safety of the SGLT2 inhibitor class [121, 123]. Their use is associated with increased risk for mycotic genital infections, which are reported to be typically mild and treatable. While SGLT2 inhibitor use can increase the risk of diabetic ketoacidosis (DKA) even with euglycaemia, the incidence is low in type 2 diabetes [123]. SGLT2 inhibitor cardiovascular outcome trials (CVOTs) have reported DKA rates of 0.1–0.6% compared with rates of <0.1–0.3% for placebo [124–128], with

very low rates in the heart failure [129–132] and CKD [133–135] outcome studies. Guidelines suggest that risk may be mitigated with education and guidance, including education on signs and symptoms of DKA, and temporary discontinuation of the medication in clinical situations that predispose to DKA (e.g. prolonged fasting or carbohydrate restriction, surgery, acute illness, infection, insulin omission or dose reduction) [48, 136–141].

While early studies brought attention to several safety-related areas of interest (acute kidney injury [AKI], dehydration, orthostatic hypotension, amputation and fractures), longer-term studies that have prospectively assessed and monitored these events have not seen a significant imbalance in risks [142, 143]. Analyses based on those included in heart failure and CKD studies suggested similar benefit regardless of frailty among study participants [144, 145]. Recent register-based studies suggest the benefit can be extended to older people (aged >70 years) [146]. Analyses of SGLT2 inhibitor outcome trial data also suggest that people with type 2 diabetes and peripheral arterial disease (PAD) derive greater absolute outcome benefits from SGLT2 inhibitor therapy than those without PAD, with no increase in risk of major adverse limb events (MALE) [147]. In post hoc analyses, SGLT2 inhibitor use has been associated with reduced incidence of serious and non-serious kidney-related adverse events in people with type 2 diabetes and CKD and greater full recovery from AKI [148].

GLP-1 RAs GLP-1 RAs augment glucose-dependent insulin secretion and glucagon suppression, decelerate gastric emptying, curb post-meal glycaemic increments, and reduce appetite, energy intake, and body weight [149]. In addition to their physiological effects, GLP-1 RAs have been shown to influence health behaviours, such as shifting food-purchasing patterns toward minimally processed foods [150]. Beyond improving HbA_{1c} in adults with type 2 diabetes, specific GLP-1 RAs have received regulatory approval for the following:

- reducing risk of MACE in adults with type 2 diabetes with established CVD (dulaglutide, liraglutide, and s.c. as well as oral semaglutide) or multiple CVD risk factors (dulaglutide)
- reducing the risk of progression of CKD in adults with type 2 diabetes and CKD (s.c. semaglutide) (Table 1)
- improving heart failure symptoms in individuals with heart failure with preserved ejection fraction (HFpEF), type 2 diabetes and obesity (s.c. semaglutide) [151]
- improving liver histological findings in people with MASLD and moderate or advanced liver fibrosis (s.c. semaglutide) [152]
- chronic weight management (s.c. liraglutide 3.0 mg once daily; s.c. semaglutide 1.7 mg, 2.4 mg or 7.2 mg once

weekly; oral semaglutide 25 mg daily; and oral orforglipron [a GLP-1 RA now licensed in the USA for weight management] 17.2 mg daily) [153].

Whereas initial GLP-1 RAs were injectable peptides (s.c. injection), oral formulations of semaglutide are available [154]. Orforglipron is a small-molecule GLP-1 RA without food or water dosing restrictions. It has demonstrated greater reductions in HbA_{1c} and body weight than oral semaglutide (7–14 mg) but is currently only indicated for weight management [155]. Higher doses of dulaglutide (3.0 and 4.5 mg) have been approved for glycaemic management, and s.c. semaglutide (7.2 mg) and oral semaglutide (25 mg) for weight management. Studies have demonstrated incremental benefits of these higher doses for both glycaemic and weight management [156–159].

Dual GLP-1/GIP agonists Many nutrient-stimulated hormone-based medications and combinations are currently in development beyond GLP-1 RAs. The first of these, the dual GLP-1/GIP agonist tirzepatide, is approved for once-weekly s.c. administration to improve glucose levels in adults with type 2 diabetes and for weight management as an adjunct to healthy eating and exercise. Mechanistically, GLP-1 and GIP have overlapping and distinct effects [160] and, clinically, tirzepatide appears to be more effective than GLP-1 RAs for HbA_{1c} and weight reduction. Across the SURPASS programme, tirzepatide demonstrated superior glucose-lowering efficacy to placebo, s.c. semaglutide 1.0 mg, insulin degludec and insulin glargine. For HbA_{1c}, placebo-adjusted reductions of ~22 mmol/mol (~2%) and mean weight reductions of 7–9.5 kg were seen across doses. Up to 62% of those treated with tirzepatide reached an HbA_{1c} of <39 mmol/mol (5.7%) and up to 68% lost more than 10% of their baseline body weight [161].

Additional metabolic benefits included the following:

- improvements in liver fat content and reduced visceral and subcutaneous abdominal adipose tissue volume [162]
- improved symptoms in individuals with OSA and obesity [163], and HFpEF and obesity [164]
- in the SURPASS-CVOT, participants with type 2 diabetes and ASCVD were randomised to tirzepatide or the GLP-1 RA dulaglutide, which has previously proven to reduce the risk of MACE. Tirzepatide was non-inferior to dulaglutide with respect to a composite of death from cardiovascular causes, myocardial infarction or stroke (HR 0.92 [95.3% CI 0.83, 1.01]), and had similar incidence of serious adverse events but more gastrointestinal side effects [165]
- in an analysis comparing putative placebo from the REWIND study and participants from SURPASS-CVOT

for an indirect treatment effect comparison, tirzepatide vs putative placebo was associated with lower three-point MACE (HR 0.72 [95% CI 0.55, 0.94]), death from cardiovascular cause or heart failure events (HR 0.70 [95% CI 0.51, 0.96]) and all-cause death (HR 0.61 [95% CI 0.45, 0.82]), suggesting cardiovascular benefit of tirzepatide in this indirect comparison [166]. Tirzepatide received regulatory approval to reduce the risk of MACE in adults with type 2 diabetes at high risk for these events.

GLP-1-based therapies (both GLP-1 RAs and the dual GLP-1/GIP agonist tirzepatide): safety and tolerability The most common side effects of GLP-1-based therapies are gastrointestinal in nature (nausea, vomiting, diarrhoea and constipation), tending to occur during initiation and dose escalation and diminish over time. Education should be provided when initiating GLP-1-based therapy. Slower or flexible dose escalations can be considered in the setting of gastrointestinal intolerance [167, 168].

Data from CVOTs on other safety areas of interest (pancreatitis, pancreatic cancer, medullary thyroid cancer, retinopathy and suicide) indicate that there is no increase in these risks with GLP-1 RAs in the populations studied [169]. Gallbladder and biliary events occur at higher rates (27/10,000 person-years) with GLP-1 RAs vs placebo or non-GLP-1 RA medications, particularly at higher doses, longer duration, and when used for weight loss rather than glycaemic management [170]. GLP-1-based therapies (except lixisenatide and twice-daily exenatide) are contraindicated in people at risk for the rare medullary thyroid cancer (i.e. those with a history or family history of medullary thyroid cancer or multiple endocrine neoplasia type 2); this is related to rodent studies in which thyroid C cell tumours were more common with GLP-1 RA treatment than with placebo. GLP-1-based therapies may increase the risk of progression of diabetic retinopathy, perhaps related to rapid improvement in glucose levels, so baseline and ongoing retinal monitoring is recommended. An excess of non-arteritic anterior ischaemic optic neuropathy (NAION) was reported in people with obesity or type 2 diabetes treated with semaglutide compared with non-GLP-1 RA treatment (HR 4.28 [95% CI 1.62, 11.29]) [171]. Subsequent studies demonstrated that NAION is associated with obesity and diabetes, and is very rare (1 case per 10,000 person-years of semaglutide exposure), although its relationship to semaglutide remains unclear [172].

Metformin

Because of its high efficacy in lowering HbA_{1c}, minimal hypoglycaemia risk when used as monotherapy, weight

neutrality with the potential for modest weight loss, good safety profile and low cost, metformin has traditionally been recommended as first-line glucose-lowering therapy for the management of type 2 diabetes. However, there is increasing evidence that other approaches may be appropriate in some populations. Notably, the benefits of GLP-1 RAs and SGLT2 inhibitors for cardiovascular and kidney outcomes have been found to be independent of metformin use and, thus, these agents should be used in people with established or high risk of CVD, heart failure or CKD, independent of metformin use [173–175]. That said, these data come from subgroup analyses not protected by randomisation so the evidence is not definitive, and some may prefer to continue metformin when initiating GLP-1-based therapies or SGLT2 inhibitors. Metformin should not be used in people with an eGFR <30 ml/min per 1.73 m², and dose reduction should be considered when the eGFR is <45 ml/min per 1.73 m² [176]. Metformin use may result in lower serum vitamin B₁₂ concentrations and worsening of symptoms of neuropathy; therefore, periodic monitoring and supplementation are generally recommended if levels are deficient [177, 178].

Other glucose-lowering medications

Dipeptidyl peptidase-4 inhibitors Dipeptidyl peptidase-4 (DPP-4) inhibitors are oral medications that inhibit the enzymatic inactivation of endogenous incretin hormones (GLP-1 and GIP), resulting in glucose-dependent insulin release and a decrease in glucagon secretion. They have moderate glucose-lowering efficacy, are generally considered to be weight neutral [179], and are well tolerated with minimal risk of hypoglycaemia. CVOTs have demonstrated the cardiovascular safety, without cardiovascular risk reduction, of the DPP-4 inhibitors saxagliptin, alogliptin, sitagliptin and linagliptin [180]. As a class, DPP-4 inhibitors are associated with modest reduction in urine albumin-creatinine ratio (UACR), without significant effect on eGFR [181].

DPP-4 inhibitors have a favourable safety profile with minimal side effects. A meta-analysis suggests an increased risk of composite gallbladder/biliary disease and cholecystitis vs placebo or other glucose-lowering medications (RR 1.38 [95% CI 1.08, 1.75]), with higher risk seen in older adults and with longer duration of use [182]. An increased risk of HHF was found with saxagliptin vs placebo, and there have been rare reports of arthralgia and hypersensitivity reactions with the DPP-4 inhibitor class [183]. The high tolerability and modest efficacy of DPP-4 inhibitors may mean that they are suitable for specific populations, such as in older adults with mild hyperglycaemia or in individuals with high risk of hypoglycaemia. They are also an oral option in those with low eGFR (Table 1).

Sulfonylureas Sulfonylureas have high glucose-lowering efficacy, are inexpensive and are broadly accessible but they lack a durable effect and increase the risk for hypoglycaemia and weight gain [184]. Use of sulfonylureas or insulin for early, more-intensive blood glucose management in the UK Prospective Diabetes Study (UKPDS) significantly decreased the risk of microvascular complications [185]. Findings from systematic reviews and real-world studies suggest no increase in all-cause mortality rates with sulfonylureas compared with other active treatments [184, 186]. There may be heterogeneity across the class; specifically, glimepiride has demonstrated cardiovascular safety in comparison with the DPP-4 inhibitor linagliptin [187].

Thiazolidinediones Thiazolidinediones (TZDs) are oral medications that increase insulin sensitivity and are of high glucose-lowering efficacy [188–191]. TZDs have a high durability of glucose response, most likely through an effect on preservation of beta cell function [192]. In the Prospective Pioglitazone Clinical Trial in Macrovascular Events (PROactive) in adults with type 2 diabetes and macrovascular disease, a reduction in secondary cardiovascular endpoints was seen, although significance was not achieved for the primary outcome [193]. In the Insulin Resistance Intervention after Stroke (IRIS) study in adults without diabetes but with insulin resistance and recent history of stroke or transient ischaemic attack, there was a lower risk of stroke or myocardial infarction with pioglitazone vs placebo [194, 195]. Beneficial effects on MASLD and metabolic dysfunction-associated steatohepatitis (MASH) have been seen with pioglitazone [196, 197]. However, these benefits must be balanced against the possible side effects of fluid retention and congestive heart failure [192, 193, 198], weight gain [192–194, 198, 199] and bone fracture [200, 201] and possible increased risk of bladder cancer [202]. Side effects can be mitigated by using lower doses and combining TZD therapy with other medications (SGLT2 inhibitors and GLP-1-based therapies) that promote weight loss and sodium excretion [203].

Insulin

The primary advantage of insulin therapy is that it lowers glucose in a dose-dependent manner and thus can address almost any level of blood glucose. However, its efficacy and safety are largely dependent on the education and support provided to facilitate self-management [188–191]. Careful consideration should be given to the pharmacokinetic and pharmacodynamic profiles of the available insulins, as well as the matching of the dose and timing to an individual's physiological requirements (electronic supplementary material [ESM] Fig. 1).

Detailed descriptions of different insulins have been given in previous reports [188–191]. The preferred way of initiating insulin in people with type 2 diabetes is to give basal insulin (ESM Fig. 1). A modest but significant reduction in HbA_{1c} and the risk of total and nocturnal hypoglycaemia have been observed for basal insulin analogues vs intermediate-acting (NPH) insulin [204]. Rapid- and ultrarapid-acting insulin can be added to basal insulin to intensify therapy to address prandial blood glucose levels. Premixed insulins combine basal insulin with mealtime insulin (short- or rapid-acting) in the same vial or pen. Premixed insulin may offer convenience for some but reduces treatment flexibility. Analogue-based mixtures may be timed in closer proximity to meals. Education on the impact of dietary nutrients on glucose levels to reduce the risk of hypoglycaemia while using mixed insulin is important. Insulins with different routes of administration (inhaled, bolus-only insulin delivery patch pump) are also available [205–207].

Once-weekly insulins have now been developed, with once-weekly insulin icodec being approved for type 2 diabetes in some regions, including the USA and Europe. Once-weekly insulin icodec was found to reduce HbA_{1c} significantly more than glargine U100 in insulin-naïve adults with type 2 diabetes (estimated between-group difference [ETD] −0.19% [95% CI −0.36, −0.03]) [208]. While overall rates of hypoglycaemia were low, rates of combined clinically significant or severe hypoglycaemia were higher with insulin icodec than with insulin glargine U100 [208]. In a participant-level meta-analysis of the ONWARDS programme, icodec had greater glucose-lowering efficacy compared with daily basal insulin comparators (ETD −0.10 to −0.29%); the incidence of clinically significant hypoglycaemia was similar, though with higher event rates, equating to approximately one extra clinically significant hypoglycaemic episode per person every 7 years [209].

Once-weekly insulin efsitora alfa has completed its phase III clinical development programme in type 2 diabetes but is not approved as of June 2026. Insulin efsitora alfa was found to be non-inferior to insulin glargine and insulin degludec, with similar reductions in HbA_{1c} in QWINT-1 and QWINT-2, respectively [210, 211]. QWINT-4 evaluated once-weekly insulin efsitora alfa compared with insulin glargine U100 in the treatment context of basal-bolus insulin therapy, demonstrating non-inferiority for glucose-lowering efficacy, with no difference in hypoglycaemia [212].

Combination GLP-1 RA–insulin therapy Two fixed-ratio combinations of GLP-1 RA with daily basal insulin analogue are available: insulin degludec plus liraglutide (IDegLira) and insulin glargine plus lixisenatide (iGlarLixi). In

addition, a once-weekly formulation of insulin icodec plus semaglutide is available in Europe, based on the COMBINE trials in adults with type 2 diabetes [213–215]. The combination of basal insulin with GLP-1 RA results in greater glucose-lowering efficacy than the monocomponents, with less weight gain and lower rates of hypoglycaemia than with intensified insulin regimens, and better gastrointestinal tolerability than with GLP-1 RA alone [213, 214, 216, 217].

Less commonly used glucose-lowering medications

α -Glucosidase inhibitors improve glucose levels by reducing postprandial glucose excursions and may provide specific benefits in those with high carbohydrate consumption or reactive hypoglycaemia [218, 219]. Other glucose-lowering medications (i.e. meglitinides, colesevelam, quick-release bromocriptine, and pramlintide) are not commonly used in the USA for type 2 diabetes, and most are not licensed in Europe. There was no new evidence that impacts clinical practice.

Combination of glucose-lowering therapies

The underlying pathophysiology of type 2 diabetes is complex, with multiple contributing abnormalities resulting in a naturally progressive disease and increasing HbA_{1c} over time in many individuals with the disease. Increasing data suggest benefits of combination approaches early on in diabetes care.

Combination of SGLT2 inhibitors and GLP-1-based therapies

Studies of concomitant SGLT2 inhibitors and GLP-1-based therapy show benefits for HbA_{1c}, BP and weight [220, 221]. Prespecified and post hoc subgroup analyses demonstrate that adding an SGLT2 inhibitor to background GLP-1-based therapy or vice versa may further reduce cardiovascular risk [220, 222–225]. Therefore, the use of a combination of SGLT2 inhibitor and GLP-1-based therapy can be considered to improve glucose levels (especially adding GLP-1-based therapy to an SGLT2 inhibitor), and cardiovascular and kidney outcomes [226].

Other considerations

Hypercortisolism Hypercortisolism may be associated with hyperglycaemia in approximately one-quarter of individuals with inadequate glycaemic management despite multiple medications [20]. Baseline characteristics that increase the odds of having hypercortisolism include older age,

lower BMI, higher medication burden for hypertension, taking analgesics or fibrates, and taking SGLT2 inhibitors, tirzepatide and high-dose GLP-1 RAs. In individuals with an HbA_{1c} of above 58 mmol/mol (7.5%) despite multiple glucose-lowering medications and non-ACTH dependent hypercortisolism, cortisol-directed medical therapy with mifepristone reduced HbA_{1c} substantially and may be beneficial for the management of hyperglycaemia [227]. However, treatment was associated with high rates of adverse events and withdrawal symptoms; these should be managed proactively and by employing mineralocorticoid receptor antagonists (MRAs) to avoid hypokalaemia, as appropriate. Mifepristone is currently only approved in the USA. Other cortisol-directed therapies are available but have not been tested in this context.

Non-steroidal MRAs For decades, MRAs (spironolactone and eplerenone) have been used in heart failure with reduced ejection fraction (HFrEF) and in resistant hypertension. In CKD, these agents have not been used due to side effects including high risk for hyperkalaemia. Recently, non-steroidal MRAs have been tested in type 2 diabetes with CKD, with most data available on finerenone. Two phase III trials in type 2 diabetes with CKD (FIGARO-DKD and FIDELIO-DKD) included participants with eGFR 25–90 ml/min per 1.73 m² and UACR >3.0 mg/mmol (>30 mg/g) on maximal tolerated renin–angiotensin system inhibitors and with potassium <4.8 mmol/l at screening [228, 229]. Studies were combined in a patient-level analysis, FIDELITY, and among 13,026 people with a median follow-up of 3.0 years. The composite cardiovascular outcome was reduced with finerenone compared with placebo (HR 0.86 [95% CI 0.78, 0.95], $p=0.0018$). The composite kidney outcome was also reduced (HR 0.77 [95% CI 0.67, 0.88], $p=0.0002$). Overall safety outcomes were generally similar between treatment arms. Hyperkalaemia leading to permanent treatment discontinuation occurred more frequently in people receiving finerenone (1.7%) than placebo (0.6%) [230].

Colchicine It has been discussed for many years whether chronic low-grade inflammation should be targeted in individuals with ASCVD. An old and affordable drug, colchicine, has been tested in six trials including 21,000 participants for secondary prevention of MACE in established ASCVD. A recent meta-analysis suggested that it achieved a 25% relative reduction in MACE [231], with no interaction with diabetes (23% of the participants). In COLCOT, conducted in people with type 2 diabetes and a recent myocardial infarction, low-dose colchicine (0.5 mg daily) reduced cardiovascular events [232]. The heterogeneity between

trials, populations and doses, as well as rare but serious side effects, calls for caution.

Weight and body composition management beyond lifestyle interventions

Medications for weight loss in type 2 diabetes

Weight loss medications are effective adjuncts to lifestyle interventions and healthy behaviours for the management of weight and have also been found to improve glucose levels in people with type 2 diabetes [233]. Semaglutide and tirzepatide are the most effective agents, with tirzepatide showing superiority for weight reduction [234]. Orforglipron, an oral small-molecule GLP-1 RA (17.2 mg oral daily), as well as higher-dose semaglutide (7.2 mg s.c. and 25 mg orally) have not been specifically compared with tirzepatide but are unlikely to be more efficacious [156, 157, 235, 236].

Metabolic surgery

Metabolic surgery should be considered as a treatment option in adults with type 2 diabetes who are appropriate surgical candidates [233, 237]. In the Alliance of Randomised Trials of Medicine vs Metabolic Surgery in Type 2 Diabetes (ARMSS-T2D) study, the rate of remission was 37.5% in the metabolic surgery group vs 2.6% in the medical/lifestyle group at 3 years; at 7 years the rate of remission was 18% in the metabolic surgery group and 6% in the medical/lifestyle group. Surgery produced improved health-related quality of life and health utility in individuals with type 2 diabetes and obesity compared with medical therapy up to 12 years after intervention. Anaemia, fractures and gastrointestinal adverse events were more common after metabolic surgery [238–240]. In a meta-analysis of seven studies in individuals with type 2 diabetes and BMI <35 kg/m² (*n*=544), metabolic surgery was more effective than non-surgical treatment in achieving diabetes remission (OR 25.06; 64% vs 2.8%) [241]. However, it is important to note that many of these estimates of benefit included data from non-randomised studies and compared outcomes with medical treatments for obesity that were less effective than those available today [242].

In individuals with a BMI <35 kg/m², those with younger age, short diabetes duration, higher levels of obesity, better glucose levels and better beta cell function were more likely to achieve diabetes remission after metabolic surgery [243]. Gastric bypass is superior to sleeve gastrectomy regarding long-term remission of type 2 diabetes, weight loss and cardiovascular risk factors, albeit at the expense of a higher frequency of symptomatic postprandial hypoglycaemia [244].

Reductions in CVD, CVD mortality and all-cause mortality among individuals with type 2 diabetes have been seen in observational and matched-cohort studies of metabolic surgery [245, 246]. Furthermore, metabolic surgery is also associated with a lower risk of nephropathy [245, 247] and retinopathy [245] vs treatment with GLP-1 RAs and can improve liver outcomes among individuals with biopsy-proven MASH [248, 249]. Metabolic surgery for people with type 2 diabetes and a BMI ≥30 kg/m² (or ≥27.5 kg/m² for Asian American individuals) [250] is recommended by The American Society for Metabolic and Bariatric Surgery [251], although the European Association for the Study of Obesity framework considers metabolic surgery in people with a BMI ≥35 kg/m² with an obesity-related disease or complication, or with BMI ≥30 kg/m² with poorly managed glucose levels despite optimal medical therapy [252].

Consensus recommendation

- Metabolic surgery could be considered for people with type 2 diabetes and a BMI ≥30 kg/m² (or ≥27.5 kg/m² for people of Asian ancestry) and should be considered for people with a BMI ≥35 kg/m² (or ≥32.5 kg/m² for people of Asian ancestry).

Skeletal muscle and body composition

Type 2 diabetes with obesity is often characterised by excess adiposity and low muscle mass/function and is referred to as sarcopenic obesity, a condition increasingly recognised for its clinical and functional features that negatively influence important person-centred outcomes [253–256].

Both obesity pharmacotherapy and metabolic surgery reduce body weight by lowering fat mass and fat-free mass. This has raised concern about the loss of fat-free mass (particularly skeletal muscle and bone) and its potential long-term consequences on strength, physical function, resting energy expenditure and longer-term risks of frailty, sarcopenia and sarcopenic obesity. Reported changes in lean mass vary: some studies show lean mass accounting for 40–60% of weight lost; while other studies report reductions closer to 15% [43, 101, 102, 257–259]. A recent meta-analysis in individuals living with type 2 diabetes reported a non-significant mean reduction in muscle mass measures with GLP-1-based therapies, despite reductions in fat mass [260]. In the SURPASS-3 MRI substudy, tirzepatide improved body weight and fat distribution, and was associated with favourable changes in muscle fat infiltration and reductions in muscle volume generally aligned with the expected changes relative to weight loss [256]. GLP-1-based therapy has also been linked to improvements in self-reported outcomes of physical function [261, 262].

Overall, MRI-based and clinical data suggest that skeletal muscle changes with GLP-1-based therapies are largely adaptive: reductions in muscle volume appear proportionate with ageing, disease status and the degree of weight loss achieved, while improvements in insulin sensitivity and muscle fat infiltration may enhance muscle quality, lowering the probability for loss in strength and function [256, 263].

Engagement in structured exercise before and after metabolic surgery can improve muscle strength [264, 265], reduce weight regain [266, 267], enhance insulin sensitivity [268] and improve body-composition outcomes [269]. Similarly, combining structured exercise with obesity pharmacotherapy appears to yield complementary effects, including improved glycaemic and inflammation profiles, reduced abdominal adiposity and more favourable body composition [47, 270–273].

Personalised approach to treatment based on individual characteristics and MLTCs: recommended process for glucose-lowering medication selection

Use of agents such as SGLT2 inhibitors and GLP-1-based therapies in the care of individuals with or at high risk for cardio-kidney complications is of proven benefit in improving outcomes. New evidence continues to support the care of at-risk individuals, independent of their need for additional glucose lowering [274–277]. For feasibility reasons, most trials have focused upon the effects of therapies in people with established CVD or kidney disease; however, people with type 2 diabetes are fundamentally at increased risk of such MLTCs compared with the general population [278]. This risk is not always appreciated early in the course of type 2 diabetes, a problem that is compounded by low rates of screening for complications such as kidney disease [279]. This provides a greater impetus for the use of beneficial agents from the time of diabetes diagnosis (Fig. 4).

People with cardio-kidney MLTCs

Established ASCVD

A recent meta-analysis of ten RCTs [169], including the most recent trials SOUL and FLOW, showed that the GLP-1 RA class reduces MACE by 14% in people with type 2 diabetes and CVD or at high cardiovascular risk. In SOUL, conducted in people with established ASCVD and/or CKD, oral semaglutide (14 mg) significantly reduced the primary outcome (a composite of cardiovascular death, non-fatal myocardial infarction or non-fatal stroke) by 14% compared with placebo [280]. A post hoc analysis showed that this benefit occurred regardless of concomitant SGLT2 inhibitor

use [281]. In people with type 2 diabetes and ASCVD, the dual GLP-1/GIP agonist tirzepatide was also found to be cardioprotective, as non-inferiority to dulaglutide with respect to a composite of death from cardiovascular causes, myocardial infarction, or stroke was demonstrated in the dedicated SURPASS-CVOT [165], together with superiority over an imputed placebo in an indirect prespecified exploratory comparison [166]. The protective effects of GLP-1 RAs on cardio-kidney outcomes may be dose-dependent [282, 283]. A meta-analysis demonstrates that the cardio-kidney benefits of GLP-1 RAs are consistent, regardless of SGLT2 inhibitor use [284].

The salutary effect of GLP-1 RAs on ASCVD appears to extend to PAD, as shown by STRIDE, in which semaglutide increased walking distance in people with symptomatic type 2 diabetes and PAD [285], and SOUL, in which MALE were reduced 29% by semaglutide [280]. GLP-1 RAs were associated with fewer PAD-related clinical events and a reduced need for revascularisation in three meta-analyses of RCTs [286–288].


Further evidence of the cardioprotective effects of glucose-lowering therapies has emerged from secondary analyses and evidence syntheses. In a post hoc analysis of CANVAS and CREDENCE, canagliflozin reduced MACE and other cardiovascular and kidney outcomes regardless of baseline PAD, with greater absolute benefits in those with PAD and without increasing the risk of MALE [147]. A meta-regression analysis suggested that SGLT2 inhibitor therapy was more effective in reducing three-point MACE in people with eGFR <60 ml/min per 1.73 m² and albuminuria than in those with normal kidney function, whereas age, sex, BMI, HbA_{1c} and pre-existing CVD or heart failure did not modify SGLT2 inhibitor efficacy [289].

For GLP-1 RAs, no differences were shown in MACE and mortality outcomes [290–292] in metformin users compared with non-users. Similarly, for SGLT2 inhibitors, no differences were observed in MACE, cardiovascular death or HHF, major kidney outcomes, or mortality rates in those using vs not using metformin [174]. These data support the use of GLP-1 RAs and SGLT2 inhibitors in individuals with compelling indications, independent of metformin use.

Regarding non-glucose-lowering therapies, a meta-analysis of 18 RCTs showed that both steroidal and non-steroidal MRAs significantly reduced MACE by 19%, cardiovascular mortality by 14% and HHF by 23% [293].

Heart failure

Dedicated heart failure outcome trials (DAPA-HF, DELIVER, EMPEROR-Reduced, EMPEROR-Preserved and SOLOIST-WHF) support a consistent class benefit of



SGLT2 inhibitors on heart failure outcomes, including cardiovascular death, HHF or urgent hospital visits for heart failure, across left ventricular ejection fraction ranges [294]. Updated meta-analyses confirm that SGLT2 inhibitors reduce heart failure events and cardiovascular death in cohorts with varying combinations of heart failure, type 2 diabetes and CKD [295, 296], and in people with type 2 diabetes aged >65 years or with frailty [297]. A meta-analysis of DAPA-HF and DELIVER suggests that dapagliflozin may lead to larger risk reductions in cardiovascular death and HHF in people with type 2 diabetes and heart failure who have concomitant neuropathy than in those who have not [298].

Recent evidence is refining the role of GLP-1-based therapies in HFpEF, particularly in people with type 2 diabetes and/or obesity. In STEP-HFpEF DM, semaglutide 2.4 mg improved heart failure health status and exercise capacity in people with type 2 diabetes, obesity and HFpEF [151]. A prespecified pooled individual-participant data analysis of STEP-HFpEF and STEP-HFpEF DM showed consistent benefits across key subgroups [299]. Beyond symptoms and function, analyses suggest potential reductions in clinical heart failure events with semaglutide in higher-risk settings: in a secondary analysis of FLOW in people with type 2 diabetes and CKD, semaglutide reduced heart failure events or cardiovascular death, with effects independent of prior heart failure history [300]; a pooled analysis showed that semaglutide reduced the composite of cardiovascular death and worsening heart failure in HFpEF, driven mainly by fewer worsening heart failure events rather than cardiovascular death [301]. Similarly, in a subgroup analysis of SUMMIT, tirzepatide reduced time to first cardiovascular death or worsening heart failure event and improved KCCQ-CSS, with similar effects in individuals with HFpEF but without type 2 diabetes [302]. However, not all GLP-1 RA data are positive for heart failure outcomes: in a post hoc analysis from REWIND, dulaglutide was not associated with a reduction in heart failure events [303]. A systematic review/meta-analysis focusing on people with type 2 diabetes without pre-existing heart failure suggested that GLP-1 RAs may decrease the risk of new-onset heart failure independent of HbA_{1c} or weight reduction but correlated with protective effects on MACE, as heart failure prevention effects were more pronounced in studies restricted to people with ASCVD [304].

Recent analyses clarify the cardio-kidney profile of finerenone across heart failure and CKD phenotypes. In FINEARTS-HF, conducted in people with heart failure and mildly reduced or preserved ejection fraction (46.2% with diabetes at baseline), finerenone resulted in a significantly lower rate of a composite of total worsening heart failure events and cardiovascular death when compared with placebo [305]; these effects were not modified by glycaemic status [306]. Furthermore, in a prespecified participant-level pooled analysis integrating FIDELIO-DKD, FIGARO-DKD and FINEARTS-HF,

finerenone reduced HHF and improved a broad range of outcomes, including cardiovascular events, kidney outcomes and all-cause mortality [307]. A prespecified analysis from FIDELIO-DKD also demonstrated that finerenone improved cardio-kidney outcomes in people with type 2 diabetes and CKD regardless of prior heart failure [308].

Consensus recommendations

- Both SGLT2 inhibitors and GLP-1-based therapy confer cardiovascular benefits independent of metformin and should be first-line therapeutic considerations.
- In people with established CVD, GLP-1-based therapies with proven benefit should be used to reduce MACE and all-cause mortality, or an SGLT2 inhibitor with proven benefit should be used to reduce MACE, heart failure and all-cause mortality and to improve kidney outcomes.
- As benefits may be additive, combination therapy with SGLT2 inhibitors and GLP-1-based therapy could be considered in those at high risk for CVD or with established CVD or kidney disease irrespective of HbA_{1c} levels.
- In people with PAD, semaglutide can be used to improve symptoms.
- In individuals without established CVD but with multiple cardiovascular risk factors (e.g. age ≥ 55 years, obesity, hypertension, smoking, dyslipidaemia or albuminuria) a GLP-1-based therapy with proven benefit could be used to reduce MACE and improve kidney outcomes, or an SGLT2 inhibitor with proven benefit could be used to reduce MACE and heart failure and improve kidney outcomes. The level of certainty in this recommendation is lower for this subgroup, because some CVOTs recruited exclusively people with established CVD, and fewer events were recorded among those with cardiovascular risk factors only in trials that enrolled both subgroups. In addition, definitions of risk factors were not identical across CVOTs, but generally comprised age ≥ 55 years plus two or more additional risk factors, including obesity, hypertension, smoking, dyslipidaemia or albuminuria. Furthermore, in terms of absolute effects, cardiovascular benefits of GLP-1 RAs and SGLT2 inhibitors were less pronounced in people with three or more cardiovascular risk factors than in those with established CVD [309].
- In people with heart failure (with or without reduced ejection fraction), SGLT2 inhibitors should be used to improve heart failure and kidney outcomes.
- In people with obesity and HFpEF, semaglutide or tirzepatide should be used to improve heart failure symptoms.
- In people with HFpEF or heart failure with mildly reduced ejection fraction, a non-steroidal MRA with proven benefit should be used to improve heart failure and mortality.

- To reduce progression of CKD and CVD in type 2 diabetes with albuminuria, addition of a non-steroidal MRA with proven benefit is recommended when eGFR >25 ml/min per 1.73 m².

Atrial arrhythmias

Growing evidence suggests that GLP-1-based therapies and SGLT2 inhibitors may confer clinical benefits on atrial arrhythmias, particularly atrial fibrillation, in people with type 2 diabetes and related cardiometabolic disease. Across randomised and observational evidence, GLP-1 RAs appear to be associated with a lower risk of atrial arrhythmias, effects that may be more pronounced in higher-risk subgroups such as individuals with type 2 diabetes and prior myocardial infarction [310]. In a secondary analysis of STEP-HFpEF and STEP-HFpEF DM, semaglutide improved heart failure-related symptoms regardless of the presence of atrial fibrillation and across atrial fibrillation subtypes [311]. A systematic review/meta-analysis of 30 RCTs reported that semaglutide was associated with a 27% reduction in atrial fibrillation risk and a 78% reduction in complete atrioventricular block in people with type 2 diabetes [312]. Real-world evidence also suggests benefit with tirzepatide [313].

In parallel, evidence syntheses support anti-arrhythmic benefits with SGLT2 inhibitors. In people with diabetes undergoing catheter ablation, SGLT2 inhibitors were associated with a significant reduction in atrial fibrillation recurrence [314, 315]. Evidence combining RCTs and observational studies indicates that SGLT2 inhibitors reduce the risk of new-onset atrial fibrillation in people with type 2 diabetes when compared with GLP-1 RAs, DPP-4 inhibitors and placebo [316–318].

Consensus recommendation

- In people at high risk for atrial arrhythmias, semaglutide or SGLT2 inhibitors with proven benefit could be considered to reduce atrial fibrillation incidence.

CKD

Lifestyle and multiple glucose-lowering and cardio-kidney-protective drug classes have been evaluated for prevention or slowing of CKD in type 2 diabetes. In older adults with type 2 diabetes (aged ≥60 years), an intensive lifestyle intervention in Look AHEAD was associated with reduced kidney disease progression [319]. Consistent with the importance of durable weight and metabolic improvement, in a systematic review/meta-analysis of 25 RCTs, bariatric surgery was associated with lower odds of kidney complications [320].

A large body of evidence supports the use of SGLT2 inhibitors as foundational kidney-protective therapy across

CKD risk strata. A systematic review/meta-analysis reported that SGLT2 inhibitors are consistently beneficial for eGFR slope improvement and composite kidney outcomes, regardless of CKD at baseline [321]. Network meta-analyses and comparative evidence suggest that SGLT2 inhibitors provide the largest combined kidney/cardiovascular risk reductions in type 2 diabetes with CKD, followed by GLP-1 RAs and MRAs [322], and may be particularly well suited to complement metabolic management in preventing progression of kidney composite outcomes compared with GLP-1 RAs and finerenone [323]. Additional evidence suggests that SGLT2 inhibitors significantly reduce AKI risk in people with CKD, CVD and type 2 diabetes, with greater efficacy in those with higher baseline eGFR [324], and provide consistent kidney benefits across MLTCs [325]. Post hoc analyses from CVOTs suggest SGLT2 inhibitor kidney benefit across CKD phenotypes and background therapies and across type 2 diabetes subgroups, including those with non-albuminuric CKD [326]. DECLARE–TIMI 58 post hoc analyses showed that dapagliflozin mitigated kidney function decline in individuals with type 2 diabetes at high cardiovascular risk, including in those at low KDIGO risk [327]. A post hoc analysis suggested that SGLT2 inhibitor effects on kidney composite outcomes did not differ by baseline use of RAAS inhibitors, diuretics (including loop diuretics) or MRAs [328].

Multiple levels of evidence support kidney-relevant benefits of GLP-1-based therapies, particularly in higher-risk CKD. In FLOW, conducted in people with type 2 diabetes and albuminuric CKD, semaglutide 1 mg reduced the risk of adverse kidney outcomes by 24% and cardiovascular death by 29% vs placebo [329]. Post hoc analyses of FLOW also indicated that semaglutide reduced MACE across KDIGO categories [330]. Across post hoc analyses from PIONEER and SUSTAIN-6, semaglutide improved eGFR slope and reduced a composite kidney outcome irrespective of baseline UACR strata and across KDIGO categories, alongside reduced risk of developing CKD and reduced MACE [274, 331, 332]. A systematic review/meta-analysis reported that semaglutide reduced major kidney-related adverse events [333]. In the SOUL trial in participants with type 2 diabetes and ASCVD and/or CKD but mostly preserved eGFR, oral semaglutide slowed eGFR decline vs placebo although it did not significantly reduce adverse kidney outcomes [334]. In a post hoc analysis of REWIND, dulaglutide reduced the hazard of a kidney function-related outcome compared with placebo [335]. In SURPASS–CVOT, tirzepatide was non-inferior to dulaglutide with respect to change in eGFR over time [165]. A prespecified exploratory analysis of SURPASS–CVOT also showed that tirzepatide was associated with a reduced risk of major kidney events, compared with dulaglutide, primarily driven by a reduction in new-onset macroalbuminuria in people with low-to-moderate

risk of CKD and slowed decline in kidney function in people at high risk of CKD [336]. Overall, evidence syntheses show that GLP-1 RAs reduce a composite kidney outcome by ~17–24% [169, 337, 338]. In a retrospective cohort study of kidney transplant recipients with type 2 diabetes, GLP-1 RA use was associated with better graft and patient survival [339]. The salutary effects of GLP-1 RAs on kidney outcomes may be additive to those of SGLT2 inhibitors and MRAs, as benefits occur regardless of background SGLT2 inhibitor or MRA use [284, 340, 341].

In people with type 2 diabetes and CKD, finerenone has demonstrated broad kidney benefits across kidney risk strata. In the FIDELITY prespecified analysis of two phase III trials, finerenone reduced a CKD-associated composite outcome, as well as cardiovascular events and first and recurrent heart failure events [230]. Cardiovascular and heart failure benefits were observed consistently across eGFR and/or UACR categories [342, 343]. Additional FIDELITY post hoc analyses reported reductions in all-cause, sudden and cardiovascular death across a broad range of CKD stages [344]. Cardio-kidney benefits of finerenone were observed irrespective of background SGLT2 inhibitor use [345]; a mediation analysis suggested that early albuminuria reduction predicted kidney benefit more strongly than cardiovascular benefit [346].

Combination approaches are also emerging in type 2 diabetes with CKD. In CONFIDENCE, initial combination therapy with finerenone plus empagliflozin led to a greater reduction in UACR than either therapy alone [347]. Trial-level estimates integrating data from CREDENCE and FIDELIO suggest that combining an SGLT2 inhibitor with an MRA may substantially increase years free from kidney failure and mortality [348].

Emerging RCT and real-world evidence suggests that benefits are generally maintained when SGLT2 inhibitors, GLP-1-based therapies or finerenone are combined [225, 284, 345, 347, 349].

Consensus recommendations

- In people with CKD, an SGLT2 inhibitor with proven benefit should be initiated to improve kidney and heart failure outcomes and reduce MACE and should be continued until kidney replacement therapy is indicated, regardless of UACR or albuminuria.
- In people with CKD, GLP-1-based therapy with proven benefit should be initiated to improve kidney and heart failure outcomes and reduce MACE. Semaglutide is indicated to reduce the risk of CKD progression.
- In people with CKD and UACR >3.0 mg/mmol (>30 mg/g), a non-steroidal MRA with proven benefit should be used to improve kidney and heart failure outcomes.

- SGLT2 inhibitors should form the foundation for heart failure/CKD protection; GLP-1-based therapies could be added for incremental MACE and kidney benefit plus weight/metabolic management and finerenone could be added, particularly in albuminuric CKD to further reduce cardio-kidney events.
- Early combination therapy should be considered in people with concomitant CVD, CKD and heart failure.
- Choice among individual SGLT2 inhibitors and GLP-1-based therapy should be based on country-specific indications and evidence on efficacy, safety and outcome benefits, considering within-class heterogeneity.

Cardio-kidney benefits of GLP-1-based therapies and SGLT2 inhibitors in lower-risk populations

In lower-risk populations with type 2 diabetes (e.g. preserved kidney function, low levels of albuminuria and no established heart failure/ASCVD), the cardio-kidney benefits of GLP-1-based therapies and SGLT2 inhibitors should be interpreted primarily through the distinction between relative and absolute treatment effects. While meta-analyses support consistent RR reductions for major outcomes, the absolute risk reduction over typical trial follow-up is often modest when baseline event rates are low. Conversely, as baseline cardio-kidney risk increases (e.g. albuminuric CKD, reduced eGFR, established ASCVD or MLTCs), similar RR reductions translate into larger absolute risk reductions and more favourable numbers needed to treat, supporting earlier prioritisation and layering of therapies. Evidence syntheses suggest that the absolute benefit of SGLT2 inhibitors on MACE reduction increases with baseline cardio-kidney risk [309]. In high-risk CKD, dedicated outcome trials further illustrate clinically meaningful absolute benefits, such as FLOW, in which semaglutide reduced kidney outcomes and cardiovascular death [329]. In a UK primary care study in type 2 diabetes (in individuals with eGFR ≥ 60 ml/min per 1.73 m², UACR <30 mg/mmol (<265 mg/g), without heart failure/ASCVD), a risk model combining baseline CKD with real-world-confirmed SGLT2 inhibitor effect (HR 0.58) estimated individual 3 year absolute kidney-protection benefit and could prevent >10% more progression events by identifying a subgroup with greater absolute benefit [350].

Consensus recommendation

- Treatment decisions should be individualised based on baseline absolute cardio-kidney risk and time horizon, as absolute benefit is substantially greater in people at higher cardio-kidney risk.

Additional clinical considerations

Age: younger people with diabetes

Incidence and prevalence of type 2 diabetes have increased significantly in concert with obesity among the adolescent and young adult population, with minority populations disproportionately affected [351, 352]. A younger age at type 2 diabetes diagnosis has consistently been associated with a higher body weight [353] and affected young people have a more rapid deterioration in blood glucose levels, an attenuated response to diabetes medication, more rapid development of diabetes complications and greater loss of life-years [354, 355]. Early disease onset, higher levels of hyperglycaemia and the multiple cardiometabolic risk factors found in younger adults with impaired glucose tolerance all contribute to an increase in risk of adverse outcomes [356]. Most adolescents who develop type 2 diabetes will have microvascular complications by young adulthood [357]. In addition, the UKPDS has found that individuals with type 2 diabetes onset before age 40 years (often referred to as early-onset type 2 diabetes) have greater risks of complications, poorer glucose levels and excess mortality [26].

Most of the evidence for health behaviour interventions, glucose-lowering approaches and the efficacy of medications to improve cardiovascular and kidney outcomes in younger people with diabetes is poorly understood due to limited enrolment of this group in trials [358]. Meta-analyses and individual trials suggest that SGLT2 inhibitors and GLP-1 RAs can be used to lower HbA_{1c} in young people with type 2 diabetes, with safety similar to that seen in older adults [359–365]. The dual GLP-1/GIP agonist tirzepatide has also been found to significantly improve both HbA_{1c} and BMI in youth with inadequately controlled type 2 diabetes [366]. Early use of combination therapy may be considered, as the Vildagliptin Efficacy in Combination with Metformin for Early Treatment of T2D (VERIFY) trial and other analyses suggest that this approach provides superior and more durable effects on blood glucose levels than monotherapy in people with early-onset diabetes and those with later-onset diabetes [367, 368]. Both dulaglutide and empagliflozin have also been found to attenuate hyperfiltration and either proteinuria or albuminuria in youth with type 2 diabetes [369, 370]; however, the durability of drug effects and any impact on clinically important cardio-kidney and other outcomes with use of any glucose-lowering medication in children and young adults remain unknown [371]. Interventions targeting weight reduction in those living with overweight and obesity are essential in this group, as they are likely to not only reverse the aetiological processes of type 2 diabetes but also reduce the risk of obesity-associated complications.

Consensus recommendations

- Interventions targeting weight reduction are essential in people living with early-onset type 2 diabetes to reduce the risk of future complications.
- Early-onset type 2 diabetes is associated with faster glycaemic deterioration and earlier onset of complications, thus early deployment of SGLT2 inhibitors and GLP-1-based therapies, either alone or in combination, should be prioritised.
- Earlier use of GLP-1-based therapy or SGLT2 inhibitors must be accompanied by explicit counselling in women of reproductive potential regarding contraception and avoidance of exposure to medications that are currently not approved for use during pregnancy and could adversely affect a fetus (see [Sex differences](#), below).

Age: older people with diabetes

Informed decisions regarding treatment of older adults (aged >65 years) with diabetes are limited by the historical underrepresentation of this group in clinical trials. Underlying pathophysiology and functional status are generally more important considerations in prescribing than age. Meta-analyses of data from large outcomes trials have found that the reductions in mortality and overall burden of cardiovascular events conveyed by SGLT2 inhibitors and GLP-1 RAs are generally consistent across age groups [289, 372], even though the glycaemic and weight loss effects of treatment may be attenuated in older age [373–375]. One systematic review and network meta-analysis has suggested some heterogeneity in the cardioprotective effects of SGLT2 inhibitors and GLP-1 RAs by age; however, such conclusions are limited by the absence of comparative trials [373]. A pooled analysis of data from two large outcomes trials found that the safety and beneficial effects of finerenone on cardiovascular and kidney outcomes in people with type 2 diabetes and CKD were not modified by age [376]. Older age should not be an obstacle to treatment of individuals with established, or at high risk for, ASCVD, heart failure or CKD. Because older adults often are at higher risk for cardiovascular and kidney events, they may derive greater benefits from the protective effects of these therapies [377].

The side effect and safety profiles of SGLT2 inhibitors and GLP-1-based therapies appear generally consistent across age groups, with a lower risk of hypoglycaemia compared with sulfonylurea treatment [377]. However, some meta-analyses and analyses of real-world evidence have suggested that older adults may be at increased risk for AKI, DKA and genital mycotic infections with SGLT2 inhibitor therapy and at higher risk for nausea and vomiting

with GLP-1-based therapy [146, 378]. People with diabetes should understand and be able to appropriately modify use of their prescribed medications during times of illness.

Consensus recommendations

- In general, the selection of medications to improve cardiovascular and kidney outcomes should not differ for older people with diabetes.
- Medication choices for people who are older or frail, or who have MLTCs, may require modification for safety and tolerability.

Frailty

Importantly, not all older adults with diabetes are frail, and frailty may occur at younger ages. Frailty is a clinical syndrome characterised by decreased physiological reserve and resistance to stressors across multiple organ systems. Type 2 diabetes represents a model of accelerated biological ageing, associated with declines in physical capacity, underpinned by dysfunction within skeletal muscle. The ability of people with type 2 diabetes to undertake activities of daily living and physical functioning in middle age has been shown to be similar to the ability of those at least a decade older within the general population [379].

Individuals with frailty are at increased risk for adverse outcomes (e.g. trials such as Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation [ADVANCE] suggested that more frail individuals have worse outcomes and benefit less from intensive control of blood glucose levels and BP [380]). De-prescribing medication to avoid unnecessary medication or medications associated with harm, such as hypoglycaemia and hypotension, may be important. Analyses of more recent trials of SGLT2 inhibitors and GLP-1-based therapies confirm that greater frailty is associated with poorer outcomes, including higher rates of both medication side effects and cardiovascular and kidney outcome events. However, few such trial participants had severe frailty, and frailty status is often not well captured [381, 382]. Where available, though, the data are reassuring. Analyses of CANVAS and CREDENCE data found consistent reductions in total and cardiovascular mortality and MACE with canagliflozin therapy in both frail and non-frail subgroups [383], and a meta-analysis of trials assessing outcomes in frail or older people (age ≥ 65 years) with type 2 diabetes and heart failure found significant reductions in the risk of all-cause and cardiovascular mortality and HHF with SGLT2 inhibitor treatment compared with placebo [297]. The effects of finerenone on kidney and cardiovascular outcomes appear consistent across frailty categories [382].

Race and ethnicity

Although trial participants from minority ethnicity groups may have higher rates of cardiovascular and other MLTCs than White cohorts, they traditionally comprise small proportions of overall enrolled trial populations [384]. While some analyses are limited by small numbers of participants from ethnic minority groups, thus far the large outcomes trials of SGLT2 inhibitors, GLP-1-based therapies and finerenone have demonstrated beneficial effects and similar safety profiles in enrolled participants, irrespective of ethnicity [385–389]. The increased burden of complications in under-represented populations with diabetes should be factored into personalised treatment plans, and beneficial medications should be used irrespective of race or ethnicity. Ongoing and future trials should recruit to be representative of the overall population of people with diabetes so that the effects of interventions in understudied subgroups may be better ascertained [390, 391].

Consensus recommendation

- Selection of medications to improve cardiovascular and kidney outcomes should not differ by race or ethnicity. However, race and ethnicity may intersect with genetic ancestry, SDOH, access to care and differential burden of cardiovascular, kidney and other MLTCs. These factors should be considered within individualised risk assessment and may support earlier initiation, intensification of therapy, use of more-advanced treatment strategies, or more ambitious treatment goals in populations or individuals at higher risk.

Sex differences

In women with reproductive potential, the use of highly effective contraception should be ensured, such as long-acting reversible contraception (intrauterine device or progesterone implant), prior to prescribing medications that may adversely affect a fetus. Diabetes significantly increases the risk of cardiovascular complications in both sexes, and CVD causes most hospitalisations and deaths in women and men with diabetes [392, 393]. In the general population, premenopausal women are at lower risk for cardiovascular events than men of the same age; however, this vascular protection or advantage is reduced in women who develop type 2 diabetes [394, 395]. In fact, the increase in RR of CVD due to type 2 diabetes is greater in women than in men [396–398]. Despite this, women have been under-represented in recent outcomes trials in diabetes, generally comprising about one-third of participants [373]. Women tend to have differing patterns of cardiovascular complications compared with men, and consistently poorer management of cardiovascular

risk factors [399, 400]. Within-trial analyses and meta-analyses suggest no significant heterogeneity by sex in the effects of SGLT2 inhibitors, GLP-1-based therapies and finerenone on cardiovascular and kidney outcomes [289, 373, 400–402]. Continued efforts should be made to enrol women in outcomes trials and to identify and address modifiable cardiovascular risk factors in women with diabetes.

Consensus recommendation

- Selection of medications to improve cardiovascular and kidney outcomes should not differ by sex. However, it is important to counsel women of reproductive potential regarding contraception and avoidance of exposure to medications that are currently not approved for use during pregnancy and may adversely affect a fetus.

People with obesity-related conditions

MASLD and MASH

MASLD is a disease spectrum defined by the presence of hepatic steatosis together with at least one cardiometabolic risk factor, after exclusion of significant alcohol intake and other secondary causes. It affects more than 70% of individuals with type 2 diabetes, among whom more than half develop MASH, the progressive inflammatory form characterised histologically by steatosis with lobular inflammation and hepatocellular injury, with or without fibrosis. Fibrosis, particularly stages $\geq$ F2, determines prognosis and is strongly associated with increased liver-related, cardiovascular and all-cause mortality, and CKD [403, 404].

Management of MASLD and MASH in people with type 2 diabetes requires an integrated strategy addressing metabolic control, cardiovascular and kidney risk reduction, and liver-specific outcomes. Although MASLD can occur in lean individuals, overweight and obesity substantially exacerbate steatohepatitis and fibrosis risk. Weight reduction is therefore a primary therapeutic target: a loss of at least 5% of body weight improves hepatic steatosis, while reductions of $\geq$ 7–10% are associated with resolution of MASH and regression of fibrosis, albeit with marked interindividual variability [405]. Dietary interventions should aim to create a sustained energy deficit and are broadly aligned with recommendations for diabetes and obesity [403]. Among dietary patterns, the Mediterranean diet has strong evidence for combined hepatic and cardiometabolic benefit [406]. Regular physical activity is an essential adjunct, improving liver fat, aminotransferases and insulin sensitivity, partly independent of weight loss. Both

aerobic and resistance exercise are effective, tailored to individual capacity and preferences [407–409].

In type 2 diabetes, pharmacological management of MASLD and MASH should be embedded within a comprehensive cardiometabolic strategy that prioritises early intervention, given the high prevalence of at-risk disease and the absence of effective therapies once cirrhosis is established. Optimisation of glucose-lowering and weight management therapies offers a dual opportunity to address diabetes and obesity while modifying the natural history of liver disease. Semaglutide has the most robust data and is currently the only glucose-lowering or obesity medication approved for non-cirrhotic MASH with moderate or advanced fibrosis. In the 72 weeks phase III ESSENCE trial that included 320 people with biopsy-proven MASH and stage 2 or 3 fibrosis, 56% of whom had type 2 diabetes, semaglutide achieved both resolution of steatohepatitis without fibrosis worsening and improvement in fibrosis without worsening of MASH [152]. Mediation analyses suggest that its histological benefits are only partly explained by weight loss [410]. However, semaglutide has not demonstrated histological efficacy in compensated MASH-related cirrhosis [411], underscoring the importance of treatment before cirrhosis develops. Other GLP-1-based therapies have more limited histological data; liraglutide demonstrated resolution of steatohepatitis and reduced fibrosis progression in the LEAN study [412], while dulaglutide and exenatide have shown solely reductions in liver fat on MRI-based endpoints in small, short-term RCTs [413, 414]. In the SYNERGY-NASH trial, a phase II, 52 week, paired-biopsy trial in people with biopsy-confirmed MASH with F2–F3 fibrosis, 58% of whom had type 2 diabetes, tirzepatide achieved high rates of MASH resolution without fibrosis worsening and greater fibrosis improvement compared with placebo [415]. These data support preferential use of GLP-1-based therapies, particularly semaglutide or tirzepatide, for glycaemic management in individuals with type 2 diabetes and biopsy-proven MASH or high fibrosis risk, especially given the established cardiovascular benefits of this therapy. Pioglitazone remains an important therapeutic option, with multiple randomised trials [196, 416] and meta-analyses [417, 418] demonstrating improvement in steatohepatitis and a possible, albeit modest, effect on fibrosis, its benefits being consistent across histological and non-invasive endpoints [419–421]. Pioglitazone improves insulin sensitivity and lipid metabolism, which are key drivers of MASH pathophysiology. Nevertheless its clinical use is limited by dose-dependent weight gain, fluid retention and fracture risk, and caution is warranted in individuals with heart failure. Importantly, weight gain can be mitigated or reversed when pioglitazone is combined with a GLP-1 RA or an SGLT2 inhibitor, making

combination therapy an attractive strategy in selected individuals [422–424], although confirmatory phase III trials with histological endpoints are still lacking.

SGLT2 inhibitors consistently reduce hepatic steatosis and improve non-invasive fibrosis markers [425–427]. Histological evidence remains limited, although a recent trial with dapagliflozin reported modest improvements in MASH resolution and fibrosis endpoints among people with biopsy-proven MASH (including people with type 2 diabetes) in China [428]. Hence, SGLT2 inhibitors should therefore be continued for their glycaemic, cardiovascular and kidney benefits but not selected primarily for liver disease modification. Other glucose-lowering agents generally lack evidence for histological benefit [429].

Beyond glucose-lowering therapies, resmetirom represents a major advance as the first agent approved specifically for non-cirrhotic MASH with moderate to advanced fibrosis. As a thyroid hormone receptor β -agonist, it improves hepatic fat metabolism and fibrosis without affecting body weight or glycaemic management. Resmetirom was reported to significantly increase MASH resolution and fibrosis improvement compared with placebo, with effects independent of background GLP-1 RA or SGLT2 inhibitor therapy [430]. Gastrointestinal adverse effects are common but generally manageable, while changes in thyroid hormone parameters warrant monitoring. Patient and selection complexity and monitoring requirements suggest that initiation of resmetirom should occur within specialist care.

Finally, for individuals with decompensated cirrhosis, insulin remains the preferred therapy for glycaemic management, given the limited safety data for most oral and injectable agents, whereas GLP-1-based therapies appear safe in compensated cirrhosis but lack proven efficacy [411].

Consensus recommendations

- For people with diabetes and MASLD, weight reduction should be a primary therapeutic target, and lifestyle modification is foundational. Physical activity should be encouraged.
- For people with obesity, type 2 diabetes and MASLD, a GLP-1-based therapy with proven benefit should be used.
- For people with diabetes and biopsy-proven MASH, a GLP-1-based therapy with proven benefit should be preferred. Pioglitazone or tirzepatide could also be used.
- Combination regimens with pioglitazone and GLP-1-based therapy should be considered for enhanced effect, while treatment with other glucose-lowering agents can be continued as indicated.
- Specifically for people with decompensated cirrhosis, insulin is the preferred agent. For individuals with moderate (stage F2) or advanced (stage F3) liver fibrosis, referral

to a hepatologist should be coordinated to consider treatment with a thyroid hormone receptor β -agonist.

Obstructive sleep apnoea

OSA is highly prevalent in people with type 2 diabetes, particularly in the presence of obesity. Continuous positive airway pressure (CPAP) remains the standard of care. Weight loss is an effective means for improving or resolving OSA, whether by lifestyle efforts, surgery or medications. Pharmacological therapy should be viewed as complementary to established OSA treatments. Weight-reducing glucose-lowering agents are of particular interest given the strong pathophysiological link between adiposity and OSA.

Among GLP-1-based therapies, tirzepatide has demonstrated the most pronounced effects on OSA severity. In the SURMOUNT-OSA trials in adults with obesity and moderate-to-severe OSA without diabetes, weekly tirzepatide reduced the apnoea–hypopnoea index (AHI) by approximately 20–24 events per hour, and improved sleep-related person-reported outcomes over 52 weeks [163]. GLP-1 RAs also reduce OSA severity, though with more modest effects. In individuals with obesity without diabetes [431] and people with type 2 diabetes and severe OSA treated with CPAP [432], liraglutide improved AHI, a finding also verified in a relevant meta-analysis, with larger reductions observed with tirzepatide than with a GLP-1 RA [433].

SGLT2 inhibitors may also confer benefit in selected populations. In a randomised trial in people with heart failure and OSA (including individuals with type 2 diabetes), dapagliflozin reduced AHI, oxygen desaturation index and hypoxic time over 3 months [434]. CVOT subgroup exploratory analyses further suggest reduced incident OSA with empagliflozin and ertugliflozin in people with type 2 diabetes [435, 436].

Consensus recommendations

- For people with obesity, type 2 diabetes and OSA, tirzepatide or a GLP-1 RA with proven benefit could be prioritised.

Osteoarthritis

In people with diabetes complicated by obesity and symptomatic knee osteoarthritis, selection of glucose-lowering therapy could prioritise agents that promote weight reduction. A recent 6 month randomised trial in 107 adults with overweight or obesity without diabetes demonstrated that metformin 2000 mg daily improved WOMAC pain, stiffness and function [437], broadly consistent with the findings of a small network meta-analysis [438]. In contrast, liraglutide

3.0 mg daily did not improve knee-specific outcomes over 52 weeks despite weight loss [439], whereas semaglutide 2.4 mg weekly significantly improved pain and physical function in the STEP 9 trial [440]. Importantly, all these studies excluded individuals with diabetes.

Cognitive decline

Diabetes is associated with an increased risk of dementia, yet data from comparative effectiveness trials have not demonstrated consistent differences in cognitive outcomes across glucose-lowering drug classes [441]. Recent meta-analyses suggest a possible reduction in cognitive impairment with GLP-1-based therapy, whereas SGLT2 inhibitors and pioglitazone appear neutral [442], although effect sizes are modest and not uniformly replicated [443]. Emerging signals from small RCTs in Alzheimer's disease populations without diabetes, including studies of liraglutide and other incretin-based therapies, suggest potential neurobiological effects [444]; however, larger phase III trials have not shown clinical benefit [445]. Accordingly, current practice should align with current standards of care: simplify regimens, individualise glycaemic targets and minimise hypoglycaemia, while encouraging exercise, which has demonstrated moderate cognitive benefit in people with diabetes [446, 447].

Consensus recommendation

- There is not yet evidence to support preferred use of any glucose-lowering agents on cognitive outcomes. Hence, selection of glucose-lowering therapy for individuals with cognitive impairment should prioritise safety and simplicity.

Putting it all together: strategies for implementation

General approach to person-centred care

The overall goal of the management of type 2 diabetes is to maintain or improve quality of life and avoid (acute and chronic) complications. Glucose management, weight and cardiovascular risk factor management and early use of organ-protective therapies are integral aspects of the holistic approach to achieve these goals.

The individual living with type 2 diabetes should be at the centre of integrated care, and the management approach should account for the life-long nature of type 2 diabetes (Fig. 1). The integrated care of people living with type 2 diabetes must consider the individual's specific preferences and values, SDOH, barriers to care, MLTCs, degree

of hyperglycaemia, risks of complications and susceptibility to medication side effects. SDOH must be assessed and addressed [14] to help achieve health equity. Recognition of the presence of MLTCs in type 2 diabetes is paramount [13]. For example, type 2 diabetes is associated with an increased risk of cognitive impairment and dementia; this relationship is complicated and includes the contribution of both long-term hyperglycaemia and hypoglycaemia [448]. Clinicians should be aware of the co-existence of type 2 diabetes with conditions such as dementia and mental health issues and refer when appropriate. The prevalence of mental health issues such as depression, diabetes distress, stigma and disordered eating is high in people living with type 2 diabetes, particularly in those with early-onset type 2 diabetes [449], which has a detrimental effect on diabetes self-management and outcomes [450]. Early identification through routine screening and appropriate treatment through DSMES, behavioural interventions and person-centred care are essential to alleviating the rising burden of mental health issues in people with type 2 diabetes.

Communication between people living with type 2 diabetes and healthcare team members is at the core of integrated care, and clinicians must recognise the importance of language in diabetes care: it should be neutral, free of stigma and based on facts; it must be strength-based (focus on what is working), respectful and inclusive; it must encourage collaboration; and it must be person-centred [451, 452].

Much of the management of type 2 diabetes (e.g. self-management, health behaviours, pharmacotherapy, etc.) is goal-based, making it important to incorporate 'SMART' (specific, measurable, achievable, realistic, time-limited) goals to achieve improvements in care [2, 3]. These goals need to be agreed in partnership with the person living with type 2 diabetes and revisited regularly.

Consensus recommendations

- Type 2 diabetes care should be integrated, with the person living with type 2 diabetes at the centre.
- Care teams should identify and address the MLTCs present in people living with type 2 diabetes as part of integrated diabetes care, including those relating to mental health.
- Effective communication between all team members and the person living with type 2 diabetes should be maintained throughout care delivery.
- Goals of treatment should be specific, measurable, attainable, relevant, time-based, and identified collaboratively, and be agreed upon and revisited regularly with the person living with type 2 diabetes.
- Developing weight targets (achieved by any means) are as essential in diabetes management as glycaemic targets.

Health behaviours

Facilitating healthy behaviours is central to the comprehensive management of type 2 diabetes and should begin at diagnosis and continue throughout the life course. Core health behaviours include weight loss, the 24 h physical behaviours (the five Ss: standing; stepping; sweating; strengthening; and sleep) and smoking cessation (Figs 2, 3). These behaviours should be assessed routinely, particularly when glycaemic targets are not met or when initiating new pharmacological therapies or interventions such as metabolic surgery. Addressing health behaviours is foundational, not adjunctive, to effective type 2 diabetes care.

The five Ss underscore how to incorporate 24 h physical behaviours into type 2 diabetes care. Gradual increases in activity volume and intensity generally do not require medical clearance, though additional assessment may be warranted for individuals with advanced microvascular complications, unstable heart failure, insulin use or a history of hypoglycaemia. Activity plans should be individualised based on preferences, functional status and motivation. Special attention needs to be paid to increasing/maintaining muscle mass and strength in those at risk of sarcopenia, particularly in those treated with weight-loss interventions. Resistance exercise is important in this context.

All individuals with type 2 diabetes should be offered MNT [49] to develop a personalised eating plan, focused on diet quality, eating patterns and energy restriction, that reflects individual preferences, cultural context and clinical goals. There is no single dietary pattern appropriate for all people living with type 2 diabetes; multiple dietary approaches, particularly the Mediterranean diet and low-carbohydrate diet, and potentially ketogenic diet and intermittent fasting strategies, can be effective when they are structured, sustainable and aligned with the individual's circumstances. The need for ongoing or additional dietary counselling should be reassessed over time as clinical status and treatment goals evolve. The rapid uptake of GLP-1-based therapies and their major impact on weight has highlighted the importance of inclusion of integrated dietitian-led care in the treatment paradigm to safeguard the quality of food intake (e.g. protein) and mitigate nutritional risk and loss of lean mass [453].

Behavioural targets should follow the 'SMART' principle, as these goals are more effective for achieving behaviour change than nonspecific recommendations [454]. Goals and targets should be routinely reviewed in clinical encounters. An 'all-or-none' approach related to behavioural goals should be avoided, as any improvement in healthy behaviours can have a positive impact [455, 456]. Self-monitoring

of health behaviours and achievements (e.g. physical activity monitoring, step count and weight measurement) is crucial to the achievement of health behaviour goals as it reinforces engagement and accountability.

Consensus recommendations

- All individuals with type 2 diabetes should be offered MNT and plans should be reassessed regularly, paying attention to individualisation of interventions.
- The 'five S' physical behaviour principles should be considered an essential component of type 2 diabetes management.
- People with type 2 diabetes undergoing interventions associated with significant weight loss, such as metabolic surgery or GLP-1-based therapies, should receive guidance on adequate protein intake and resistance exercise to help prevent lean mass loss.
- Goals for health behaviour interventions should be 'SMART', agreed upon collaboratively and revisited at regular intervals.

DSMES

DSMES is as important to the management of type 2 diabetes as the selection of medication [2, 3, 457, 458]. DSMES is a structured, evidence-based intervention that covers the span of topics important for self-management of diabetes, including nutrition, self-monitoring, pharmacotherapy and reduction of risk of complications. DSMES should be offered on an ongoing basis and should be provided by trained diabetes care and education specialists; DSMES can be delivered using multiple approaches and in a variety of settings [2, 3]. There are four critical times for DSMES: at diagnosis; annually to address changes in medications and support health behaviours; at onset of new complications; and upon transitions in care. Evidence has consistently shown that DSMES significantly improves knowledge, glucose levels, and clinical and psychological outcomes, and is cost-effective [459–465]. Unfortunately, DSMES is underutilised [466–468]. The care team must be aware of the available local DSMES resources and how to access them. DSMES is not a replacement for referral to mental health services. Psychiatric disorders, including disordered eating behaviours, are common, often unrecognised and contribute to poor outcomes in diabetes [469]. Emerging evidence demonstrates the benefits of telehealth or web-based DSMES programmes [470, 471]. Standardised DSMES programmes are not accessible to everyone and can fall short of meeting person-centred diabetes education and support needs. The critical issue is the importance of ongoing access to person-centred care addressing individual risks and barriers to care as well as empowering self-management. This should be provided by trained personnel or validated programmes.

Consensus recommendations

- DSMES should be offered to all those living with type 2 diabetes and revisited regularly.

Therapeutic inertia

Therapeutic inertia describes a lack of treatment intensification when targets or goals are not met. It also includes failure to de-intensify management when people are overtreated. Interventions targeting therapeutic inertia have facilitated improvements in glycaemic management and timely insulin intensification. For example, authorisation for non-physicians to prescribe (e.g. pharmacists, specialist nurses) may reduce therapeutic inertia [472].

Treatment behaviours and persistence

Suboptimal medication-taking behaviour and low rates of continued medication use, or what is termed ‘persistence to therapy plans’, affects almost half of people with type 2 diabetes, leading to suboptimal management as well as increased risks of diabetes complications, mortality and increased healthcare costs [473, 474]. Multiple factors contribute to inconsistent medication use and treatment discontinuation among people with diabetes, including perceived lack of efficacy, fear of hypoglycaemia, lack of access and adverse effects of medication [475]. Focusing on facilitators of optimal medication-taking behaviour, such as social/family/provider support, motivation, education, access to medications/foods and personal preference, can provide benefits [476, 477].

Weight and body composition management in the treatment of type 2 diabetes

Weight management should be a central focus for people living with type 2 diabetes. For many, a weight loss target of $\geq 5\%$ confers meaningful metabolic benefit but increasing evidence from programmes offering intense MNT and physical activity as well as those using newer, glucose- and weight-lowering pharmacological agents (e.g. GLP-1-based therapy) demonstrates that more substantial weight loss (approaching or exceeding 15%) can be achieved. This weight loss, particularly early in the disease course, increases the likelihood of achieving normoglycaemia and thus diabetes remission [71, 478, 479]. Equally, metabolic surgery, particularly early in the disease course, is also associated with diabetes remission [240].

Health behaviours, facilitated by MNT and DSMES, contribute to weight management but it is the availability

of agents such as GLP-1-based therapy, that allows high weight-loss efficacy and offers the opportunity to reach more ambitious targets ($>15\%$ weight loss). These pharmacological agents should be prioritised in the choice of glucose-lowering agents when overweight or obesity is present. Metabolic surgery can be considered for people with a BMI ≥ 30 kg/m² and type 2 diabetes. The benefits of metabolic surgery need to be balanced against potential adverse effects, which vary by procedure and include surgical complications, late metabolic or nutritional complications, and impact on psychological health [188–191, 233, 238]. People being considered for metabolic surgery should be evaluated for associated psychological conditions and social and situational circumstances that may interfere with surgery outcomes. People who undergo metabolic surgery should receive long-term medical and behavioural support. Metabolic surgery should be performed in high-volume centres with experienced multidisciplinary teams [233, 251].

With the increasing use of GLP-1-based therapies, the maintenance of weight, once the weight-loss goal is achieved, is an increasingly important consideration, as clinical trials demonstrate weight regain with cessation of GLP-1-based therapy [480]. Furthermore, weight regain following initial weight loss is associated with an overall loss of lean mass and a return of fat mass to baseline levels [481], illustrating a potential detrimental effect of weight cycling on body composition. Optimal strategies for weight maintenance are emerging but the following strategies can be considered: an individualised, dose-tapering approach to a maintenance dose; a focus on health behaviours, including nutrition and physical activity; and use of other weight-lowering medications.

Consensus recommendations

- DSMES and MNT should be offered to people with type 2 diabetes to identify and address barriers to health behaviour change and support weight loss.
- Weight management goals should be individualised and agreed upon collaboratively, balancing clinical ambition with personal feasibility.
- In people with type 2 diabetes and overweight or obesity, use of agents with weight-lowering effects should be preferred as glucose-lowering therapy, and metabolic surgery should be considered.
- Focus on weight maintenance should be kept after goals are achieved.

Choice of glucose-lowering medication

The choice of glucose-lowering agents should be directed by the individual profile of the person with type 2 diabetes,

USE OF GLUCOSE-LOWERING MEDICATIONS EARLY IN CARE

GOAL: PREVENT LONGITUDINAL COMPLICATIONS ASSOCIATED WITH T2D		
Incorporate SGLT2i or/and GLP-1-based therapy [§] early to modify disease and complication risk*		
Phenotype	SGLT2i [†]	GLP-1-based therapy ^{‡,§}
 Glucose-lowering efficacy	+	++
 Weight-lowering efficacy	+	++
 ASCVD/high-risk ASCVD	**	**
 CKD	**	**
 HF		
-HFrEF	**	
-HFpEF [‡]	**	**
 MASH/MASLD [§]	*	**

******: Outcomes evidence; *****: Improvement in markers
++: Highest efficacy; **+**: High efficacy
^{*} Use combination therapy based on target achievement and individual CVD and CKD risk.
[†] Pioglitazone may be considered.
[‡] Where evidence and/or label indicate (Table 1).
[§] Trials of GLP-1-based therapies only included participants with a BMI ≥ 30 kg/m².
[§] Includes GLP-1 RA and the dual GLP-1/GIP agonist tirzepatide.

ASCVD - Atherosclerotic cardiovascular disease; CKD - Chronic kidney disease; HF - Heart failure; HFpEF - Heart failure with preserved ejection fraction; HFrEF - Heart failure with reduced ejection fraction; MASH - Metabolic dysfunction-associated steatohepatitis; MASLD - Metabolic dysfunction-associated steatotic liver disease; SGLT2i - SGLT2 inhibitor; T2D - Type 2 diabetes.

Fig. 5 Use of glucose-lowering medications early in care

in particular the presence of overweight and MLTCs, risk of side effects, preferences and context (Fig. 4). The selection of glucose-lowering therapy should be based on evidence originating from randomised clinical trials, supplemented by real-world evidence, as well as the impact of interventions on person-related outcomes. This is equally true for initial therapy and modifying therapy later based on disease progression or new insights. Pharmacological treatment of hyperglycaemia must be integrated with DSMES and accompanied by a focus on healthy behaviours considering SDOH from diagnosis onwards. The holistic, multifactorial approach to type 2 diabetes must include evidence-based therapies for glycaemic, weight, BP and lipid management, as well as direct organ (heart/kidney/liver) protection (Fig. 5). For the last three decades, the standard approach was to add medications as needed. Today, we are recommending the use of best evidence and person preferences to craft an individualised programme of behavioural approaches and medications to reach goals, which could involve both adding and subtracting medications.

An important reality is that type 2 diabetes is often accompanied by the presence of MLTCs from diagnosis, particularly in those with early-onset type 2 diabetes. Considering the growing evidence from clinical trials and

observational studies, confirmed by real-world evidence, most people with type 2 diabetes should receive early on, potentially from diagnosis, a combination of cardiovascular risk factor management and DSMES, alongside health behaviour interventions, an SGLT2 inhibitor or/and a GLP-1-based therapy. This approach targets both glucose-lowering (without a risk of hypoglycaemia) and weight management and targets direct organ protection. Moreover, this approach helps to avoid clinical inertia and has the potential of achieving normoglycaemia. This preferred, proactive approach is supported by the overwhelming evidence on glucose-lowering efficacy and direct organ protection of these pharmacological agents, together with the observation that they are now part of the essential medicines as defined by WHO, and affordability and access is improving as patents expire. In people with BMI >35 kg/m², in addition to DSMES, dietary interventions and physical activity, early introduction of metabolic surgery is an option. In the presence of MASLD, alongside use of GLP-1-based therapy with proven benefits, SGLT2 inhibitors, pioglitazone or metabolic surgery could be considered.

In people with lower risk, such as those with minimal hyperglycaemia, lesser degrees of excess weight and no organ damage, or limited life expectancy, a more stepwise

approach may be considered. In the setting of resource constraints, prioritisation of the highest risk groups for access to more expensive pharmacological agents may be needed, with consideration of absolute risk reductions in addition to RR reductions.

In others, SGLT2 inhibitors or/and GLP-1-based therapy may not be tolerated or may even be contraindicated. Then, other glucose-lowering medications should be considered. The evidence on other glucose-lowering agents (i.e. metformin, DPP-4 inhibitors, TZDs, sulfonylureas) has not changed in recent years but they, in particular metformin, still have value in many people living with type 2 diabetes, as they offer robust glucose lowering. The selection of these glucose-lowering agents should be determined by the balance between their glucose-lowering efficacy and the side effect profile of the individual agents (Table 1).

Although longer-term evidence on durability of glucose-lowering efficacy by newer pharmacological agents and metabolic surgery is growing, many people living with type 2 diabetes will see a deterioration of glucose levels, despite maximal dietary and physical activity measures, reflecting the inability of these interventions to arrest the deterioration of beta cell function. Thus, many require a combination of agents, and some will need introduction of insulin to maintain good glucose levels, essential to prevention of microvascular disease. As stated in previous consensus documents, the preferred way of initiating insulin in people living with type 2 diabetes remains basal insulin, as it is easy to manage and achieves the main goal of insulin therapy in type 2 diabetes, namely the suppression of hepatic glucose output and lowering fasting glucose levels (ESM Fig. 1). Basal insulin analogues are preferred over NPH insulin, based on their lower risk of (mostly nocturnal) hypoglycaemia. When initiating insulin, health behaviours should be revisited and rereferral to DSMES is warranted, as well as a review of concomitant glucose-lowering therapies. As such, medications that promote hypoglycaemia and weight gain (such as sulfonylureas) should be stopped, while agents that promote weight loss, reduce insulin needs and limit hypoglycaemia (such as metformin, SGLT2 inhibitors or GLP-1-based therapy) should be maintained or introduced simultaneously. Use of fixed-dose combinations may help limit the number of medications and injections needed [482].

Since the last consensus report, once-weekly insulins have been introduced, offering a more convenient form of insulin therapy. These provide a safe and effective way of introducing basal insulin in people living with type 2 diabetes, with fewer injections, although careful dose titration and monitoring for hypoglycaemia remain important [208, 210] (ESM Fig. 1).

The use of prandial insulin, administered via multiple daily injections of insulin, inhaled insulin, premixed insulin

formulations, combination of basal and prandial insulin, or continuous insulin delivery (insulin pumps and automated insulin delivery [AID] systems; see below), may be required when postprandial glucose levels remain suboptimal despite optimal lifestyle, pharmacological or surgical interventions. Extra support is required as the introduction of prandial insulin can be associated with further weight increase and increased risk of hypoglycaemia [483]. In individuals on longstanding insulin therapy, introduction of a GLP-1-based therapy or/and an SGLT2 inhibitor is warranted to limit insulin doses and weight as well as exploit their organ-protecting effects [48]. Upon addition of a highly effective medication on the background of insulin therapy, insulin dose reductions, increased monitoring and more frequent dose adjustments are required, particularly in those whose glucose levels are near target (e.g. <8%) [484, 485].

Therapeutic inertia in intensification of glucose-lowering therapy, including the introduction of insulin, should be avoided. When clinicians are not familiar with insulin therapy, referral to specialist care is warranted. A critical appraisal of diabetes subtype in people not reaching glycaemic targets should be conducted to avoid misdiagnosis.

When introduction of insulin is required, or when agents such as sulfonylureas are used, special attention needs to be given to populations in which hypoglycaemia is most dangerous, such as people with frailty or older people who live alone. Consideration of less-stringent targets in such settings is prudent, and de-prescribing should be considered if asymptomatic or severe hypoglycaemia ensues. In addition, in people with frailty, potential health gains achieved by using potent agents such as GLP-1-based therapies or SGLT2 inhibitors need to be evaluated carefully, considering potential undesirable losses of lean mass [43, 101, 257, 260].

Finally, it needs to be stated that, although improving, the evidence on interventions generally in specific subpopulations (e.g. younger and older people, women and various racial/ethnic groups) continues to be limited. This lack of evidence is, however, not a reason to withhold interventions, including pharmacotherapies, in these subpopulations, given their proven benefits in the general population.

Consensus recommendations

- The choice of glucose-lowering agents should be individualised based on the clinical profile of the person living with type 2 diabetes, including the presence of overweight, obesity or sarcopenia, as well as other MLTCs, adverse effect profile of agents, individual preferences and personal circumstances.
- In addition to DSMES and interventions focused on health behaviours, most people living with type 2 diabetes would benefit from early introduction of an SGLT2 inhibitor or/and GLP-1-based therapy, potentially from diagnosis.

- When clinically indicated, insulin should be initiated as basal insulin only, usually after GLP-1-based therapy, while maintaining other glucose-lowering agents, particularly cardio-kidney-protective agents such as SGLT2 inhibitors. Further intensification of therapy should be individualised based on the person's clinical profile, risk, circumstances and preferences.
- De-intensification of glucose-lowering therapy associated with hypoglycaemia risk (particularly sulfonylurea) should be addressed in people with frailty and type 2 diabetes.
- Targeted screening for secondary causes of hyperglycaemia (e.g. hypercortisolism) should be considered for adults with treatment-resistant type 2 diabetes despite guideline-directed therapy with multiple agents.

Place of technology

People with type 2 diabetes are increasingly using CGM for monitoring glucose levels, either continuously or periodically. A growing body of evidence supports the use of CGM in people with type 2 diabetes, including clinically meaningful improvements in glucose levels and self-management, particularly among people treated with insulin [27, 28, 486, 487]. A growing number of clinical trials report statistically significant improvements in HbA_{1c} and TIR, with reductions in time spent above and below range, but overall, the effect size is modest, and most trials are often of short duration and small [28, 488]. Most studies report an improvement in person-reported outcomes with CGM, independent of the type of CGM, thus supporting use, at least periodically, of CGM by those living with type 2 diabetes [488].

AID has been evaluated in people living with type 2 diabetes and suggests an improved TIR (3.9–10.0 mmol/l [70–180 mg/dl]), with decreased time spent above range [489–491]. Time spent in hypoglycaemia was not affected. Weight was slightly increased in those using AID, highlighting the importance of using AID alongside other interventions such as DSMES and other glucose-lowering agents that may prevent weight gain.

Novel technologies are also entering the hospital setting, where CGM is now widely used, independent of diabetes subtype. CGM use is accompanied by a modest improvement in overall glucose levels, with less time spent in hypoglycaemia. However, incorporating CGM use in non-endocrine wards requires adaptation of the hospital organisation and additional training of healthcare professionals. Trials with closed-loop insulin delivery systems in the hospital setting are ongoing. First reports suggest improvements in glucose levels with less time spent in hyperglycaemia, compared with use of CGM only, with no effect on time spent in hypoglycaemia. Again, trials have been small and short in duration [492].

SDOH must be addressed to ensure equitable access to diabetes technology for all those with type 2 diabetes who stand to benefit.

Consensus recommendations


- Evidence-based diabetes technologies, with proven benefits in people with type 2 diabetes, should be considered as adjunctive tools within a comprehensive, integrated diabetes management plan and should be individualised based on clinical need, preference and skill level.
- CGM should be considered in people living with type 2 diabetes, especially those on insulin.

Implementation of evidence-based interventions for type 2 diabetes: importance of organisation of care

Real-world and modelling evidence on newer therapies shows that SGLT2 inhibitors and GLP-1-based therapies provide cardiovascular, kidney, metabolic and healthcare utilisation benefits [493–499] but their population impact is constrained by access, utilisation, persistence and cost [500, 501]. Cost and access barriers are being mitigated in many countries, related to patent expirations and market forces. Therapeutic inertia is recognised as a major factor in the underuse of evidence-based screening for complications and interventions for type 2 diabetes management [502].

An important strategy to overcome therapeutic inertia in the management of type 2 diabetes is the adaptation of healthcare systems. Ideally, this entails the adoption of community-based, multidisciplinary primary care that incorporates non-physician healthcare providers [503]. Individualisation of care, and consideration of preferences and SDOH are also key for implementation of clinical guidelines (Fig. 6).

Systems of care have a significant role in improving diabetes management and outcomes because they can facilitate the implementation of evidence-based interventions (Fig. 6). The structure and organisation of the healthcare team will vary across systems but generally involve multiple disciplines [2, 3]. It is increasingly recognised that wider team-based care (e.g. including nurses, pharmacists and dietitians as key members of the healthcare team [504–506]) has the potential to improve diabetes care. Technology is now an important tool to enhance communication, support and monitoring, and digital health interventions demonstrate the potential to improve outcomes such as glucose levels [507]. However, digital tools, such as telehealth and mHealth interventions that include apps, wearables and digital coaching, have been shown to be most effective when they are multi-component, interactive, personalised, sustained over 6–12 months and clinician-led, with modest but consistent HbA_{1c} reductions [507–509]. Social media health information



AI - Artificial intelligence; EHR - Electronic health record; PROMs - Patient reported outcome measures; QoL - Quality of life; T2D - Type 2 diabetes.

Fig. 6 A learning health system framework for quality and outcomes in type 2 diabetes

should be recognised as an important determinant of treatment implementation and diabetes self-management, as digital narratives can shape peoples' expectations, perceptions of benefits and harms, medication-taking behaviours and decisions to continue or discontinue therapy; accordingly, it represents a relevant domain for communication between healthcare professionals and people with diabetes and a priority area for future research [11]. Novel treatment-support modalities (nurse-led coaching, clinician feedback, pharmacist-led telemonitoring) offer benefits beyond glucose lowering by improving access, engagement, satisfaction and cost-effectiveness, outperforming passive apps or DSMES alone [470, 504, 510, 511]. Combining behavioural interventions with digital technology seems to be a particularly useful implementation strategy that enhances feasibility. Behavioural interventions such as transtheoretical model (TTM)-based motivational interviewing have been shown to produce additive glucose-lowering benefits by improving self-management and self-efficacy [512], and TTM-based, telemedicine lifestyle interventions can achieve improvements in self-management, self-efficacy and glucose levels [513]. Models to integrate care infrastructure and pathways (e.g. shared-care, chronic care model) for such interventions can improve health outcomes in people living with type 2 diabetes (Fig. 6) but poor sustainability due to workforce, time and cost constraints is a limiting factor [514]. Another novel approach is pairing training of primary healthcare professionals with patient pre-visit prompting, which has proved to be a cost-effective and safe way of de-prescribing of glucose-lowering drugs with hypoglycaemia risk in older adults with type 2 diabetes [515].

Finally, health systems must attend to equity in the delivery of all diabetes care, including access to DSMES and the more expensive, organ-protecting pharmacotherapies (SGLT2 inhibitors and GLP-1-based therapy) and technologies (e.g. CGM) [516–518]. Improving the care of type 2 diabetes by integrating DSMES, promotion of health behaviours and use of glucose-lowering pharmacotherapy tailored to the individual (including MLTCs) continues to require system-level change, which should empower primary care as the central hub of care in many settings. Innovative models of care that include remote e-health interventions and combinations of digital–human interventions are needed to support people living with type 2 diabetes (Fig. 6). Notably, equitable access to diabetes technology remains a major challenge in both low- and high-income countries. In addition to cost, the digital divide (including limited access to compatible smartphones, reliable high-speed internet and cloud-based platforms) as well as poor health and digital literacy, particularly among older adults, can substantially hinder the adoption and effective use of diabetes technologies across nations and socioeconomic groups.

Consensus recommendations

- Healthcare systems should be organised to deliver individualised diabetes care that is integrated into the daily lives of people with type 2 diabetes.
- Care for people with type 2 diabetes should be individualised, with explicit consideration of each person's clinical risks, personal preferences, lived context and SDOH, including socioeconomic status, food security, housing stability and access to care.
- The management plan for people with type 2 diabetes should incorporate all MLTCs, with treatment priorities, glycaemic targets and pharmacological choices informed by the overall disease burden.
- Care delivery for people with type 2 diabetes should leverage innovative models, including digital health tools and interprofessional team-based care, to expand access and support self-management.
- Healthcare systems should establish mechanisms to identify and address inequities in the delivery of evidence-based care for people with type 2 diabetes, ensuring that healthcare is affordable and accessible to all.

Key knowledge gaps and a call to action

This update has broadened the focus from prior statements on the management of hyperglycaemia to the holistic management of type 2 diabetes and its associated MLTCs. While suggesting individualising care for each person with diabetes, we recognise that for most people that should comprise lifestyle and behavioural coaching focusing on nutrition, physical activity, self-monitoring, DSMES and, for most, medications with disease-modifying characteristics such as GLP-1-based therapies and SGLT2 inhibitors in order to meet weight, glycaemic and cardiovascular risk targets as well as address cardiometabolic disease. There is an increasing focus on achieving remission of type 2 diabetes; however, current definitions predominantly based on glycaemic thresholds falling below the diagnostic range in the absence of glucose-lowering therapy are inherently simplistic. While useful operationally, such definitions do not fully capture the complex underpinning pathophysiology, nor the broader trajectories of cardiometabolic disease. Hyperglycaemia represents one component of disease burden and may not reflect ongoing pathophysiological processes, including excess adiposity, insulin resistance, beta cell function, inflammation and residual cardiovascular and kidney risk. Furthermore, individuals meeting current remission criteria still carry substantial long-term risk of relapse and complications. A broader conceptual framework built on type 2 diabetes modification may be more clinically meaningful,

recognising sustained improvements in metabolic health, organ protection, adiposity, functional health and long-term outcomes rather than glucose alone. Such an approach aligns more closely with contemporary understanding of type 2 diabetes as a chronic, progressive multi-system disease. As we stated in 2022, the major opportunities to improve diabetes outcomes in the near term come from more effective and equitable implementation of best evidence through organisation of care at all levels and from addressing SDOH. That said, many details of optimal management have not been established and require further study. Examples include the following:

- Consensus is emerging that early intensive therapy in type 2 diabetes is associated with sustained benefits but trial evidence for glycaemic targets of <53 mmol/mol ($<7\%$) is poorly developed and for CGM targets it is essentially non-existent. We need trials to provide convincing evidence for new targets.
- The aim of achieving ‘remission’ should perhaps be rethought as not just achieving euglycaemia absent of glucose-lowering medications for 3 months but perhaps as a means to reduce the risk of developing associated complications/conditions. In that context, should the definition of remission be broadened to include modifications of associated long-term conditions, whether or not treatment with medications continues?
- We need to develop optimal strategies to maintain remission over time.
- We have burgeoning pharmacological and technological applications in type 2 diabetes management. How can we optimally sequence them and when is enough in fact enough?
- Most studies of GLP-1-based therapies recruit people with overweight or obesity. How should GLP-1-based therapies be used in people where weight loss is not desired? Currently, in people with type 2 diabetes where GLP-1-based therapy is desired for glycaemic or cardiovascular benefit but weight loss is not desired, dulaglutide may be preferred.
- We need better trial evidence for early intensive therapy in early-onset type 2 diabetes, particularly in youth with type 2 diabetes in whom the lifetime risk of complications is highest. Similarly, there is inadequate understanding of how and when to de-intensify therapy later in life.
- Women’s health approaches in the context of diabetes management have been understudied. A new issue is how GLP-1-based treatments should be managed in the context of pregnancy. GLP-1-based therapies are not recommended for use during pregnancy and could adversely affect a fetus. However, discontinuing GLP-1-based therapies may result in excessive weight gain and loss of glycaemic management during pregnancy with potential harms for both mother and baby. Further study is desperately needed.
- How should adiposity be measured to best reflect the metabolic impact of adiposopathy and what should be targets for medical and surgical weight-loss programmes?
- What are optimal lifestyle programmes to support GLP-1-based therapy, including MNT and the five Ss to reach weight targets and preserve fat-free mass (particularly skeletal muscle mass and bone) and function? Furthermore, what are the best ways of tackling accelerated ageing, considering outcomes related to whole-body health and physical function?
- With the emergence of increasingly effective weight-loss drugs, we need to understand whether high doses of moderately effective agents are equivalent to modest doses of highly effective agents for outcomes, and also the optimum approaches for maintenance of weight loss.
- What should be the evaluation strategy for people with inadequate responses to generally effective therapies? Recent studies suggest screening for hypercortisolism identifies a treatable cause in $\sim 25\%$. There must be others.
- Developing a better understanding of the role of cortisol-directed therapy in type 2 diabetes is needed.
- We still do not have compelling evidence for whether GLP-1-based therapy and SGLT2 inhibitors should be routinely combined, or whether there is an optimal sequence by which they should be added.

Precision or personalised medicine has been a North Star for a decade but remains an evolving goal in type 2 diabetes [519]. Advances in biomarker development and leveraging artificial intelligence are potentially transformational not only in targeting treatments based on individual characteristics but also in facilitating DSMES, medication management and titration, and care coordination, essentially every aspect of modern medicine. Artificial intelligence has the potential to deliver both substantial advances and disruptive changes in medicine and wider society. The emerging nature of threats such as disinformation, climate change, water quality, atmospheric particles and pollutants, microplastics, societal stressors and lack of human engagement, among others, is recognised but not fully appreciated and their mitigation even less well understood.

We have made strong recommendations based on a high level of evidence for specific MLTCs. In approaching care holistically, it would be optimal to be able to make regulatory decisions and require equitable access in society based on broad benefits of highly effective therapies, whether behavioural or pharmacological. Regulatory and payment reform in most healthcare systems is needed.

Broad support for basic science remains foundational to the advances that will transform care in the next decade.

However, despite all the major advances in glucose-lowering and weight-loss pharmacotherapies and digital technology, perhaps the greatest opportunity to improve outcomes for people living with type 2 diabetes remains getting the fundamentals of the core components right. Timely initiation and intensification of therapy, particularly the earlier and more comprehensive use of therapies with proven cardio-kidney benefit, such as SGLT2 inhibitors and GLP-1-based therapies, have the potential to substantially reduce long-term complications and premature mortality. Equally important is universal access to high quality DSMES and well-organised systems of care. Structured surveillance for complications, combined with proactive risk management, remains essential. Collectively, with consistent delivery of these core components of care at scale, the ability to transform outcomes for people living with type 2 diabetes is within our grasp. This is not reliant on future innovations but is achievable now through consistent, equitable and systematic implementation of strategies and therapies already available.

Supplementary Information The online version of this article (<https://doi.org/10.1007/s00125-026-06855-7>) contains peer-reviewed but unedited supplementary material.

Acknowledgements M. Bonar and C. Franklin (both Leicester Diabetes Centre, University of Leicester and the University Hospitals of Leicester NHS Trust, UK) assisted with the conception and execution of figures and tables; T. Yates and J. Henson (both Leicester Diabetes Centre, University of Leicester and the University Hospitals of Leicester NHS Trust, UK) and Z. I. Saeed and J. W. Ostrowski (both Brigham and Women's Hospital, Harvard Medical School, MA, USA) supported the production and content of Fig. 3. We acknowledge the support of C. Stendall and M. Spencer (both Leicester Diabetes Centre, University of Leicester and the University Hospitals of Leicester NHS Trust, UK), R. R. Bannuru, A. Bennett and J. Neumiller (all ADA, Arlington, VA, USA), P. Niemann, M. Schönke and L. Rother (all EASD, Düsseldorf, Germany), the Committee for Clinical Affairs of the EASD and the Professional Practice Committee of the ADA.

Data availability Details of the search strategy and list of identified articles can be found at <https://doi.org/10.17605/osf.io/pu93h>.

Funding This activity was funded by the American Diabetes Association and the European Association for the Study of Diabetes.

Authors' relationships and activities MJD has acted as a consultant/advisor and speaker for Eli Lilly, Novo Nordisk and Sanofi, as a consultant/advisor for Kailera, has attended advisory boards for AbbVie, Amgen, AstraZeneca, Biomea Fusion, Carmot/Roche, Daewoong Pharmaceutical, Sanofi, Zealand Pharma, Regeneron, GSK, Innovent Bio and EktaH, and as a speaker for AstraZeneca, Boehringer Ingelheim, Obesity Alliance and Zuellig Pharma. She has received grants from AstraZeneca, Boehringer Ingelheim and Novo Nordisk. VRA has institutional contracts with Amgen, AstraZeneca, Applied Therapeutics, Biomea, Concept, Eli Lilly, Fractyl, Kailera, Novo Nordisk, Pfizer, Recordati, Rhythm and Servier and is a consultant for Baim, Mediflix, Roche and Sanofi. MB is a member of the ADA Board of Directors and has received research funding (to institution) from the ADA. He is Edi-

tor-in-Chief of BMJ Open Diabetes Research and Care. NAE has served on the advisory board for Novo Nordisk. FG has received research support from Eli Lilly and Roche Diabetes Care, consulting fees from Eli Lilly, Novo Nordisk, and Kayothera, and serves or has served on advisory boards for AstraZeneca, Biomea, Boehringer Ingelheim, Eli Lilly, Kayothera, Lifescan, Merck, Sharp & Dohme, Medtronic, Novo Nordisk, Roche Diabetes Care and Sanofi. FG serves or has served on boards for EASD/European Foundation for the Study of Diabetes (EFS), and European Diabetes Forum (EUDF). He has given lectures, presentations or educational events for AstraZeneca, Boehringer Ingelheim, Eli Lilly, Lifescan, Merck Sharp & Dohme, Medtronic, Novo Nordisk, Roche Diabetes Care, Sanofi and has received support for medical writing and statistical analysis from Eli Lilly, Novo Nordisk, Roche Diabetes Care and Sanofi. JG is or has acted as a consultant for Aqua, AstraZeneca, Bayer, Boehringer Ingelheim, Fractyl, vTv, Lilly, Novo Nordisk, Roche, Sparrow Pharmaceuticals, Vertex and Zealand. She has received research support from Boehringer Ingelheim, Cour, GentiBio, Merck and Metsera. RRR currently serves as Chief Scientific and Medical Officer of the ADA. NMM is an author of modules for Up To Date on Medical Nutrition Therapy for type 2 diabetes and prevention of type 2 diabetes. She is entitled to royalties for this authorship. CM serves or has served on the advisory panel for Novo Nordisk, Sanofi, Eli Lilly and Company, Novartis, Dexcom, Boehringer Ingelheim, Bayer, Roche, Abbott, Medtronic, Insulet, Biomea Fusion, SAB Bio, vTv Therapeutics and Vertex. Financial compensation for these activities has been received by KU Leuven; KU Leuven has received research support for CM from Dexcom, Novo Nordisk and Sanofi. CM serves or has served on the speakers bureau for Novo Nordisk, Sanofi, Eli Lilly and Company, Medtronic, Dexcom, Insulet, Abbott, Vertex and Boehringer Ingelheim. Financial compensation for these activities has been received by KU Leuven. CM is president of EUDF. All external support of EUDF can be found on www.eudf.org. SER has received research funding (to institution) from Bayer and NIDDK. She is on the Steering Committee for FineOne and has participated on the scientific advisory board for Bayer, Novo Nordisk and Trave. PR has received grants or contracts (to institution) from AstraZeneca, Bayer and Novo Nordisk, and honoraria (to institution) from AstraZeneca, Abbott, Bayer, Boehringer Ingelheim, Eli Lilly and Novo Nordisk. He has received consulting fees from AstraZeneca, Abbott, Amgen, Bayer, Boehringer Ingelheim, Novo Nordisk, Lexicon, Roche and Regeneron. He has received study medication from AstraZeneca, Bayer, Novo Nordisk and Lexicon. TT has served or has served on the advisory board for Novo Nordisk, Eli Lilly, Boehringer Ingelheim, AstraZeneca, Sanofi and Merck and on the speaker's bureau for Novo Nordisk, Sanofi, Eli Lilly, Boehringer Ingelheim, AstraZeneca, Merck, Sharp & Dohme, Servier, Merck and Medtronic. PT serves or has served on the advisory board for Abbott, AstraZeneca, Boehringer Ingelheim, Danone, Eli Lilly, Novo Nordisk and Lifescan. AT has received support for attending meetings from Bayer, Menarini and Novo Nordisk outside the submitted work. He also serves as chair of the EASD Guidelines Oversight Committee. JBB has received research support from Concept, GentiBio, Novo Nordisk and Sparrow Pharmaceuticals. He is or has acted as a paid consultant/ on the advisory board for Aardvark Therapeutics, Altimune, Alveus Therapeutics, Amgen, Antag, Aqua Medical, AstraZeneca, Concept Therapeutics, Eli Lilly, General Medicines Inc, Kayothera, Metsera, Novo Nordisk, Pfizer, Recordati, Roche, Sparrow Pharmaceuticals, Vertex, vTv Therapeutics and Zealand. He is an investor in Aardvark Therapeutics, Glyscend, Mellitus Health, Metsera, Pendulum Therapeutics, Praetego and Stability Health. TS declares that there are no relationships or activities that might bias, or be perceived to bias, his work.

Contribution statement All authors were responsible for drafting the article and revising it critically for important intellectual content. All authors approved the version to be published.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

References

- Gattrell WT, Logullo P, van Zuuren EJ et al (2024) ACCORD (ACcurate COnsensus Reporting Document): a reporting guideline for consensus methods in biomedicine developed via a modified Delphi. *PLoS Med* 21(1):e1004326. <https://doi.org/10.1371/journal.pmed.1004326>
- Davies MJ, Aroda VR, Collins BS et al (2022) Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). *Diabetologia* 65(12):1925–1966. <https://doi.org/10.1007/s00125-022-05787-2>
- Davies MJ, Aroda VR, Collins BS et al (2022) Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). *Diabetes Care* 45(11):2753–2786. <https://doi.org/10.2337/dci22-0034>
- Schandelmaier S, Briel M, Varadhan R et al (2020) Development of the Instrument to assess the Credibility of Effect Modification Analyses (ICEMAN) in randomized controlled trials and meta-analyses. *CMAJ* 192(32):E901–E906. <https://doi.org/10.1503/cmaj.200077>
- Sun X, Ioannidis JP, Agoritsas T, Alba AC, Guyatt G (2014) How to use a subgroup analysis: users' guide to the medical literature. *JAMA* 311(4):405–411. <https://doi.org/10.1001/jama.2013.285063>
- Andrews J, Guyatt G, Oxman AD et al (2013) GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations. *J Clin Epidemiol* 66(7):719–725. <https://doi.org/10.1016/j.jclinepi.2012.03.013>
- Santesso N, Glenton C, Dahm P et al (2020) GRADE guidelines 26: informative statements to communicate the findings of systematic reviews of interventions. *J Clin Epidemiol* 119:126–135. <https://doi.org/10.1016/j.jclinepi.2019.10.014>
- Peimani M, Stewart AL, Garmaroudi G, Nasli-Esfahani E (2025) Shared decision-making in type 2 diabetes: a systematic review of patients' preferences and healthcare providers' perspectives. *BMC Health Serv Res* 25(1):39. <https://doi.org/10.1186/s12913-024-12160-z>
- Vasistha S, Kanchibhatla A, Blanchette JE, Rieke J, Hughes AS (2025) The sugar-coated truth: the quality of diabetes health information on tiktok. *Clin Diabetes* 43(1):53–58. <https://doi.org/10.2337/cd24-0042>
- Elnaggar A, Ta Park V, Lee SJ, Bender M, Siegmund LA, Park LG (2020) Patients' use of social media for diabetes self-care: systematic review. *J Med Internet Res* 22(4):e14209. <https://doi.org/10.2196/14209>
- Tejera-Pérez C (2026) Viral medicine: social media and new expectations of obesity treatment. *Lancet Diabetes Endocrinol* 14(5):374. [https://doi.org/10.1016/s2213-8587\(26\)00069-0](https://doi.org/10.1016/s2213-8587(26)00069-0)
- Henson J, Baker LA, Watson E, Yates T, Davies MJ (2025) Type 2 diabetes and accelerated ageing in skeletal muscle. *Lancet Diabetes Endocrinol* 13(5):362–364. [https://doi.org/10.1016/s2213-8587\(25\)00061-0](https://doi.org/10.1016/s2213-8587(25)00061-0)
- Khunti K, Chudasama YV, Gregg EW et al (2023) Diabetes and multiple long-term conditions: a review of our current global health challenge. *Diabetes Care* 46(12):2092–2101. <https://doi.org/10.2337/dci23-0035>
- Hill-Briggs F, Adler NE, Berkowitz SA et al (2020) Social determinants of health and diabetes: a scientific review. *Diabetes Care* 44(1):258–279. <https://doi.org/10.2337/dci20-0053>
- Ahmad E, Lim S, Lamptey R, Webb DR, Davies MJ (2022) Type 2 diabetes. *Lancet* 400(10365):1803–1820. [https://doi.org/10.1016/s0140-6736\(22\)01655-5](https://doi.org/10.1016/s0140-6736(22)01655-5)
- Pellegrini V, La Grotta R, Carreras F et al (2024) Inflammatory trajectory of type 2 diabetes: novel opportunities for early and late treatment. *Cells* 13(19):1662. <https://doi.org/10.3390/cells13191662>
- Zheng WC, Chan W, Dart A, Shaw JA (2024) Novel therapeutic targets and emerging treatments for atherosclerotic cardiovascular disease. *Eur Heart J Cardiovasc Pharmacother* 10(1):53–67. <https://doi.org/10.1093/ehjcvp/pvad074>
- Evans-Molina C, Oram RA (2025) Type 1 diabetes presenting in adults: trends, diagnostic challenges and unique features. *Diabetes Obes Metab* 27(Suppl 6):57–68. <https://doi.org/10.1111/dom.16402>
- Stone SI, Balasubramanyam A, Posey JE (2024) Atypical diabetes: what have we learned and what does the future hold? *Diabetes Care* 47(5):770–781. <https://doi.org/10.2337/dci23-0038>
- Buse JB, Kahn SE, Aroda VR et al (2025) Prevalence of hypercortisolism in difficult-to-control type 2 diabetes. *Diabetes Care* 48(12):2012–2020. <https://doi.org/10.2337/dc24-2841>
- American Diabetes Association Professional Practice Committee (2026) 2. Diagnosis and classification of diabetes: standards of care in diabetes-2026. *Diabetes Care* 49(Suppl 1):S27–s49. <https://doi.org/10.2337/dc26-S002>
- Wadivkar P, Jebasingh F, Thomas N et al (2025) Classifying a distinct form of diabetes in lean individuals with a history of undernutrition: an international consensus statement. *Lancet Glob Health* 13(10):e1771–e1776. [https://doi.org/10.1016/s2214-109x\(25\)00263-3](https://doi.org/10.1016/s2214-109x(25)00263-3)
- American Diabetes Association Professional Practice Committee (2025) 2. Diagnosis and classification of diabetes: standards of care in diabetes-2025. *Diabetes Care* 48(1 Suppl 1):S27–s49. <https://doi.org/10.2337/dc25-S002>
- American Diabetes Association Professional Practice Committee (2025) 6. Glycemic goals and hypoglycemia: standards of care in diabetes-2025. *Diabetes Care* 48(1 Suppl 1):S128–s145. <https://doi.org/10.2337/dc25-S006>
- TODAY Study Group (2023) Effect of early glycemic control in youth-onset type 2 diabetes on longer-term glycemic control and β -cell function: results from the TODAY study. *Diabetes Care* 46(8):1507–1514. <https://doi.org/10.2337/dc23-0560>
- Lin B, Coleman RL, Bragg F, Maddaloni E, Holman RR, Adler AI (2024) Younger-onset compared with later-onset type 2 diabetes: an analysis of the UK Prospective Diabetes Study (UKPDS) with up to 30 years of follow-up (UKPDS 92). *Lancet Diabetes Endocrinol* 12(12):904–914. [https://doi.org/10.1016/s2213-8587\(24\)00242-0](https://doi.org/10.1016/s2213-8587(24)00242-0)
- American Diabetes Association Professional Practice Committee (2026) 7. Diabetes technology: standards of care in diabetes-2026. *Diabetes Care* 49(Suppl 1):S150–s165. <https://doi.org/10.2337/dc26-S007>
- Jancev M, Vissers T, Visseren FLJ et al (2024) Continuous glucose monitoring in adults with type 2 diabetes: a systematic review and meta-analysis. *Diabetologia* 67(5):798–810. <https://doi.org/10.1007/s00125-024-06107-6>

29. American Diabetes Association Professional Practice Committee (2025) 10. Cardiovascular disease and risk management: standards of care in diabetes-2025. *Diabetes Care* 48(1 Suppl 1):S207–s238. <https://doi.org/10.2337/dc25-S010>
30. Blumenthal RS, Morris PB, Gaudino M et al (2026) 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *Circulation* 153(17):e1154–e1276. <https://doi.org/10.1161/cir.0000000000001423>
31. Jones DW, Ferdinand KC, Taler SJ et al (2025) 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *J Am Coll Cardiol* 86(18):1567–1678. <https://doi.org/10.1016/j.jacc.2025.05.007>
32. Mach F, Koskinas KC, Roeters van Lennep JE et al (2025) 2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias. *Eur Heart J* 46(42):4359–4378. <https://doi.org/10.1093/eurheartj/ehaf190>
33. American Diabetes Association Professional Practice Committee (2025) 4. Comprehensive medical evaluation and assessment of comorbidities: standards of care in diabetes-2025. *Diabetes Care* 48(1 Suppl 1):S59–s85. <https://doi.org/10.2337/dc25-S004>
34. Kautzky-Willer A, Leutner M, Harreiter J (2023) Sex differences in type 2 diabetes. *Diabetologia* 66(6):986–1002. <https://doi.org/10.1007/s00125-023-05891-x>
35. Zhu XB, Niu ZH, Fan WM, Sheng CS, Chen Q (2023) Type 2 diabetes mellitus and the risk of male infertility: a Mendelian randomization study. *Front Endocrinol (Lausanne)* 14:1279058. <https://doi.org/10.3389/fendo.2023.1279058>
36. Singh J, Sahoo AK, Swain J, Mangaraj S, Kanwar JB, Manglunia A (2023) Assessment of hypogonadism and its determinants among adult men with type 2 diabetes mellitus. *Prim Care Diabetes* 17(4):348–353. <https://doi.org/10.1016/j.pcd.2023.05.005>
37. Liu Q, Tang B, Zhu Z et al (2022) A genome-wide cross-trait analysis identifies shared loci and causal relationships of type 2 diabetes and glycaemic traits with polycystic ovary syndrome. *Diabetologia* 65(9):1483–1494. <https://doi.org/10.1007/s00125-022-05746-x>
38. Crețu D, Cernea S, Onea CR, Pop RM (2020) Reproductive health in women with type 2 diabetes mellitus. *Hormones (Athens)* 19(3):291–300. <https://doi.org/10.1007/s42000-020-00225-7>
39. American Diabetes Association Professional Practice Committee (2025) 11. Chronic kidney disease and risk management: standards of care in diabetes-2025. *Diabetes Care* 48(1 Suppl 1):S239–s251. <https://doi.org/10.2337/dc25-S011>
40. American Diabetes Association Professional Practice Committee (2025) 12. Retinopathy, neuropathy, and foot care: standards of care in diabetes-2025. *Diabetes Care* 48(1 Suppl 1):S252–S265. <https://doi.org/10.2337/dc25-S012>
41. American Diabetes Association Professional Practice Committee (2025) 9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes-2025. *Diabetes Care* 48(1 Suppl 1):S181–s206. <https://doi.org/10.2337/dc25-S009>
42. Prado CM, Phillips SM, Gonzalez MC, Heymsfield SB (2024) Muscle matters: the effects of medically induced weight loss on skeletal muscle. *Lancet Diabetes Endocrinol* 12(11):785–787. [https://doi.org/10.1016/s2213-8587\(24\)00272-9](https://doi.org/10.1016/s2213-8587(24)00272-9)
43. Neeland IJ, Linge J, Birkenfeld AL (2024) Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies. *Diabetes Obes Metab* 26(Suppl 4):16–27. <https://doi.org/10.1111/dom.15728>
44. Chan JCN, Lim LL, Wareham NJ et al (2021) The Lancet Commission on diabetes: using data to transform diabetes care and patient lives. *Lancet* 396(10267):2019–2082. [https://doi.org/10.1016/s0140-6736\(20\)32374-6](https://doi.org/10.1016/s0140-6736(20)32374-6)
45. Swinburn BA, Kraak VI, Allender S et al (2019) The global syndemic of obesity, undernutrition, and climate change: the lancet commission report. *Lancet* 393(10173):791–846. [https://doi.org/10.1016/s0140-6736\(18\)32822-8](https://doi.org/10.1016/s0140-6736(18)32822-8)
46. Ratter-Rieck JM, Roden M, Herder C (2023) Diabetes and climate change: current evidence and implications for people with diabetes, clinicians and policy stakeholders. *Diabetologia* 66(6):1003–1015. <https://doi.org/10.1007/s00125-023-05901-y>
47. American Diabetes Association Professional Practice Committee (2026) 5. Facilitating positive health behaviors and well-being to improve health outcomes: standards of care in diabetes-2026. *Diabetes Care* 49(Supplement_1):S89–s131. <https://doi.org/10.2337/dc26-S005>
48. American Diabetes Association Professional Practice Committee (2026) 9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes-2026. *Diabetes Care* 49(Suppl 1):S183–s215. <https://doi.org/10.2337/dc26-S009>
49. Evert AB, Dennison M, Gardner CD et al (2019) Nutrition therapy for adults with diabetes or prediabetes: a consensus report. *Diabetes Care* 42(5):731–754. <https://doi.org/10.2337/dci19-0014>
50. Barrea L, Verde L, Colao A, Mandarino LJ, Muscogiuri G (2025) Medical nutrition therapy for the management of type 2 diabetes mellitus. *Nat Rev Endocrinol* 21(12):769–782. <https://doi.org/10.1038/s41574-025-01161-5>
51. Dehghani S, Karimi P, Tarei NN et al (2025) Comparison of the effect of intermittent fasting with Mediterranean diet on glycemic, lipid, and anthropometric indices in type 2 diabetes: a review of randomized controlled trials. *Curr Hypertens Rev* 21(3):174–185. <https://doi.org/10.2174/0115734021351456250326051146>
52. Lauria F, Formisano A, Dello Russo M et al (2026) Mediterranean diet, gut microbiota, and type 2 diabetes: a systematic review and meta-analysis of intervention trials. *Nutr Metab Cardiovasc Dis* 36(5):104433. <https://doi.org/10.1016/j.numecd.2025.104433>
53. Podadera-Herreros A, Arenas-de Larriva AP, Gutierrez-Mariscal FM et al (2024) Mediterranean diet as a strategy for preserving kidney function in patients with coronary heart disease with type 2 diabetes and obesity: a secondary analysis of CORDIOPREV randomized controlled trial. *Nutr Diabetes* 14(1):27. <https://doi.org/10.1038/s41387-024-00285-3>
54. Delgado-Lista J, Alcalá-Díaz JF, Torres-Peña JD et al (2022) Long-term secondary prevention of cardiovascular disease with a Mediterranean diet and a low-fat diet (CORDIOPREV): a randomised controlled trial. *Lancet* 399(10338):1876–1885. [https://doi.org/10.1016/s0140-6736\(22\)00122-2](https://doi.org/10.1016/s0140-6736(22)00122-2)
55. Mazidi M, Katsiki N, Mikhailidis DP, Sattar N, Banach M (2019) Lower carbohydrate diets and all-cause and cause-specific mortality: a population-based cohort study and pooling of prospective studies. *Eur Heart J* 40(34):2870–2879. <https://doi.org/10.1093/eurheartj/ehz174>
56. Ghasemi P, Jafari M, Maskouni SJ et al (2024) Impact of very low carbohydrate ketogenic diets on cardiovascular risk factors among patients with type 2 diabetes; GRADE-assessed systematic review and meta-analysis of clinical trials. *Nutr Metab (Lond)* 21(1):50. <https://doi.org/10.1186/s12986-024-00824-w>
57. Kilian J, Szlęzak D, Tyszcza-Czochara M, Filipowicz-Popielarska E, Bronowicka-Adamska P (2026) The ketogenic diet in type

- 2 diabetes and obesity: a narrative review of clinical evidence. *Nutrients* 18(3):397. <https://doi.org/10.3390/nu18030397>
58. Beretta MV, Flores CAO, Colameo GF, Echabe LW, Busnello FM (2025) Low-carbohydrate dietary interventions for metabolic control in individuals with type 2 diabetes mellitus: an overview of systematic reviews. *Nutr Rev* 83(7):e1677–e1692. <https://doi.org/10.1093/nutrit/nuae123>
 59. Oliveira BF, Chang CR, Oetsch K et al (2023) Impact of a low-carbohydrate compared with low-fat breakfast on blood glucose control in type 2 diabetes: a randomized trial. *Am J Clin Nutr* 118(1):209–217. <https://doi.org/10.1016/j.ajcnut.2023.04.032>
 60. Apekey TA, Maynard MJ, Kittana M, Kunutsor SK (2022) Comparison of the effectiveness of low carbohydrate versus low fat diets, in type 2 diabetes: systematic review and meta-analysis of randomized controlled trials. *Nutrients* 14(20):4391. <https://doi.org/10.3390/nu14204391>
 61. Zeng X, Ji QP, Jiang ZZ, Xu Y (2024) The effect of different dietary restriction on weight management and metabolic parameters in people with type 2 diabetes mellitus: a network meta-analysis of randomized controlled trials. *Diabetol Metab Syndr* 16(1):254. <https://doi.org/10.1186/s13098-024-01492-9>
 62. Khalafi M, Habibi Maleki A, Symonds ME, Rosenkranz SK, Rohani H, Ehsanifar M (2024) The effects of intermittent fasting on body composition and cardiometabolic health in adults with prediabetes or type 2 diabetes: a systematic review and meta-analysis. *Diabetes Obes Metab* 26(9):3830–3841. <https://doi.org/10.1111/dom.15730>
 63. Huang X, Huang G, Wei G (2025) Intermittent fasting for glycaemic control in patients with type 2 diabetes: a meta-analysis of randomized controlled trials. *Nutr Hosp* 42(2):356–365. <https://doi.org/10.20960/nh.05521>
 64. Liu F, Zhang Z, Sun W, Li T (2025) The metabolic effects of intermittent fasting in patients with type 2 diabetes exist in the short term but disappear after its discontinuation: a systematic review and meta-analysis of randomized controlled trials. *Nutr Res* 138:135–150. <https://doi.org/10.1016/j.nutres.2025.04.008>
 65. Li M, Li J, Xu Y et al (2024) Effect of 5:2 regimens: energy-restricted diet or low-volume high-intensity interval training combined with resistance exercise on glycemic control and cardiometabolic health in adults with overweight/obesity and type 2 diabetes: a three-arm randomized controlled trial. *Diabetes Care* 47(6):1074–1083. <https://doi.org/10.2337/dc24-0241>
 66. Guo L, Xi Y, Jin W et al (2024) A 5:2 intermittent fasting meal replacement diet and glycemic control for adults with diabetes: the EARLY randomized clinical trial. *JAMA Netw Open* 7(6):e2416786. <https://doi.org/10.1001/jamanetworkopen.2024.16786>
 67. Pavlou V, Cienfuegos S, Lin S et al (2023) Effect of time-restricted eating on weight loss in adults with type 2 diabetes: a randomized clinical trial. *JAMA Netw Open* 6(10):e2339337. <https://doi.org/10.1001/jamanetworkopen.2023.39337>
 68. Jing T, Zhang S, Bai M et al (2023) Effect of dietary approaches on glycemic control in patients with type 2 diabetes: a systematic review with network meta-analysis of randomized trials. *Nutrients* 15(14):3156. <https://doi.org/10.3390/nu15143156>
 69. Churuangsu C, Hall J, Reynolds A, Griffin SJ, Combet E, Lean MEJ (2022) Diets for weight management in adults with type 2 diabetes: an umbrella review of published meta-analyses and systematic review of trials of diets for diabetes remission. *Diabetologia* 65(1):14–36. <https://doi.org/10.1007/s00125-021-05577-2>
 70. Johnsen E, Bengtsson J, Halasa T et al (2026) Achieving at least 15% weight loss within 2 years of type 2 diabetes diagnosis is associated with lower risks of macrovascular and microvascular complications: a U.K. cohort study. *Diabetes Care* 49(8):1480–1489. <https://doi.org/10.2337/dc26-0937>
 71. Lean ME, Leslie WS, Barnes AC et al (2018) Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial. *Lancet* 391(10120):541–551. [https://doi.org/10.1016/s0140-6736\(17\)33102-1](https://doi.org/10.1016/s0140-6736(17)33102-1)
 72. Riddle MC, Cefalu WT, Evans PH et al (2021) Consensus report: definition and interpretation of remission in type 2 diabetes. *Diabetes Care* 44(10):2438–2444. <https://doi.org/10.2337/dc21-0034>
 73. Lean ME, Leslie WS, Barnes AC et al (2024) 5-year follow-up of the randomised Diabetes Remission Clinical Trial (DiRECT) of continued support for weight loss maintenance in the UK: an extension study. *Lancet Diabetes Endocrinol* 12(4):233–246. [https://doi.org/10.1016/s2213-8587\(23\)00385-6](https://doi.org/10.1016/s2213-8587(23)00385-6)
 74. Wing RR (2021) Does lifestyle intervention improve health of adults with overweight/obesity and type 2 diabetes? Findings from the look AHEAD randomized trial. *Obesity* (Silver Spring) 29(8):1246–1258. <https://doi.org/10.1002/oby.23158>
 75. Gregg EW, Chen H, Bancks MP et al (2024) Impact of remission from type 2 diabetes on long-term health outcomes: findings from the Look AHEAD study. *Diabetologia* 67(3):459–469. <https://doi.org/10.1007/s00125-023-06048-6>
 76. Retnakaran R, Pu J, Emery A, Kramer CK, Zinman B (2023) Baseline determinants of remission of type 2 diabetes in response to short-term insulin-based therapy: the pivotal role of beta-cell function. *Diabetes Obes Metab* 25(9):2473–2481. <https://doi.org/10.1111/dom.15073>
 77. Kanbour S, Ageeb RA, Malik RA, Abu-Raddad LJ (2025) Impact of bodyweight loss on type 2 diabetes remission: a systematic review and meta-regression analysis of randomised controlled trials. *Lancet Diabetes Endocrinol* 13(4):294–306. [https://doi.org/10.1016/s2213-8587\(24\)00346-2](https://doi.org/10.1016/s2213-8587(24)00346-2)
 78. Jayedi A, Zeraattalab-Motlagh S, Shahinfar H, Gregg EW, Shab-Bidar S (2023) Effect of calorie restriction in comparison to usual diet or usual care on remission of type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. *Am J Clin Nutr* 117(5):870–882. <https://doi.org/10.1016/j.ajcnut.2023.03.018>
 79. Paul P, Kaul R, Harfouche M et al (2022) The effect of microbiome-modulating probiotics, prebiotics and synbiotics on glucose homeostasis in type 2 diabetes: a systematic review, meta-analysis, and meta-regression of clinical trials. *Pharmacol Res* 185:106520. <https://doi.org/10.1016/j.phrs.2022.106520>
 80. Setayesh A, Karimi M, Karimi MA et al (2026) Effects of probiotic and synbiotic supplementation on glycemic indices in adult individuals with prediabetes and type 2 diabetes mellitus: a grade-assessed systematic review and dose-response meta-analysis of RCTs. *Probiotics Antimicrob Proteins* 18(2):3181–3204. <https://doi.org/10.1007/s12602-025-10644-w>
 81. Xie W, Su F, Wang G et al (2022) Glucose-lowering effect of berberine on type 2 diabetes: a systematic review and meta-analysis. *Front Pharmacol* 13:1015045. <https://doi.org/10.3389/fphar.2022.1015045>
 82. Abdelhaleem IA, Brakat AM, Adayel HM, Asla MM, Rizk MA, Aboalfetoh AY (2022) The effects of resveratrol on glycemic control and cardiometabolic parameters in patients with T2DM: a systematic review and meta-analysis. *Med Clin (Barc)* 158(12):576–585. <https://doi.org/10.1016/j.medcli.2021.06.028>
 83. Karimi M, Bahreini N, Pirzad S et al (2025) Propolis supplementation improves cardiometabolic health in patients with type 2 diabetes mellitus: findings from a GRADE-assessed systematic review and meta-analysis of RCTs. *J Diabetes Metab Disord* 24(2):164. <https://doi.org/10.1007/s40200-025-01682-w>
 84. Fan Y, Wu L, Zhang Y et al (2025) The impact of okra (*Abelmoschus esculentus*) supplementation on diabetes and obesity biomarkers in type 2 diabetes patients: a systematic review and meta-analysis of randomized controlled trials. *Phytother Res* 39(10):4693–4703. <https://doi.org/10.1002/ptr.70071>
 85. Farahmand MA, Daneshzad E, Fung TT et al (2023) What is the impact of vitamin D supplementation on glycemic control

- in people with type-2 diabetes: a systematic review and meta-analysis of randomized controlled trials. *BMC Endocr Disord* 23(1):15. <https://doi.org/10.1186/s12902-022-01209-x>
86. Afraie M, Bahrami P, Kohnepoushi P et al (2024) The effect of vitamin D supplementation on glycemic control and cardiovascular risk factors in type 2 diabetes: an updated systematic review and meta-analysis of clinical trials. *J Diabetes Res* 2024:9960656. <https://doi.org/10.1155/2024/9960656>
 87. Cheng L, Lv C, Xue L et al (2024) The prevention and improvement effects of vitamin D on type 2 diabetes mellitus: evidence from an umbrella review on meta-analyses of cohort studies and randomized controlled trials. *Front Nutr* 11:1462535. <https://doi.org/10.3389/fnut.2024.1462535>
 88. Zhao G, Yu X, Wang L et al (2023) Serum 25-hydroxyvitamin D level is associated with short-term glycemic variability metrics derived from continuous glucose monitoring in T2DM. *Sci Rep* 13(1):18463. <https://doi.org/10.1038/s41598-023-45846-1>
 89. Kanaley JA, Colberg SR, Corcoran MH et al (2022) Exercise/physical activity in individuals with type 2 diabetes: a consensus statement from the American college of sports medicine. *Med Sci Sports Exerc* 54(2):353–368. <https://doi.org/10.1249/mss.0000000000002800>
 90. Colberg SR, Sigal RJ, Yardley JE et al (2016) Physical activity/exercise and diabetes: a position statement of the American diabetes association. *Diabetes Care* 39(11):2065–2079. <https://doi.org/10.2337/dc16-1728>
 91. Umpierre D, Ribeiro PA, Kramer CK et al (2011) Physical activity advice only or structured exercise training and association with HbA1c levels in type 2 diabetes: a systematic review and meta-analysis. *JAMA* 305(17):1790–1799. <https://doi.org/10.1001/jama.2011.576>
 92. Michielsen M, Yazig J, Hanssens M et al (2025) The effect of exercise characteristics on HbA1c and other cardiovascular risk factors in adults with type 2 diabetes: a systematic review and meta-analysis of randomised controlled trials. *Cardiovasc Diabetol* 25(1):30. <https://doi.org/10.1186/s12933-025-03048-1>
 93. Garcia SP, Cureau FV, Iorra FQ et al (2025) Effects of exercise training and physical activity advice on HbA1c in people with type 2 diabetes: a network meta-analysis of randomized controlled trials. *Diabetes Res Clin Pract* 221:112027. <https://doi.org/10.1016/j.diabres.2025.112027>
 94. Gallardo-Gómez D, Salazar-Martínez E, Alfonso-Rosa RM et al (2024) Optimal dose and type of physical activity to improve glycemic control in people diagnosed with type 2 diabetes: a systematic review and meta-analysis. *Diabetes Care* 47(2):295–303. <https://doi.org/10.2337/dc23-0800>
 95. Liang Z, Zhang M, Wang C et al (2024) The best exercise modality and dose to reduce glycosylated hemoglobin in patients with type 2 diabetes: a systematic review with pairwise, network, and dose-response meta-analyses. *Sports Med* 54(10):2557–2570. <https://doi.org/10.1007/s40279-024-02057-6>
 96. Jayedi A, Emadi A, Shab-Bidar S (2022) Dose-dependent effect of supervised aerobic exercise on HbA(1c) in patients with type 2 diabetes: a meta-analysis of randomized controlled trials. *Sports Med* 52(8):1919–1938. <https://doi.org/10.1007/s40279-022-01673-4>
 97. Poon ET, Li HY, Kong APS, Little JP (2025) Efficacy of high-intensity interval training in individuals with type 2 diabetes mellitus: an umbrella review of systematic reviews and meta-analyses. *Diabetes Obes Metab* 27(4):1719–1734. <https://doi.org/10.1111/dom.16220>
 98. Pan B, Ge L, Xun YQ et al (2018) Exercise training modalities in patients with type 2 diabetes mellitus: a systematic review and network meta-analysis. *Int J Behav Nutr Phys Act* 15(1):72. <https://doi.org/10.1186/s12966-018-0703-3>
 99. Al-Mhanna SB, Franklin BA, Jakicic JM et al (2025) Impact of resistance training on cardiometabolic health-related indices in patients with type 2 diabetes and overweight/obesity: a systematic review and meta-analysis of randomised controlled trials. *Br J Sports Med* 59(10):733–746. <https://doi.org/10.1136/bjsports-2024-108947>
 100. Sanchis-Gomar F, Neeland IJ, Lavie CJ (2025) Balancing weight and muscle loss in GLP1 receptor agonist therapy. *Nat Rev Endocrinol* 21(10):584–585. <https://doi.org/10.1038/s41574-025-01160-6>
 101. Conte C, Hall KD, Klein S (2024) Is weight loss-induced muscle mass loss clinically relevant? *JAMA* 332(1):9–10. <https://doi.org/10.1001/jama.2024.6586>
 102. Look M, Dunn JP, Kushner RF et al (2025) Body composition changes during weight reduction with tirzepatide in the SUR-MOUNT-1 study of adults with obesity or overweight. *Diabetes Obes Metab* 27(5):2720–2729. <https://doi.org/10.1111/dom.16275>
 103. Henson J, Davies MJ, Bodicoat DH et al (2016) Breaking up prolonged sitting with standing or walking attenuates the postprandial metabolic response in postmenopausal women: a randomized acute study. *Diabetes Care* 39(1):130–138. <https://doi.org/10.2337/dc15-1240>
 104. Dempsey PC, Larsen RN, Sethi P et al (2016) Benefits for type 2 diabetes of interrupting prolonged sitting with brief bouts of light walking or simple resistance activities. *Diabetes Care* 39(6):964–972. <https://doi.org/10.2337/dc15-2336>
 105. Homer AR, Taylor FC, Dempsey PC et al (2021) Frequency of interruptions to sitting time: benefits for postprandial metabolism in type 2 diabetes. *Diabetes Care* 44(6):1254–1263. <https://doi.org/10.2337/dc20-1410>
 106. Quan M, Xun P, Wu H et al (2021) Effects of interrupting prolonged sitting on postprandial glycemia and insulin responses: a network meta-analysis. *J Sport Health Sci* 10(4):419–429. <https://doi.org/10.1016/j.jshs.2020.12.006>
 107. Loh R, Stamatakis E, Folkerts D, Allgrove JE, Moir HJ (2020) Effects of interrupting prolonged sitting with physical activity breaks on blood glucose, insulin and triacylglycerol measures: a systematic review and meta-analysis. *Sports Med* 50(2):295–330. <https://doi.org/10.1007/s40279-019-01183-w>
 108. Buffey AJ, Herring MP, Langley CK, Donnelly AE, Carson BP (2022) The acute effects of interrupting prolonged sitting time in adults with standing and light-intensity walking on biomarkers of cardiometabolic health in adults: a systematic review and meta-analysis. *Sports Med* 52(8):1765–1787. <https://doi.org/10.1007/s40279-022-01649-4>
 109. Banach M, Lewek J, Surma S et al (2023) The association between daily step count and all-cause and cardiovascular mortality: a meta-analysis. *Eur J Prev Cardiol* 30(18):1975–1985. <https://doi.org/10.1093/eurjpc/zwad229>
 110. Paluch AE, Bajpai S, Bassett DR et al (2022) Daily steps and all-cause mortality: a meta-analysis of 15 international cohorts. *Lancet Public Health* 7(3):e219–e228. [https://doi.org/10.1016/s2468-2667\(21\)00302-9](https://doi.org/10.1016/s2468-2667(21)00302-9)
 111. Ding D, Nguyen B, Nau T et al (2025) Daily steps and health outcomes in adults: a systematic review and dose-response meta-analysis. *Lancet Public Health* 10(8):e668–e681. [https://doi.org/10.1016/s2468-2667\(25\)00164-1](https://doi.org/10.1016/s2468-2667(25)00164-1)
 112. Del Pozo-Cruz J, Alvarez-Barbosa F, Gallardo-Gomez D, Del Pozo Cruz B (2022) Optimal number of steps per day to prevent all-cause mortality in people with prediabetes and diabetes. *Diabetes Care* 45(9):2156–2158. <https://doi.org/10.2337/dc22-0524>
 113. Shan Z, Ma H, Xie M et al (2015) Sleep duration and risk of type 2 diabetes: a meta-analysis of prospective studies. *Diabetes Care* 38(3):529–537. <https://doi.org/10.2337/dc14-2073>
 114. Lee SWH, Ng KY, Chin WK (2017) The impact of sleep amount and sleep quality on glycemic control in type 2 diabetes: a systematic review and meta-analysis. *Sleep Med Rev* 31:91–101. <https://doi.org/10.1016/j.smrv.2016.02.001>

115. Liu J, Richmond RC, Bowden J et al (2022) Assessing the causal role of sleep traits on glycated hemoglobin: a Mendelian randomization study. *Diabetes Care* 45(4):772–781. <https://doi.org/10.2337/dc21-0089>
116. Henson J, Covenant A, Hall AP et al (2024) Waking up to the importance of sleep in type 2 diabetes management: a narrative review. *Diabetes Care* 47(3):331–343. <https://doi.org/10.2337/dci23-0037>
117. Brouwer A, van Raalte DH, Rutters F et al (2020) Sleep and HbA(1c) in patients with type 2 diabetes: which sleep characteristics matter most? *Diabetes Care* 43(1):235–243. <https://doi.org/10.2337/dc19-0550>
118. Reutrakul S, Hood MM, Crowley SJ et al (2013) Chronotype is independently associated with glycemic control in type 2 diabetes. *Diabetes Care* 36(9):2523–2529. <https://doi.org/10.2337/dc12-2697>
119. Mostafa SA, Hanif W, Crowe F et al (2025) The effect of non-pharmacological sleep interventions on glycaemic measures in adults with sleep disturbances and behaviours: a systematic review and meta-analysis. *Diab Vasc Dis Res* 22(1):14791641241307368. <https://doi.org/10.1177/14791641241307367>
120. García-Serrano C, Pujol Salud J, Aran-Solé L et al (2022) Enhancing night and day circadian contrast through sleep education in prediabetes and type 2 diabetes mellitus: a randomized controlled trial. *Biology (Basel)* 11(6):893. <https://doi.org/10.3390/biology11060893>
121. American Diabetes Association Professional Practice Committee (2026) 10. Cardiovascular disease and risk management: standards of care in diabetes-2026. *Diabetes Care* 49(Suppl 1):S216–s245. <https://doi.org/10.2337/dc26-S010>
122. Shin H, Paik JM, Everett BM et al (2025) Comparative effectiveness of individual sodium-glucose cotransporter 2 inhibitors. *JAMA Intern Med* 185(3):302–313. <https://doi.org/10.1001/jamainternmed.2024.7357>
123. McGuire DK, Shih WJ, Cosentino F et al (2021) Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis. *JAMA Cardiol* 6(2):148–158. <https://doi.org/10.1001/jamacardio.2020.4511>
124. Zinman B, Wanner C, Lachin JM et al (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. *N Engl J Med* 373(22):2117–2128. <https://doi.org/10.1056/NEJMoa1504720>
125. Neal B, Perkovic V, Mahaffey KW et al (2017) Canagliflozin and cardiovascular and renal events in type 2 diabetes. *N Engl J Med* 377(7):644–657. <https://doi.org/10.1056/NEJMoa1611925>
126. Wiviott SD, Raz I, Bonaca MP et al (2019) Dapagliflozin and cardiovascular outcomes in type 2 diabetes. *N Engl J Med* 380(4):347–357. <https://doi.org/10.1056/NEJMoa1812389>
127. Cannon CP, Pratley R, Dagogo-Jack S et al (2020) Cardiovascular outcomes with ertugliflozin in type 2 diabetes. *N Engl J Med* 383(15):1425–1435. <https://doi.org/10.1056/NEJMoa2004967>
128. Bhatt DL, Szarek M, Pitt B et al (2021) Sotagliflozin in patients with diabetes and chronic kidney disease. *N Engl J Med* 384(2):129–139. <https://doi.org/10.1056/NEJMoa2030186>
129. McMurray JJV, Solomon SD, Inzucchi SE et al (2019) Dapagliflozin in patients with heart failure and reduced ejection fraction. *N Engl J Med* 381(21):1995–2008. <https://doi.org/10.1056/NEJMoa1911303>
130. Packer M, Anker SD, Butler J et al (2020) Cardiovascular and renal outcomes with empagliflozin in heart failure. *N Engl J Med* 383(15):1413–1424. <https://doi.org/10.1056/NEJMoa2022190>
131. Bhatt DL, Szarek M, Steg PG et al (2021) Sotagliflozin in patients with diabetes and recent worsening heart failure. *N Engl J Med* 384(2):117–128. <https://doi.org/10.1056/NEJMoa2030183>
132. Anker SD, Butler J, Filippatos G et al (2021) Empagliflozin in heart failure with a preserved ejection fraction. *N Engl J Med* 385(16):1451–1461. <https://doi.org/10.1056/NEJMoa2107038>
133. Perkovic V, Jardine MJ, Neal B et al (2019) Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. *N Engl J Med* 380(24):2295–2306. <https://doi.org/10.1056/NEJMoa1811744>
134. Heerspink HJL, Stefánsson BV, Correa-Rotter R et al (2020) Dapagliflozin in patients with chronic kidney disease. *N Engl J Med* 383(15):1436–1446. <https://doi.org/10.1056/NEJMoa2024816>
135. Herrington WG, Staplin N, Wanner C et al (2023) Empagliflozin in patients with chronic kidney disease. *N Engl J Med* 388(2):117–127. <https://doi.org/10.1056/NEJMoa2204233>
136. Boehringer Ingelheim (2025) Prescribing information for JARDI-ANCE. Boehringer Ingelheim, Ingelheim am Rhein, Germany. Available from https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/204629s063lbl.pdf. Accessed 30 April 2026
137. Janssen (2024) Prescribing information for INVOKANA. Janssen, Beerse, Belgium. Available from https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/204042s043lbl.pdf. Accessed 30 April 2026
138. AstraZeneca (2024) Prescribing information for FARXIGA. AstraZeneca, Wilmington, DE, USA. Available from https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/202293s031lbl.pdf. Accessed 30 April 2026
139. Merck (2024) Prescribing information for STEGLATRO. Merck, Readington, NJ, USA. Available from https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/209803s008lbl.pdf. Accessed 30 April 2026
140. Mistry S, Eschler DC (2021) Euglycemic diabetic ketoacidosis caused by SGLT2 inhibitors and a ketogenic diet: a case series and review of literature. *AACE Clin Case Rep* 7(1):17–19. <https://doi.org/10.1016/j.aace.2020.11.009>
141. American Diabetes Association Professional Practice Committee (2026) 6. Glycemic goals, hypoglycemia, and hyperglycemic crises: standards of care in diabetes-2026. *Diabetes Care* 49(Suppl 1):S132–s149. <https://doi.org/10.2337/dc26-S006>
142. Qian BB, Chen Q, Li L, Yan CF (2020) Association between combined treatment with SGLT2 inhibitors and metformin for type 2 diabetes mellitus on fracture risk: a meta-analysis of randomized controlled trials. *Osteoporos Int* 31(12):2313–2320. <https://doi.org/10.1007/s00198-020-05590-y>
143. Dorsey-Treviño EG, González-González JG, Alvarez-Villalobos N et al (2020) Sodium-glucose cotransporter 2 (SGLT-2) inhibitors and microvascular outcomes in patients with type 2 diabetes: systematic review and meta-analysis. *J Endocrinol Invest* 43(3):289–304. <https://doi.org/10.1007/s40618-019-01103-9>
144. Vart P, Butt JH, Jongs N et al (2024) Efficacy and safety of dapagliflozin in patients with chronic kidney disease across the spectrum of frailty. *J Gerontol A Biol Sci Med Sci* 79(2):glad181. <https://doi.org/10.1093/gerona/glad181>
145. Butt JH, Jhund PS, Belohlávek J et al (2022) Efficacy and safety of dapagliflozin according to frailty in patients with heart failure: a pre-specified analysis of the DELIVER trial. *Circulation* 146(16):1210–1224. <https://doi.org/10.1161/circulationaha.122.061754>
146. Gudemann LM, Young KG, Thomas NJM et al (2024) Safety and effectiveness of SGLT2 inhibitors in a UK population with type 2 diabetes and aged over 70 years: an instrumental variable approach. *Diabetologia* 67(9):1817–1827. <https://doi.org/10.1007/s00125-024-06190-9>
147. Barraclough JY, Yu J, Figtree GA et al (2022) Cardiovascular and renal outcomes with canagliflozin in patients with peripheral arterial disease: data from the CANVAS Program and CRE-DENCE trial. *Diabetes Obes Metab* 24(6):1072–1083. <https://doi.org/10.1111/dom.14671>
148. Staplin N, Roddick AJ, Neuen BL et al (2026) Effects of sodium glucose cotransporter 2 inhibitors by diabetes status and level of albuminuria: a meta-analysis. *JAMA* 335(3):220–232. <https://doi.org/10.1001/jama.2025.20835>

149. Nauck MA, Quast DR, Wefers J, Meier JJ (2021) GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. *Mol Metab* 46:101102. <https://doi.org/10.1016/j.molmet.2020.101102>
150. Sørensen KK, Møller FT, Yazdanfar PDW et al (2026) Consumer food purchases after glucagon-like peptide-1 receptor agonist initiation. *JAMA Netw Open* 9(1):e2555449. <https://doi.org/10.1001/jamanetworkopen.2025.55449>
151. Kosiborod MN, Petrie MC, Borlaug BA et al (2024) Semaglutide in patients with obesity-related heart failure and type 2 diabetes. *N Engl J Med* 390(15):1394–1407. <https://doi.org/10.1056/NEJMoa2313917>
152. Sanyal AJ, Newsome PN, Kliers I et al (2025) Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis. *N Engl J Med* 392(21):2089–2099. <https://doi.org/10.1056/NEJMoa2413258>
153. Anderer S (2026) FDA approves GLP-1 obesity pill without food or water restrictions. *JAMA* 335(18):1564. <https://doi.org/10.1001/jama.2026.2113>
154. Novo Nordisk (2019) Prescribing information for RYBELSUS. Novo Nordisk, Plainsboro, NJ, USA. Available from https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/213051s0181bl.pdf. Accessed 30 April 2026
155. Rosenstock J, Yabe D, Cox D et al (2026) Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial. *Lancet* 407(10534):1147–1160. [https://doi.org/10.1016/s0140-6736\(26\)00202-3](https://doi.org/10.1016/s0140-6736(26)00202-3)
156. Aroda VR, Aberle J, Bardtrum L et al (2023) Efficacy and safety of once-daily oral semaglutide 25 mg and 50 mg compared with 14 mg in adults with type 2 diabetes (PIONEER PLUS): a multicentre, randomised, phase 3b trial. *Lancet* 402(10403):693–704. [https://doi.org/10.1016/s0140-6736\(23\)01127-3](https://doi.org/10.1016/s0140-6736(23)01127-3)
157. Lingvay I, Bergenheim SJ, Buse JB et al (2025) Once-weekly semaglutide 7.2 mg in adults with obesity and type 2 diabetes (STEP UP T2D): a randomised, controlled, phase 3b trial. *Lancet Diabetes Endocrinol* 13(11):935–948. [https://doi.org/10.1016/s2213-8587\(25\)00225-6](https://doi.org/10.1016/s2213-8587(25)00225-6)
158. Duong A, Heacock S, Amering S, Brennan L, Venci J, Acquisto NM (2024) Real-world impact of 3 and 4.5 mg doses of dulaglutide on weight and hemoglobin A1c in patients with type 2 diabetes mellitus. *Ann Pharmacother* 58(6):589–597. <https://doi.org/10.1177/10600280231199852>
159. Frias JP, Bonora E, Nevarez Ruiz L et al (2021) Efficacy and safety of dulaglutide 3.0 mg and 4.5 mg versus dulaglutide 1.5 mg in metformin-treated patients with type 2 diabetes in a randomized controlled trial (AWARD-11). *Diabetes Care* 44(3):765–773. <https://doi.org/10.2337/dc20-1473>
160. Hammoud R, Drucker DJ (2023) Beyond the pancreas: contrasting cardiometabolic actions of GIP and GLP1. *Nat Rev Endocrinol* 19(4):201–216. <https://doi.org/10.1038/s41574-022-00783-3>
161. Nauck MA, D'Alessio DA (2022) Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction. *Cardiovasc Diabetol* 21(1):169. <https://doi.org/10.1186/s12933-022-01604-7>
162. Gastaldelli A, Cusi K, Fernández Landó L, Bray R, Brouwers B, Rodríguez Á (2022) Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial. *Lancet Diabetes Endocrinol* 10(6):393–406. [https://doi.org/10.1016/s2213-8587\(22\)00070-5](https://doi.org/10.1016/s2213-8587(22)00070-5)
163. Malhotra A, Grunstein RR, Fietze I et al (2024) Tirzepatide for the treatment of obstructive sleep apnea and obesity. *N Engl J Med* 391(13):1193–1205. <https://doi.org/10.1056/NEJMoa2404881>
164. Packer M, Zile MR, Kramer CM et al (2025) Tirzepatide for heart failure with preserved ejection fraction and obesity. *N Engl J Med* 392(5):427–437. <https://doi.org/10.1056/NEJMoa2410027>
165. Nicholls SJ, Pavo I, Bhatt DL et al (2025) Cardiovascular outcomes with tirzepatide versus dulaglutide in type 2 diabetes. *N Engl J Med* 393(24):2409–2420. <https://doi.org/10.1056/NEJMoa2505928>
166. Sattar N, Gerstein HC, D'Alessio D et al (2026) Estimating the true MACE benefits from tirzepatide in SURPASS-CVOT using an imputed placebo analysis of REWIND. *Diabetes Care* dc260298. <https://doi.org/10.2337/dc26-0298>
167. Wharton S, Davies M, Dicker D et al (2022) Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity: recommendations for clinical practice. *Postgrad Med* 134(1):14–19. <https://doi.org/10.1080/00325481.2021.2002616>
168. Peng H, Want LL, Aroda VR (2016) Safety and tolerability of glucagon-like peptide-1 receptor agonists utilizing data from the exenatide clinical trial development program. *Curr Diab Rep* 16(5):44. <https://doi.org/10.1007/s11892-016-0728-4>
169. Lee MMY, Sattar N, Pop-Busui R et al (2025) Cardiovascular and kidney outcomes and mortality with long-acting injectable and oral glucagon-like peptide 1 receptor agonists in individuals with type 2 diabetes: a systematic review and meta-analysis of randomized trials. *Diabetes Care* 48(5):846–859. <https://doi.org/10.2337/dc25-0241>
170. He L, Wang J, Ping F et al (2022) Association of glucagon-like peptide-1 receptor agonist use with risk of gallbladder and biliary diseases: a systematic review and meta-analysis of randomized clinical trials. *JAMA Intern Med* 182(5):513–519. <https://doi.org/10.1001/jamainternmed.2022.0338>
171. Hathaway JT, Shah MP, Hathaway DB et al (2024) Risk of non-arteritic anterior ischemic optic neuropathy in patients prescribed semaglutide. *JAMA Ophthalmol* 142(8):732–739. <https://doi.org/10.1001/jamaophthalmol.2024.2296>
172. Abdelaal A, Abu Serhan H, Alsaadi M, Yaldo L, Gaier ED, Elhusseiny AM (2026) Semaglutide and the risk of nonarteritic ischemic optic neuropathy: a systematic review and certainty of evidence meta-analysis. *Ophthalmology* 133(6):799–810. <https://doi.org/10.1016/j.ophtha.2026.02.013>
173. Crowley MJ, McGuire DK, Alexopoulos AS et al (2020) Effects of liraglutide on cardiovascular outcomes in type 2 diabetes patients with and without baseline metformin use: post hoc analyses of the LEADER trial. *Diabetes Care* 43(9):e108–e110. <https://doi.org/10.2337/dc20-0437>
174. Neuen BL, Arnott C, Perkovic V et al (2021) Sodium-glucose co-transporter-2 inhibitors with and without metformin: a meta-analysis of cardiovascular, kidney and mortality outcomes. *Diabetes Obes Metab* 23(2):382–390. <https://doi.org/10.1111/dom.14226>
175. Masson W, Lavallo-Cobo A, Lobo M, Masson G, Molinero G (2021) Novel antidiabetic drugs and risk of cardiovascular events in patients without baseline metformin use: a meta-analysis. *Eur J Prev Cardiol* 28(1):69–75. <https://doi.org/10.1093/eurjpc/zwaa074>
176. Lalau JD, Kajbaf F, Bennis Y, Hurtel-Lemaire AS, Belpaire F, De Broe ME (2018) Metformin treatment in patients with type 2 diabetes and chronic kidney disease stages 3A, 3B, or 4. *Diabetes Care* 41(3):547–553. <https://doi.org/10.2337/dc17-2231>
177. Out M, Kooy A, Leher P, Schalkwijk CA, Stehouwer CDA (2018) Long-term treatment with metformin in type 2 diabetes and methylmalonic acid: post hoc analysis of a randomized controlled 4.3-year trial. *J Diabetes Complications* 32(2):171–178. <https://doi.org/10.1016/j.jdiacomp.2017.11.001>
178. Aroda VR, Edelstein SL, Goldberg RB et al (2016) Long-term metformin use and vitamin B12 deficiency in the diabetes prevention program outcomes study. *J Clin Endocrinol*

- Metab 101(4):1754–1761. <https://doi.org/10.1210/jc.2015-3754>
179. Drake T, Landsteiner A, Langsetmo L et al (2024) Newer pharmacologic treatments in adults with type 2 diabetes: a systematic review and network meta-analysis for the American College of Physicians. *Ann Intern Med* 177(5):618–632. <https://doi.org/10.7326/m23-1490>
 180. American Diabetes Association Professional Practice Committee (2022) 10. Cardiovascular disease and risk management: standards of medical care in diabetes-2022. *Diabetes Care* 45(Suppl 1):S144–s174. <https://doi.org/10.2337/dc22-S010>
 181. Gong Y, Bai X, Zhang D et al (2024) Effect of DPP-4i inhibitors on renal function in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials. *Lipids Health Dis* 23(1):157. <https://doi.org/10.1186/s12944-024-02132-x>
 182. Yu M, Yang Z, Chen C et al (2022) Association of the gallbladder or biliary diseases with dipeptidyl peptidase 4 inhibitors in patients with type 2 diabetes: a meta-analysis of randomized controlled trials. *Diabetol Metab Syndr* 14(1):153. <https://doi.org/10.1186/s13098-022-00924-8>
 183. American Diabetes Association Professional Practice Committee (2022) 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2022. *Diabetes Care* 45(Suppl 1):S125–s143. <https://doi.org/10.2337/dc22-S009>
 184. Khunti K, Chatterjee S, Gerstein HC, Zoungas S, Davies MJ (2018) Do sulphonylureas still have a place in clinical practice? *Lancet Diabetes Endocrinol* 6(10):821–832. [https://doi.org/10.1016/s2213-8587\(18\)30025-1](https://doi.org/10.1016/s2213-8587(18)30025-1)
 185. UK Prospective Diabetes Study (UKPDS) Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). *Lancet* 352(9131):837–853
 186. Wang H, Cordiner RLM, Huang Y et al (2023) Cardiovascular safety in type 2 diabetes with sulfonylureas as second-line drugs: a nationwide population-based comparative safety study. *Diabetes Care* 46(5):967–977. <https://doi.org/10.2337/dc22-1238>
 187. Rosenstock J, Kahn SE, Johansen OE et al (2019) Effect of linagliptin vs glimepiride on major adverse cardiovascular outcomes in patients with type 2 diabetes: the CAROLINA randomized clinical trial. *JAMA* 322(12):1155–1166. <https://doi.org/10.1001/jama.2019.13772>
 188. Davies MJ, D'Alessio DA, Fradkin J et al (2018) Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). *Diabetologia* 61(12):2461–2498. <https://doi.org/10.1007/s00125-018-4729-5>
 189. Buse JB, Wexler DJ, Tsapas A et al (2020) 2019 update to: management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). *Diabetologia* 63(2):221–228. <https://doi.org/10.1007/s00125-019-05039-w>
 190. Davies MJ, D'Alessio DA, Fradkin J et al (2018) Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). *Diabetes Care* 41(12):2669–2701. <https://doi.org/10.2337/dci18-0033>
 191. Buse JB, Wexler DJ, Tsapas A et al (2020) 2019 update to: management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). *Diabetes Care* 43(2):487–493. <https://doi.org/10.2337/dci19-0066>
 192. Kahn SE, Haffner SM, Heise MA et al (2006) Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. *N Engl J Med* 355(23):2427–2443. <https://doi.org/10.1056/NEJMo>
 193. Dormandy JA, Charbonnel B, Eckland DJ et al (2005) Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitazone Clinical Trial In macroVascular Events): a randomised controlled trial. *Lancet* 366(9493):1279–1289. [https://doi.org/10.1016/s0140-6736\(05\)67528-9](https://doi.org/10.1016/s0140-6736(05)67528-9)
 194. Kernan WN, Viscoli CM, Furie KL et al (2016) Pioglitazone after ischemic stroke or transient ischemic attack. *N Engl J Med* 374(14):1321–1331. <https://doi.org/10.1056/NEJMoA1506930>
 195. Spence JD, Viscoli CM, Inzucchi SE et al (2019) Pioglitazone therapy in patients with stroke and prediabetes: a post hoc analysis of the IRIS randomized clinical trial. *JAMA Neurol* 76(5):526–535. <https://doi.org/10.1001/jamaneurol.2019.0079>
 196. Cusi K, Orsak B, Bril F et al (2016) Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial. *Ann Intern Med* 165(5):305–315. <https://doi.org/10.7326/m15-1774>
 197. Della Pepa G, Russo M, Vitale M et al (2021) Pioglitazone even at low dosage improves NAFLD in type 2 diabetes: clinical and pathophysiological insights from a subgroup of the TOSCA.IT randomised trial. *Diabetes Res Clin Pract* 178:108984. <https://doi.org/10.1016/j.diabres.2021.108984>
 198. Home PD, Pocock SJ, Beck-Nielsen H et al (2009) Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. *Lancet* 373(9681):2125–2135. [https://doi.org/10.1016/s0140-6736\(09\)60953-3](https://doi.org/10.1016/s0140-6736(09)60953-3)
 199. Hanefeld M, Brunetti P, Scherthaner GH, Matthews DR, Charbonnel BH (2004) One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes. *Diabetes Care* 27(1):141–147. <https://doi.org/10.2337/diacare.27.1.141>
 200. Viscoli CM, Inzucchi SE, Young LH et al (2017) Pioglitazone and risk for bone fracture: safety data from a randomized clinical trial. *J Clin Endocrinol Metab* 102(3):914–922. <https://doi.org/10.1210/jc.2016-3237>
 201. Kahn SE, Zinman B, Lachin JM et al (2008) Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT). *Diabetes Care* 31(5):845–851. <https://doi.org/10.2337/dc07-2270>
 202. Baddam S, Banka AV, Divity S, Sandesara M, Vityala Y (2024) Association between pioglitazone use and bladder cancer: a systematic review. *Bladder (San Franc)* 11(4):e21200023. <https://doi.org/10.14440/bladder.2024.0039>
 203. DeFronzo RA, Inzucchi S, Abdul-Ghani M, Nissen SE (2019) Pioglitazone: the forgotten, cost-effective cardioprotective drug for type 2 diabetes. *Diab Vasc Dis Res* 16(2):133–143. <https://doi.org/10.1177/1479164118825376>
 204. Mannucci E, Caiulo C, Naletto L, Madama G, Monami M (2021) Efficacy and safety of different basal and prandial insulin analogues for the treatment of type 2 diabetes: a network meta-analysis of randomized controlled trials. *Endocrine* 74(3):508–517. <https://doi.org/10.1007/s12020-021-02889-6>
 205. Chan J, Cheng-Lai A (2017) Inhaled insulin: a clinical and historical review. *Cardiol Rev* 25(3):140–146. <https://doi.org/10.1097/crd.0000000000000143>
 206. Bergenstal RM, Peyrot M, Dreon DM et al (2019) Implementation of basal-bolus therapy in type 2 diabetes: a randomized controlled trial comparing bolus insulin delivery using an insulin patch with an insulin pen. *Diabetes Technol Ther* 21(5):273–285. <https://doi.org/10.1089/dia.2018.0298>
 207. Heinemann L, Parkin CG (2018) Rethinking the viability and utility of inhaled insulin in clinical practice. *J Diabetes Res* 2018:4568903. <https://doi.org/10.1155/2018/4568903>

208. Rosenstock J, Bain SC, Gowda A et al (2023) Weekly icodex versus daily glargine U100 in type 2 diabetes without previous insulin. *N Engl J Med* 389(4):297–308. <https://doi.org/10.1056/NEJMoa2303208>
209. Bajaj HS, Ásbjörnsdóttir B, Bari TJ, Begtrup K, Vilsbøll T, Rosenstock J (2024) Once-weekly insulin icodex compared with daily basal insulin analogues in type 2 diabetes: participant-level meta-analysis of the ONWARDS 1–5 trials. *Diabetes Obes Metab* 26(9):3810–3820. <https://doi.org/10.1111/dom.15726>
210. Rosenstock J, Bailey T, Connery L et al (2025) Weekly fixed-dose insulin efsitora in type 2 diabetes without previous insulin therapy. *N Engl J Med* 393(4):325–335. <https://doi.org/10.1056/NEJMoa2502796>
211. Wysham C, Bajaj HS, Del Prato S et al (2024) Insulin efsitora versus degludec in type 2 diabetes without previous insulin treatment. *N Engl J Med* 391(23):2201–2211. <https://doi.org/10.1056/NEJMoa2403953>
212. Blevins T, Dahl D, Pérez Manghi FC et al (2025) Once-weekly insulin efsitora alfa versus once-daily insulin glargine U100 in adults with type 2 diabetes treated with basal and prandial insulin (QWINT-4): a phase 3, randomised, non-inferiority trial. *Lancet* 405(10497):2290–2301. [https://doi.org/10.1016/s0140-6736\(25\)01069-4](https://doi.org/10.1016/s0140-6736(25)01069-4)
213. Mathieu C, Giorgino F, Kim SG et al (2025) Once-weekly IcoSema versus once-weekly insulin icodex in type 2 diabetes management (COMBINE 1): an open-label, multicentre, treat-to-target, randomised, phase 3a trial. *Lancet Diabetes Endocrinol* 13(7):568–579. [https://doi.org/10.1016/s2213-8587\(25\)00096-8](https://doi.org/10.1016/s2213-8587(25)00096-8)
214. Lingvay I, Benamar M, Chen L et al (2025) Once-weekly IcoSema versus once-weekly semaglutide in adults with type 2 diabetes: the COMBINE 2 randomised clinical trial. *Diabetologia* 68(4):739–751. <https://doi.org/10.1007/s00125-024-06348-5>
215. Billings LK, Andreozzi F, Frederiksen M et al (2025) Once-weekly IcoSema versus multiple daily insulin injections in type 2 diabetes management (COMBINE 3): an open-label, multicentre, treat-to-target, non-inferiority, randomised, phase 3a trial. *Lancet Diabetes Endocrinol* 13(7):556–567. [https://doi.org/10.1016/s2213-8587\(25\)00052-x](https://doi.org/10.1016/s2213-8587(25)00052-x)
216. Aroda VR, Arulandu JR, Cannon AJ (2018) Insulin/glucagon-like peptide-1 receptor agonist combination therapy for the treatment of type 2 diabetes: are two agents better than one? *Clin Diabetes* 36(2):138–147. <https://doi.org/10.2337/cd17-0065>
217. Maiorino MI, Chiodini P, Bellastella G et al (2018) Free and fixed-ratio combinations of basal insulin and GLP-1 receptor agonists versus basal insulin intensification in type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. *Diabetes Obes Metab* 20(9):2309–2313. <https://doi.org/10.1111/dom.13343>
218. Kasthuri S, Poongothai S, Anjana RM et al (2021) Comparison of glycemic excursion using flash continuous glucose monitoring in patients with type 2 diabetes mellitus before and after treatment with voglibose. *Diabetes Technol Ther* 23(3):213–220. <https://doi.org/10.1089/dia.2019.0484>
219. Dalsgaard NB, Gasbjerg LS, Hansen LS et al (2021) The role of GLP-1 in the postprandial effects of acarbose in type 2 diabetes. *Eur J Endocrinol* 184(3):383–394. <https://doi.org/10.1530/eje-20-1121>
220. Wu Y, Yang Z, Cao Q (2024) Efficacy and safety of GLP-1 receptor agonists combined with SGLT-2 inhibitors in elderly patients with type 2 diabetes: a meta-analysis. *Am J Transl Res* 16(11):6852–6866. <https://doi.org/10.62347/mcee4840>
221. Ludvik B, Frías JP, Tinahones FJ et al (2018) Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial. *Lancet Diabetes Endocrinol* 6(5):370–381. [https://doi.org/10.1016/s2213-8587\(18\)30023-8](https://doi.org/10.1016/s2213-8587(18)30023-8)
222. Apperloo EM, Neuen BL, Fletcher RA et al (2024) Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1 receptor agonists: a SMART-C collaborative meta-analysis of randomised controlled trials. *Lancet Diabetes Endocrinol* 12(8):545–557. [https://doi.org/10.1016/s2213-8587\(24\)00155-4](https://doi.org/10.1016/s2213-8587(24)00155-4)
223. Simms-Williams N, Treves N, Yin H et al (2024) Effect of combination treatment with glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors on incidence of cardiovascular and serious renal events: population based cohort study. *BMJ* 385:e078242. <https://doi.org/10.1136/bmj-2023-078242>
224. Neves JS, Borges-Canha M, Vasques-Nóvoa F et al (2023) GLP-1 receptor agonist therapy with and without SGLT2 inhibitors in patients with type 2 diabetes. *J Am Coll Cardiol* 82(6):517–525. <https://doi.org/10.1016/j.jacc.2023.05.048>
225. Colombijn JMT, de Leijer JF, Visseren FLJ et al (2026) Effectiveness and safety of combining SGLT2 inhibitors and GLP-1 receptor agonists in individuals with type 2 diabetes: a systematic review and meta-analysis of cohort studies. *Diabetologia* 69(1):36–49. <https://doi.org/10.1007/s00125-025-06565-6>
226. Shokravi A, Seth J, Mancini GBJ (2025) Cardiovascular and renal outcomes of dual combination therapies with glucagon-like peptide-1 receptor agonists and sodium-glucose transport protein 2 inhibitors: a systematic review and meta-analysis. *Cardiovasc Diabetol* 24(1):370. <https://doi.org/10.1186/s12933-025-02900-8>
227. DeFronzo RA, Fonseca V, Aroda VR et al (2025) Inadequately controlled type 2 diabetes and hypercortisolism: improved glycemia with mifepristone treatment. *Diabetes Care* 48(12):2036–2044. <https://doi.org/10.2337/dc25-1055>
228. Bakris GL, Agarwal R, Anker SD et al (2020) Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. *N Engl J Med* 383(23):2219–2229. <https://doi.org/10.1056/NEJMoa2025845>
229. Pitt B, Filippatos G, Agarwal R et al (2021) Cardiovascular events with finerenone in kidney disease and type 2 diabetes. *N Engl J Med* 385(24):2252–2263. <https://doi.org/10.1056/NEJMoa2110956>
230. Agarwal R, Filippatos G, Pitt B et al (2022) Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. *Eur Heart J* 43(6):474–484. <https://doi.org/10.1093/eurheartj/ehab777>
231. Samuel M, Berry C, Dubé MP et al (2025) Long-term trials of colchicine for secondary prevention of vascular events: a meta-analysis. *Eur Heart J* 46(26):2552–2563. <https://doi.org/10.1093/eurheartj/ehaf174>
232. Roubille F, Bouabdallaoui N, Kouz S et al (2024) Low-dose colchicine in patients with type 2 diabetes and recent myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT). *Diabetes Care* 47(3):467–470. <https://doi.org/10.2337/dc23-1825>
233. American Diabetes Association Professional Practice Committee (2022) 8. Obesity and weight management for the prevention and treatment of type 2 diabetes: standards of medical care in diabetes-2022. *Diabetes Care* 45(Suppl 1):S113–S124. <https://doi.org/10.2337/dc22-S008>
234. Aronne LJ, Horn DB, le Roux CW et al (2025) Tirzepatide as compared with semaglutide for the treatment of obesity. *N Engl J Med* 393(1):26–36. <https://doi.org/10.1056/NEJMoa2416394>
235. Horn DB, Ryan DH, Kis SG et al (2026) Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial. *Lancet* 406(10522):2927–2944. [https://doi.org/10.1016/s0140-6736\(25\)02165-8](https://doi.org/10.1016/s0140-6736(25)02165-8)

236. Wharton S, Lingvay I, Bogdanski P et al (2025) Oral semaglutide at a dose of 25 mg in adults with overweight or obesity. *N Engl J Med* 393(11):1077–1087. <https://doi.org/10.1056/NEJMoa2500969>
237. Rubino F, Nathan DM, Eckel RH et al (2016) Metabolic surgery in the treatment algorithm for type 2 diabetes: a joint statement by international diabetes organizations. *Diabetes Care* 39(6):861–877. <https://doi.org/10.2337/dc16-0236>
238. Simonson DC, Gourash WF, Arterburn DE et al (2025) Health-related quality of life and health utility after metabolic/bariatric surgery versus medical/lifestyle intervention in individuals with type 2 diabetes and obesity: the ARMMS-T2D study. *Diabetes Care* 48(4):537–545. <https://doi.org/10.2337/dc24-2046>
239. Kirwan JP, Courcoulas AP, Cummings DE et al (2022) Diabetes Remission in the Alliance of Randomized Trials of Medicine Versus Metabolic Surgery in Type 2 Diabetes (ARMMS-T2D). *Diabetes Care* 45(7):1574–1583. <https://doi.org/10.2337/dc21-2441>
240. Courcoulas AP, Patti ME, Hu B et al (2024) Long-term outcomes of medical management vs bariatric surgery in type 2 diabetes. *JAMA* 331(8):654–664. <https://doi.org/10.1001/jama.2024.0318>
241. Zhou X, Zeng C (2023) Diabetes remission of bariatric surgery and nonsurgical treatments in type 2 diabetes patients who failure to meet the criteria for surgery: a systematic review and meta-analysis. *BMC Endocr Disord* 23(1):46. <https://doi.org/10.1186/s12902-023-01283-9>
242. Gul D, Khan AW, Butt MA et al (2025) Clinical outcomes of roux-en-Y gastric bypass versus medical therapy in type 2 diabetes mellitus: a systematic review and meta-analysis. *J Diabetes Metab Disord* 24(1):43. <https://doi.org/10.1007/s40200-024-01526-z>
243. Yi X, Zhu L, Zhu S (2023) Predictors of T2DM remission after bariatric surgery in patients with a BMI < 35 kg/m²: a meta-analysis. *Obes Surg* 33(8):2342–2355. <https://doi.org/10.1007/s11695-023-06671-7>
244. Wågen Hauge J, Borgeaas H, Birkeland KI et al (2025) Effect of gastric bypass versus sleeve gastrectomy on the remission of type 2 diabetes, weight loss, and cardiovascular risk factors at 5 years (Oseberg): secondary outcomes of a single-centre, triple-blind, randomised controlled trial. *Lancet Diabetes Endocrinol* 13(5):397–409. [https://doi.org/10.1016/s2213-8587\(24\)00396-6](https://doi.org/10.1016/s2213-8587(24)00396-6)
245. Gasoyan H, Alavi MH, Zajichek A et al (2025) Macrovascular and microvascular outcomes of metabolic surgery versus GLP-1 receptor agonists in patients with diabetes and obesity. *Nat Med* 31(10):3341–3349. <https://doi.org/10.1038/s41591-025-03893-3>
246. Obeso-Fernández J, Millan-Alanis JM, Sáenz-Flores M et al (2024) Benefits of metabolic surgery on macrovascular outcomes in adult patients with type 2 diabetes: a systematic review and meta-analysis. *Surg Obes Relat Dis* 20(2):202–212. <https://doi.org/10.1016/j.soard.2023.08.016>
247. Einafshar N, Esparham A, Moghani MS, Radboy M, Ghamari MJ, Zandbaf T (2025) The impact of metabolic and bariatric surgery on diabetic kidney disease in patients with type 2 diabetes: a systematic review and meta-analysis. *Obes Surg* 35(1):329–340. <https://doi.org/10.1007/s11695-024-07612-8>
248. Verrastro O, Panunzi S, Castagneto-Gissey L et al (2023) Bariatric-metabolic surgery versus lifestyle intervention plus best medical care in non-alcoholic steatohepatitis (BRAVES): a multicentre, open-label, randomised trial. *Lancet* 401(10390):1786–1797. [https://doi.org/10.1016/s0140-6736\(23\)00634-7](https://doi.org/10.1016/s0140-6736(23)00634-7)
249. Aminian A, Al-Kurd A, Wilson R et al (2021) Association of bariatric surgery with major adverse liver and cardiovascular outcomes in patients with biopsy-proven nonalcoholic steatohepatitis. *JAMA* 326(20):2031–2042. <https://doi.org/10.1001/jama.2021.19569>
250. American Diabetes Association Professional Practice Committee (2026) 8. Obesity and weight management for the prevention and treatment of diabetes: standards of care in diabetes-2026. *Diabetes Care* 49(Suppl 1):S166–s182. <https://doi.org/10.2337/dc26-S008>
251. Eisenberg D, Shikora SA, Aarts E et al (2023) 2022 American Society of Metabolic and Bariatric Surgery (ASMBS) and International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO) Indications for Metabolic and Bariatric Surgery. *Obes Surg* 33(1):3–14. <https://doi.org/10.1007/s11695-022-06332-1>
252. Busetto L, Dicker D, Frühbeck G et al (2024) A new framework for the diagnosis, staging and management of obesity in adults. *Nat Med* 30(9):2395–2399. <https://doi.org/10.1038/s41591-024-03095-3>
253. Lisco G, Disoteo OE, De Tullio A et al (2023) Sarcopenia and diabetes: a detrimental liaison of advancing age. *Nutrients* 16(1):63. <https://doi.org/10.3390/nu16010063>
254. Donini LM, Busetto L, Bischoff SC et al (2022) Definition and diagnostic criteria for sarcopenic obesity: ESPEN and EASO consensus statement. *Obes Facts* 15(3):321–335. <https://doi.org/10.1159/000521241>
255. Wong L, Duque G, McMahon LP (2021) Sarcopenia and frailty: challenges in mainstream nephrology practice. *Kidney Int Rep* 6(10):2554–2564. <https://doi.org/10.1016/j.ekir.2021.05.039>
256. Sattar N, Neeland IJ, Dahlqvist Leinhard O et al (2025) Tirzepatide and muscle composition changes in people with type 2 diabetes (SURPASS-3 MRI): a post-hoc analysis of a randomised, open-label, parallel-group, phase 3 trial. *Lancet Diabetes Endocrinol* 13(6):482–493. [https://doi.org/10.1016/s2213-8587\(25\)00027-0](https://doi.org/10.1016/s2213-8587(25)00027-0)
257. Sargeant JA, Henson J, King JA, Yates T, Khunti K, Davies MJ (2019) A review of the effects of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors on lean body mass in humans. *Endocrinol Metab (Seoul)* 34(3):247–262. <https://doi.org/10.3803/EnM.2019.34.3.247>
258. McCrimmon RJ, Catarig AM, Frias JP et al (2020) Effects of once-weekly semaglutide vs once-daily canagliflozin on body composition in type 2 diabetes: a substudy of the SUSTAIN 8 randomised controlled clinical trial. *Diabetologia* 63(3):473–485. <https://doi.org/10.1007/s00125-019-05065-8>
259. Jendle J, Nauck MA, Matthews DR et al (2009) Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. *Diabetes Obes Metab* 11(12):1163–1172. <https://doi.org/10.1111/j.1463-1326.2009.01158.x>
260. Anyiam O, Ardavani A, Rashid RSA, Panesar A, Idris I (2025) How do glucagon-like peptide-1 receptor agonists affect measures of muscle mass in individuals with, and without, type 2 diabetes: a systematic review and meta-analysis. *Obes Rev* 26(7):e13916. <https://doi.org/10.1111/obr.13916>
261. Ahmad E, Arsenyadis F, Almaqhawi A et al (2023) Impact of novel glucose-lowering therapies on physical function in people with type 2 diabetes: a systematic review and meta-analysis of randomised placebo-controlled trials. *Diabet Med* 40(6):e15083. <https://doi.org/10.1111/dme.15083>
262. Schmidt PHS, de Souza VSN, Machado LG et al (2026) Tirzepatide on physical function in adults with overweight or obesity: a systematic review and meta-analysis. *Diabetes Obes Metab* 28(4):3335–3343. <https://doi.org/10.1111/dom.70529>
263. Pandey A, Patel KV, Segar MW et al (2024) Effect of liraglutide on thigh muscle fat and muscle composition in adults with overweight or obesity: results from a randomized clinical trial. *J Cachexia Sarcopenia Muscle* 15(3):1072–1083. <https://doi.org/10.1002/jcsm.13445>
264. Bopp G, Diniz-Sousa F, Veras L et al (2024) Impact of a multicomponent exercise training program on muscle

- strength after bariatric surgery: a randomized controlled trial. *Obes Surg* 34(5):1704–1716. <https://doi.org/10.1007/s11695-024-07173-w>
265. In G, Taskin HE, Al M et al (2021) Comparison of 12-week fitness protocols following bariatric surgery: aerobic exercise versus aerobic exercise and progressive resistance. *Obes Surg* 31(4):1475–1484. <https://doi.org/10.1007/s11695-020-05144-5>
 266. Herring LY, Stevinson C, Carter P et al (2017) The effects of supervised exercise training 12–24 months after bariatric surgery on physical function and body composition: a randomised controlled trial. *Int J Obes (Lond)* 41(6):909–916. <https://doi.org/10.1038/ijo.2017.60>
 267. Bellicha A, Ciangura C, Roda C et al (2022) Effect of exercise training after bariatric surgery: a 5-year follow-up study of a randomized controlled trial. *PLoS One* 17(7):e0271561. <https://doi.org/10.1371/journal.pone.0271561>
 268. Coen PM, Tanner CJ, Helbling NL et al (2015) Clinical trial demonstrates exercise following bariatric surgery improves insulin sensitivity. *J Clin Invest* 125(1):248–257. <https://doi.org/10.1172/jci78016>
 269. Carnero EA, Dubis GS, Hames KC et al (2017) Randomized trial reveals that physical activity and energy expenditure are associated with weight and body composition after RYGB. *Obesity (Silver Spring)* 25(7):1206–1216. <https://doi.org/10.1002/oby.21864>
 270. Ingersen A, Schmücker M, Alexandersen C et al (2023) Effects of aerobic training and semaglutide treatment on pancreatic β -cell secretory function in patients with type 2 diabetes. *J Clin Endocrinol Metab* 108(11):2798–2811. <https://doi.org/10.1210/clinem/dgad326>
 271. Jensen SBK, Juhl CR, Janus C et al (2023) Weight loss maintenance with exercise and liraglutide improves glucose tolerance, glucagon response, and beta cell function. *Obesity (Silver Spring)* 31(4):977–989. <https://doi.org/10.1002/oby.23715>
 272. Sandsdal RM, Juhl CR, Jensen SBK et al (2023) Combination of exercise and GLP-1 receptor agonist treatment reduces severity of metabolic syndrome, abdominal obesity, and inflammation: a randomized controlled trial. *Cardiovasc Diabetol* 22(1):41. <https://doi.org/10.1186/s12933-023-01765-z>
 273. Lundgren JR, Janus C, Jensen SBK et al (2021) Healthy weight loss maintenance with exercise, liraglutide, or both combined. *N Engl J Med* 384(18):1719–1730. <https://doi.org/10.1056/NEJMoa2028198>
 274. Apperloo EM, Cherney DZI, Kuhlman AB et al (2025) Effect of semaglutide on kidney function across different levels of baseline HbA1c, blood pressure, body weight and albuminuria in SUSTAIN 6 and PIONEER 6. *Nephrol Dial Transplant* 40(2):352–359. <https://doi.org/10.1093/ndt/gfae150>
 275. Inzucchi SE, Claggett BL, Vaduganathan M et al (2022) Efficacy and safety of dapagliflozin in patients with heart failure with mildly reduced or preserved ejection fraction by baseline glycaemic status (DELIVER): a subgroup analysis from an international, multicentre, double-blind, randomised, placebo-controlled trial. *Lancet Diabetes Endocrinol* 10(12):869–881. [https://doi.org/10.1016/s2213-8587\(22\)00308-4](https://doi.org/10.1016/s2213-8587(22)00308-4)
 276. Davies MJ, van der Meer P, Verma S et al (2025) Semaglutide in obesity-related heart failure with preserved ejection fraction and type 2 diabetes across baseline HbA1c levels (STEP-HFpEF DM): a prespecified analysis of heart failure and metabolic outcomes from a randomised, placebo-controlled trial. *Lancet Diabetes Endocrinol* 13(3):196–209. [https://doi.org/10.1016/s2213-8587\(24\)00304-8](https://doi.org/10.1016/s2213-8587(24)00304-8)
 277. McGill JB, Agarwal R, Anker SD et al (2023) Effects of finerenone in people with chronic kidney disease and type 2 diabetes are independent of HbA1c at baseline, HbA1c variability, diabetes duration and insulin use at baseline. *Diabetes Obes Metab* 25(6):1512–1522. <https://doi.org/10.1111/dom.14999>
 278. Sattar N, Presslie C, Rutter MK, McGuire DK (2024) Cardiovascular and kidney risks in individuals with type 2 diabetes: contemporary understanding with greater emphasis on excess adiposity. *Diabetes Care* 47(4):531–543. <https://doi.org/10.2337/dci23-0041>
 279. Tuttle KR, Wong L, St Peter W et al (2022) Moving from evidence to implementation of breakthrough therapies for diabetic kidney disease. *Clin J Am Soc Nephrol* 17(7):1092–1103. <https://doi.org/10.2215/cjn.02980322>
 280. McGuire DK, Marx N, Mulvagh SL et al (2025) Oral semaglutide and cardiovascular outcomes in high-risk type 2 diabetes. *N Engl J Med* 392(20):2001–2012. <https://doi.org/10.1056/NEJMoa2501006>
 281. Marx N, Deanfield JE, Mann JFE et al (2025) Oral semaglutide and cardiovascular outcomes in people with type 2 diabetes, according to SGLT2i use: prespecified analyses of the SOUL randomized trial. *Circulation* 151(23):1639–1650. <https://doi.org/10.1161/circulationaha.125.074545>
 282. Marso SP, Bain SC, Consoli A et al (2016) Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. *N Engl J Med* 375(19):1834–1844. <https://doi.org/10.1056/NEJMoa1607141>
 283. Gerstein HC, Sattar N, Rosenstock J et al (2021) Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes. *N Engl J Med* 385(10):896–907. <https://doi.org/10.1056/NEJMoa2108269>
 284. Neuen BL, Fletcher RA, Heath L et al (2024) Cardiovascular, kidney, and safety outcomes with GLP-1 receptor agonists alone and in combination with SGLT2 inhibitors in type 2 diabetes: a systematic review and meta-analysis. *Circulation* 150(22):1781–1790. <https://doi.org/10.1161/circulationaha.124.071689>
 285. Bonaca MP, Catarig AM, Houliand K et al (2025) Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trial. *Lancet* 405(10489):1580–1593. [https://doi.org/10.1016/s0140-6736\(25\)00509-4](https://doi.org/10.1016/s0140-6736(25)00509-4)
 286. Garagoli F, Masson W, Barbagelata L, Lobo M (2025) Effect of glucagon-like peptide-1 receptor agonists on the risk of major adverse limb events in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized clinical trials. *Endocrinol Diabetes Nutr (Engl Ed)* 72(5):501562. <https://doi.org/10.1016/j.endien.2025.501562>
 287. Dutta D, Mahajan K, Kamrul-Hasan ABM, Mahajan N, Sharma M, Vohra S (2026) Impact of glucagon-like peptide-1 receptor agonism-based therapies on limb outcomes in peripheral artery disease and type 2 diabetes: an updated systematic review and meta-analysis. *Diabetes Obes Metab* 28(3):2075–2084. <https://doi.org/10.1111/dom.70391>
 288. Cesaro A, Acerbo V, Longo M et al (2026) Impact of semaglutide on limb events: a meta-analysis of randomized controlled trials. *Eur J Prev Cardiol* zwag077. <https://doi.org/10.1093/eurjpc/zwag077>
 289. Sohn M, Dietrich JW, Nauck MA, Lim S (2023) Characteristics predicting the efficacy of SGLT-2 inhibitors versus GLP-1 receptor agonists on major adverse cardiovascular events in type 2 diabetes mellitus: a meta-analysis study. *Cardiovasc Diabetol* 22(1):153. <https://doi.org/10.1186/s12933-023-01877-6>
 290. Tsapas A, Karagiannis T, Avgerinos I, Liakos A, Bekiari E (2021) GLP-1 receptor agonists for cardiovascular outcomes with and without metformin. A systematic review and meta-analysis of cardiovascular outcomes trials. *Diabetes Res Clin Pract* 177:108921. <https://doi.org/10.1016/j.diabres.2021.108921>
 291. Lavalle-Cobo A, Masson W, Lobo M, Masson G, Molinero G (2021) Glucagon-like peptide-1 receptor agonists and cardioprotective benefit in patients with type 2 diabetes without baseline metformin: a systematic review and update meta-analysis. *High*

- Blood Press Cardiovasc Prev 28(6):605–612. <https://doi.org/10.1007/s40292-021-00479-1>
292. Husain M, Consoli A, De Remigis A, Pettersson Meyer AS, Rasmussen S, Bain S (2022) Semaglutide reduces cardiovascular events regardless of metformin use: a post hoc subgroup analysis of SUSTAIN 6 and PIONEER 6. *Cardiovasc Diabetol* 21(1):64. <https://doi.org/10.1186/s12933-022-01489-6>
 293. Fan Q, Qin G, Du B et al (2026) Evidence-based validation of cardiovascular benefits from novel MRAs in type 2 diabetes: a meta-analysis of over 30,000 patients. *J Diabetes Complications* 40(1):109236. <https://doi.org/10.1016/j.jdiacomp.2025.109236>
 294. Vaduganathan M, Docherty KF, Claggett BL et al (2022) SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials. *Lancet* 400(10354):757–767. [https://doi.org/10.1016/s0140-6736\(22\)01429-5](https://doi.org/10.1016/s0140-6736(22)01429-5)
 295. Usman MS, Siddiqi TJ, Anker SD et al (2023) Effect of SGLT2 inhibitors on cardiovascular outcomes across various patient populations. *J Am Coll Cardiol* 81(25):2377–2387. <https://doi.org/10.1016/j.jacc.2023.04.034>
 296. Usman MS, Bhatt DL, Hameed I et al (2024) Effect of SGLT2 inhibitors on heart failure outcomes and cardiovascular death across the cardiometabolic disease spectrum: a systematic review and meta-analysis. *Lancet Diabetes Endocrinol* 12(7):447–461. [https://doi.org/10.1016/s2213-8587\(24\)00102-5](https://doi.org/10.1016/s2213-8587(24)00102-5)
 297. Aldafas R, Crabtree T, Alkharaiji M, Vinogradova Y, Idris I (2024) Sodium-glucose cotransporter-2 inhibitors (SGLT2) in frail or older people with type 2 diabetes and heart failure: a systematic review and meta-analysis. *Age Ageing* 53(1):afad254. <https://doi.org/10.1093/ageing/afad254>
 298. Butt JH, Shen L, Inzucchi SE et al (2024) Dapagliflozin in heart failure, type 2 diabetes, and neuropathy: a meta-analysis of DAPA-HF and DELIVER. *JACC Heart Fail* 12(11):1946–1948. <https://doi.org/10.1016/j.jchf.2024.07.017>
 299. Butler J, Shah SJ, Petrie MC et al (2024) Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials. *Lancet* 403(10437):1635–1648. [https://doi.org/10.1016/s0140-6736\(24\)00469-0](https://doi.org/10.1016/s0140-6736(24)00469-0)
 300. Pratley RE, Tuttle KR, Rossing P et al (2024) Effects of semaglutide on heart failure outcomes in diabetes and chronic kidney disease in the FLOW trial. *J Am Coll Cardiol* 84(17):1615–1628. <https://doi.org/10.1016/j.jacc.2024.08.004>
 301. Kosiborod MN, Deanfield J, Pratley R et al (2024) Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials. *Lancet* 404(10456):949–961. [https://doi.org/10.1016/s0140-6736\(24\)01643-x](https://doi.org/10.1016/s0140-6736(24)01643-x)
 302. Packer M, Zile MR, Kramer CM et al (2025) Influence of type 2 diabetes on the effects of tirzepatide in patients with heart failure and a preserved ejection fraction with obesity: a prespecified stratification-based analysis. *J Am Coll Cardiol* 86(10):696–707. <https://doi.org/10.1016/j.jacc.2025.06.058>
 303. Banerjee M, Maisnam I, Mukhopadhyay S (2024) Impact of heart failure history at baseline on cardiovascular effects of GLP-1 receptor agonists in type 2 diabetes: a meta-analysis. *Cardiovasc Drugs Ther* 38(4):739–746. <https://doi.org/10.1007/s10557-023-07432-5>
 304. Neves JS, Lobato CB, Leite AR et al (2026) GLP-1 receptor agonists for the prevention of new-onset heart failure: a systematic review and meta-analysis of placebo-controlled randomized clinical trials. *Obes Rev* 27(4):e70043. <https://doi.org/10.1111/obr.70043>
 305. Solomon SD, McMurray JJV, Vaduganathan M et al (2024) Finerenone in heart failure with mildly reduced or preserved ejection fraction. *N Engl J Med* 391(16):1475–1485. <https://doi.org/10.1056/NEJMoa2407107>
 306. Butt JH, Jhund PS, Henderson AD et al (2025) Finerenone, glycaemic status, and heart failure with mildly reduced or preserved ejection fraction: a prespecified analysis of the FINEARTS-HF trial. *Eur J Heart Fail* 27(7):1326–1341. <https://doi.org/10.1002/ehf.3649>
 307. Vaduganathan M, Filippatos G, Claggett BL et al (2024) Finerenone in heart failure and chronic kidney disease with type 2 diabetes: FINE-HEART pooled analysis of cardiovascular, kidney and mortality outcomes. *Nat Med* 30(12):3758–3764. <https://doi.org/10.1038/s41591-024-03264-4>
 308. Filippatos G, Pitt B, Agarwal R et al (2022) Finerenone in patients with chronic kidney disease and type 2 diabetes with and without heart failure: a prespecified subgroup analysis of the FIDELIO-DKD trial. *Eur J Heart Fail* 24(6):996–1005. <https://doi.org/10.1002/ehf.2469>
 309. Palmer SC, Tendal B, Mustafa RA et al (2021) Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials. *BMJ* 372:m4573. <https://doi.org/10.1136/bmj.m4573>
 310. Liu Z, Bian N, Wu S et al (2022) A meta-analysis evaluating indirectly GLP-1 receptor agonists and arrhythmias in patients with type 2 diabetes and myocardial infarction. *Front Cardiovasc Med* 9:1019120. <https://doi.org/10.3389/fcvm.2022.1019120>
 311. Verma S, Butler J, Borlaug BA et al (2024) Atrial fibrillation and semaglutide effects in obesity-related heart failure with preserved ejection fraction: STEP-HFpEF program. *J Am Coll Cardiol* 84(17):1603–1614. <https://doi.org/10.1016/j.jacc.2024.08.023>
 312. Wu R, Xing B, Huang Y et al (2025) Effect of semaglutide on arrhythmic, major cardiovascular, and microvascular outcomes in patients with type 2 diabetes: a systematic review and meta-analysis. *Front Endocrinol (Lausanne)* 16:1554795. <https://doi.org/10.3389/fendo.2025.1554795>
 313. Wu JY, Tseng KJ, Kao CL, Hung KC, Yu T, Lin YM (2025) Clinical effectiveness of tirzepatide for patients with atrial fibrillation and type 2 diabetes: a retrospective cohort study. *Diabetes Res Clin Pract* 225:112279. <https://doi.org/10.1016/j.diabres.2025.112279>
 314. Abdelhadi NA, Ragab KM, Elkholy M, Koneru J, Ellenbogen KA, Pillai A (2025) Impact of sodium-glucose co-transporter 2 inhibitors on atrial fibrillation recurrence post-catheter ablation among patients with type 2 diabetes mellitus: a systematic review and meta-analysis. *J Cardiovasc Electrophysiol* 36(3):673–682. <https://doi.org/10.1111/jce.16544>
 315. Li J, Zhang F, Fan S et al (2025) Association of SGLT2 inhibitors with post-ablation atrial fibrillation recurrence in individuals with heart failure or type 2 diabetes mellitus: a systematic review and meta-analysis. *Front Cardiovasc Med* 12:1710123. <https://doi.org/10.3389/fcvm.2025.1710123>
 316. Kidess GG, Hamza M, Goru R, Basit J, Alraiyes M, Alraiyes MC (2025) The impact of sodium-glucose cotransporter-2 inhibitors on atrial fibrillation burden in diabetic patients. *Am J Cardiol* 246:65–70. <https://doi.org/10.1016/j.amjcard.2025.03.002>
 317. Yin Z, Zheng H, Guo Z (2022) Effect of sodium-glucose cotransporter protein 2 inhibitors on arrhythmia in heart failure patients with or without type 2 diabetes: a meta-analysis of randomized controlled trials. *Front Cardiovasc Med* 9:902923. <https://doi.org/10.3389/fcvm.2022.902923>
 318. Liang X, Dai J, Wang F (2025) Sodium glucose co-transporter 2 (SGLT2) inhibitors versus dipeptidyl peptidase-4 (DPP-4) inhibitors and the risk of atrial fibrillation in patients with type 2 diabetes mellitus: a meta-analysis. *BMC Cardiovasc Disord* 25(1):59. <https://doi.org/10.1186/s12872-024-04442-5>
 319. Knowler WC, Chen H, Bahnson JL et al (2024) Within and post-trial effects of an intensive lifestyle intervention on kidney

- disease in adults with overweight or obesity and type 2 diabetes mellitus: a secondary analysis of the Look AHEAD clinical trial. *BMJ Open Diabetes Res Care* 12(3):e004079. <https://doi.org/10.1136/bmjdr-2024-004079>
320. Obeso-Fernández J, Millan-Alanis JM, Rodríguez-Bautista M et al (2023) Benefits of bariatric surgery on microvascular outcomes in adult patients with type 2 diabetes: a systematic review and meta-analysis. *Surg Obes Relat Dis* 19(8):916–927. <https://doi.org/10.1016/j.soard.2023.02.024>
 321. Mavrakanas TA, Tsoukas MA, Brophy JM, Sharma A, Gariani K (2023) SGLT-2 inhibitors improve cardiovascular and renal outcomes in patients with CKD: a systematic review and meta-analysis. *Sci Rep* 13(1):15922. <https://doi.org/10.1038/s41598-023-42989-z>
 322. Nguyen BN, Nguyen L, Mital S, Bugden S, Nguyen HV (2023) Comparative efficacy of sodium-glucose co-transporter-2 inhibitors, glucagon-like peptide-1 receptor agonists and non-steroidal mineralocorticoid receptor antagonists in chronic kidney disease and type 2 diabetes: a systematic review and network meta-analysis. *Diabetes Obes Metab* 25(6):1614–1623. <https://doi.org/10.1111/dom.15009>
 323. Ghosal S, Sinha B (2023) Assessing the effects of modern renoprotective agents in preventing progression of renal composite outcomes in patients with type 2 diabetes: a network meta-analysis. *Diabetes Ther* 14(2):415–424. <https://doi.org/10.1007/s13300-022-01359-0>
 324. Dong Z, Mo W, Ling Z, Hou L, Deng T (2025) Efficacy of SGLT2 inhibitors on acute kidney injury in patients with chronic kidney disease, cardiovascular disease, and type 2 diabetes: a meta-analysis. *J Natl Med Assoc* 117(6):458–469. <https://doi.org/10.1016/j.jnma.2025.08.110>
 325. Siddiqi TJ, Cherney D, Siddiqi HF et al (2025) Effects of sodium-glucose cotransporter-2 inhibitors on kidney outcomes across baseline cardiovascular-kidney-metabolic conditions: a systematic review and meta-analyses. *J Am Soc Nephrol* 36(2):242–255. <https://doi.org/10.1681/asn.0000000000000491>
 326. Cherney DZI, Dagogo-Jack S, Cosentino F et al (2022) Heart and kidney outcomes with ertugliflozin in people with non-albuminuric diabetic kidney disease: a post hoc analysis from the randomized VERTIS CV trial. *Kidney Int Rep* 7(8):1782–1792. <https://doi.org/10.1016/j.ekir.2022.05.007>
 327. Mosenzon O, Raz I, Wiviott SD et al (2022) Dapagliflozin and prevention of kidney disease among patients with type 2 diabetes: post hoc analyses from the DECLARE-TIMI 58 trial. *Diabetes Care* 45(10):2350–2359. <https://doi.org/10.2337/dc22-0382>
 328. Cherney DZI, Frederich R, Pratley RE et al (2025) Cardiovascular and renal outcomes with ertugliflozin by baseline use of renin-angiotensin-aldosterone system inhibitors or diuretics, including mineralocorticoid receptor antagonist: analyses from the VERTIS CV trial. *Kidney Dis (Basel)* 11(1):63–74. <https://doi.org/10.1159/000543162>
 329. Perkovic V, Tuttle KR, Rossing P et al (2024) Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. *N Engl J Med* 391(2):109–121. <https://doi.org/10.1056/NEJMoA2403347>
 330. Mahaffey KW, Tuttle KR, Arici M et al (2025) Cardiovascular outcomes with semaglutide by severity of chronic kidney disease in type 2 diabetes: the FLOW trial. *Eur Heart J* 46(12):1096–1108. <https://doi.org/10.1093/eurheartj/ehae613>
 331. Wang J, Yang J, Jiang W et al (2024) Effect of semaglutide on primary prevention of diabetic kidney disease in people with type 2 diabetes: a post hoc analysis of the SUSTAIN 6 randomized controlled trial. *Diabetes Obes Metab* 26(11):5157–5166. <https://doi.org/10.1111/dom.15860>
 332. Tuttle KR, Bain SC, Bosch-Traberg H et al (2024) Effects of once-weekly semaglutide on kidney disease outcomes by KDIGO risk category in the SUSTAIN 6 trial. *Kidney Int Rep* 9(7):2006–2015. <https://doi.org/10.1016/j.ekir.2024.04.028>
 333. Abdullah A, Sagreka FNU, Aniket GA et al (2025) Safety and efficacy of semaglutide in patients with chronic kidney disease, with or without type 2 diabetes: a systematic review and meta-analysis. *Endocrinol Diabetes Metab* 8(6):e70136. <https://doi.org/10.1002/edm2.70136>
 334. Mann JFE, Marx N, Deanfield JE et al (2026) Impact of oral semaglutide on kidney outcomes in people with type 2 diabetes: results from the SOUL randomized trial. *Diabetes Care* 49(2):257–265. <https://doi.org/10.2337/dc25-1080>
 335. Botros FT, Gerstein HC, Malik R et al (2023) Dulaglutide and kidney function-related outcomes in type 2 diabetes: a REWIND post hoc analysis. *Diabetes Care* 46(8):1524–1530. <https://doi.org/10.2337/dc23-0231>
 336. Zoungas S, D'Alessio D, Pavo I et al (2026) A comparison of the effects of tirzepatide and dulaglutide on major kidney events in people with type 2 diabetes: pre-specified exploratory analyses of the SURPASS-CVOT trial. *Lancet Diabetes Endocrinol* 14(7):544–557. [https://doi.org/10.1016/s2213-8587\(26\)00032-x](https://doi.org/10.1016/s2213-8587(26)00032-x)
 337. Badve SV, Bilal A, Lee MMY et al (2025) Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials. *Lancet Diabetes Endocrinol* 13(1):15–28. [https://doi.org/10.1016/s2213-8587\(24\)00271-7](https://doi.org/10.1016/s2213-8587(24)00271-7)
 338. Yeo D, Jo Y, Jeong J et al (2026) Efficacy and safety of glucagon-like peptide 1 receptor agonists across all health outcomes in type 2 diabetes: an umbrella review and evidence map of randomised controlled trials. *Diabetes Obes Metab* 28(2):1136–1149. <https://doi.org/10.1111/dom.70298>
 339. Orandi BJ, Chen Y, Li Y et al (2025) GLP-1 receptor agonists in kidney transplant recipients with pre-existing diabetes: a retrospective cohort study. *Lancet Diabetes Endocrinol* 13(5):374–383. [https://doi.org/10.1016/s2213-8587\(24\)00371-1](https://doi.org/10.1016/s2213-8587(24)00371-1)
 340. Rossing P, Bakris G, Perkovic V et al (2025) Effects of semaglutide with or without concomitant mineralocorticoid receptor antagonist use in participants with type 2 diabetes and chronic kidney disease: a FLOW trial prespecified secondary analysis. *Diabetes Care* 48(11):1878–1887. <https://doi.org/10.2337/dc25-0472>
 341. Mann JFE, Rossing P, Bakris G et al (2024) Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial. *Nat Med* 30(10):2849–2856. <https://doi.org/10.1038/s41591-024-03133-0>
 342. Agarwal R, Pitt B, Rossing P et al (2023) Modifiability of composite cardiovascular risk associated with chronic kidney disease in type 2 diabetes with finerenone. *JAMA Cardiol* 8(8):732–741. <https://doi.org/10.1001/jamacardio.2023.1505>
 343. Filippatos G, Anker SD, Pitt B et al (2022) Finerenone and heart failure outcomes by kidney function/albuminuria in chronic kidney disease and diabetes. *JACC Heart Fail* 10(11):860–870. <https://doi.org/10.1016/j.jchf.2022.07.013>
 344. Filippatos G, Anker SD, August P et al (2023) Finerenone and effects on mortality in chronic kidney disease and type 2 diabetes: a FIDELITY analysis. *Eur Heart J Cardiovasc Pharmacother* 9(2):183–191. <https://doi.org/10.1093/ehjcvp/pvad001>
 345. Rossing P, Anker SD, Filippatos G et al (2022) Finerenone in patients with chronic kidney disease and type 2 diabetes by sodium-glucose cotransporter 2 inhibitor treatment: the FIDELITY analysis. *Diabetes Care* 45(12):2991–2998. <https://doi.org/10.2337/dc22-0294>

346. Agarwal R, Tu W, Farjat AE et al (2023) Impact of finerenone-induced albuminuria reduction on chronic kidney disease outcomes in type 2 diabetes: a mediation analysis. *Ann Intern Med* 176(12):1606–1616. <https://doi.org/10.7326/m23-1023>
347. Agarwal R, Green JB, Heerspink HJL et al (2025) Finerenone with empagliflozin in chronic kidney disease and type 2 diabetes. *N Engl J Med* 393(6):533–543. <https://doi.org/10.1056/NEJMoa2410659>
348. Heerspink HJL, Vart P, Jongs N et al (2023) Estimated lifetime benefit of novel pharmacological therapies in patients with type 2 diabetes and chronic kidney disease: a joint analysis of randomized controlled clinical trials. *Diabetes Obes Metab* 25(11):3327–3336. <https://doi.org/10.1111/dom.15232>
349. Blum MF, Mehta S, Surapaneni A et al (2026) A target trial emulation study of SGLT2 inhibitors, GLP-1 receptor agonists, and combination therapy in preventing kidney failure in type 2 diabetes. *Clin J Am Soc Nephrol* 21(3):437–445. <https://doi.org/10.2215/cjn.0000000902>
350. Jansz TT, Young KG, Hopkins R et al (2026) Precision medicine in type 2 diabetes: targeting SGLT2 inhibitor treatment for kidney protection. *Diabetologia* 69(2):374–385. <https://doi.org/10.1007/s00125-025-06577-2>
351. Wagenknecht LE, Lawrence JM, Isom S et al (2023) Trends in incidence of youth-onset type 1 and type 2 diabetes in the USA, 2002–18: results from the population-based SEARCH for Diabetes in Youth study. *Lancet Diabetes Endocrinol* 11(4):242–250. [https://doi.org/10.1016/s2213-8587\(23\)00025-6](https://doi.org/10.1016/s2213-8587(23)00025-6)
352. Fang M, Xu Y, Selvin E, Shin JI (2026) Trends in youth-onset type 2 diabetes, 2013–2024. *N Engl J Med* 394(14):1451–1453. <https://doi.org/10.1056/NEJMc2507615>
353. Wright AK, Welsh P, Gill JMR et al (2020) Age-, sex- and ethnicity-related differences in body weight, blood pressure, HbA(1c) and lipid levels at the diagnosis of type 2 diabetes relative to people without diabetes. *Diabetologia* 63(8):1542–1553. <https://doi.org/10.1007/s00125-020-05169-6>
354. Nadeau KJ, Mayer-Davis EJ, Gubitosi-Klug R, Zeitler PS, Kahn SE, Dabelea D (2025) Youth-onset type 2 diabetes: what we've learned from key youth-onset type 2 diabetes studies, what we still don't know, and why it is important. *Diabetes Care* 48(7):1136–1149. <https://doi.org/10.2337/dc25-0001>
355. Emerging Risk Factors Collaboration (2023) Life expectancy associated with different ages at diagnosis of type 2 diabetes in high-income countries: 23 million person-years of observation. *Lancet Diabetes Endocrinol* 11(10):731–742. [https://doi.org/10.1016/s2213-8587\(23\)00223-1](https://doi.org/10.1016/s2213-8587(23)00223-1)
356. Andes LJ, Cheng YJ, Rolka DB, Gregg EW, Imperatore G (2020) Prevalence of prediabetes among adolescents and young adults in the United States, 2005–2016. *JAMA Pediatr* 174(2):e194498. <https://doi.org/10.1001/jamapediatrics.2019.4498>
357. Bjornstad P, Drews KL, Caprio S et al (2021) Long-term complications in youth-onset type 2 diabetes. *N Engl J Med* 385(5):416–426. <https://doi.org/10.1056/NEJMoa2100165>
358. Sargeant JA, Brady EM, Zaccardi F et al (2020) Adults with early-onset type 2 diabetes (aged 18–39 years) are severely underrepresented in diabetes clinical research trials. *Diabetologia* 63(8):1516–1520. <https://doi.org/10.1007/s00125-020-05174-9>
359. Tamborlane WV, Laffel LM, Shehadeh N et al (2022) Efficacy and safety of dapagliflozin in children and young adults with type 2 diabetes: a prospective, multicentre, randomised, parallel group, phase 3 study. *Lancet Diabetes Endocrinol* 10(5):341–350. [https://doi.org/10.1016/s2213-8587\(22\)00052-3](https://doi.org/10.1016/s2213-8587(22)00052-3)
360. Nadgir U, Ali SR, Gogate J, Shaw W, Antunes J, Fonseca S (2025) Treatment with canagliflozin versus placebo in children and adolescents with type 2 diabetes: a randomized clinical trial. *Ann Intern Med* 178(9):1217–1226. <https://doi.org/10.7326/annals-24-04017>
361. Laffel LM, Danne T, Klingensmith GJ et al (2023) Efficacy and safety of the SGLT2 inhibitor empagliflozin versus placebo and the DPP-4 inhibitor linagliptin versus placebo in young people with type 2 diabetes (DINAMO): a multicentre, randomised, double-blind, parallel group, phase 3 trial. *Lancet Diabetes Endocrinol* 11(3):169–181. [https://doi.org/10.1016/s2213-8587\(22\)00387-4](https://doi.org/10.1016/s2213-8587(22)00387-4)
362. Tamborlane WV, Bishai R, Geller D et al (2022) Once-weekly exenatide in youth with type 2 diabetes. *Diabetes Care* 45(8):1833–1840. <https://doi.org/10.2337/dc21-2275>
363. Arslanian SA, Hannon T, Zeitler P et al (2022) Once-weekly dulaglutide for the treatment of youths with type 2 diabetes. *N Engl J Med* 387(5):433–443. <https://doi.org/10.1056/NEJMoa2204601>
364. Yugar LBT, Sedenho-Prado LG, da Silva Ferreira IMC, Silva CAM, Sposito AC, Cercato C (2024) The efficacy and safety of GLP-1 receptor agonists in youth with type 2 diabetes: a meta-analysis. *Diabetol Metab Syndr* 16(1):92. <https://doi.org/10.1186/s13098-024-01337-5>
365. Kotecha P, Huang W, Yeh YY et al (2025) Efficacy and safety of GLP-1 RAs in children and adolescents with obesity or type 2 diabetes: a systematic review and meta-analysis. *JAMA Pediatr* 179(12):1308–1317. <https://doi.org/10.1001/jamapediatrics.2025.3243>
366. Hannon TS, Chao LC, Barrientos-Pérez M et al (2025) Efficacy and safety of tirzepatide in children and adolescents with type 2 diabetes (SURPASS-PEDS): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet* 406(10511):1484–1496. [https://doi.org/10.1016/s0140-6736\(25\)01774-x](https://doi.org/10.1016/s0140-6736(25)01774-x)
367. Chan JCN, Paldanius PM, Mathieu C, Stumvoll M, Matthews DR, Del Prato S (2021) Early combination therapy delayed treatment escalation in newly diagnosed young-onset type 2 diabetes: a subanalysis of the VERIFY study. *Diabetes Obes Metab* 23(1):245–251. <https://doi.org/10.1111/dom.14192>
368. Wu S, He Y, Wu Y et al (2022) Comparative efficacy and safety of glucose-lowering drugs in children and adolescents with type 2 diabetes: a systematic review and network meta-analysis. *Front Endocrinol (Lausanne)* 13:897776. <https://doi.org/10.3389/fendo.2022.897776>
369. Bjornstad P, Arslanian SA, Hannon TS et al (2024) Dulaglutide and glomerular hyperfiltration, proteinuria, and albuminuria in youth with type 2 diabetes: post hoc analysis of the AWARD-PEDS study. *Diabetes Care* 47(9):1617–1621. <https://doi.org/10.2337/dc24-0322>
370. Bjornstad P, Danne T, Klingensmith GJ et al (2026) Impact of empagliflozin on glomerular hyperfiltration and albuminuria in youth with type 2 diabetes: post hoc analysis of DINAMO. *Clin J Am Soc Nephrol* 21(2):273–282. <https://doi.org/10.2215/cjn.0000000889>
371. Shamim MA, Patil AN, Amin U et al (2024) Glucagon-like peptide-1 receptor agonists in adolescents with overweight or obesity with or without type 2 diabetes multimorbidity: a systematic review and network meta-analysis. *Diabetes Obes Metab* 26(10):4302–4317. <https://doi.org/10.1111/dom.15777>
372. Pratley RE, Cannon CP, Cherney DZI et al (2023) Cardiorenal outcomes, kidney function, and other safety outcomes with ertugliflozin in older adults with type 2 diabetes (VERTIS CV): secondary analyses from a randomised, double-blind trial. *Lancet Healthy Longev* 4(4):e143–e154. [https://doi.org/10.1016/s2666-7568\(23\)00032-6](https://doi.org/10.1016/s2666-7568(23)00032-6)
373. Hanlon P, Butterly E, Wei L et al (2025) Age and sex differences in efficacy of treatments for type 2 diabetes: a network meta-analysis. *JAMA* 333(12):1062–1073. <https://doi.org/10.1001/jama.2024.27402>
374. Bain SC, Belmar N, Hoff ST et al (2025) Cardiovascular, metabolic, and safety outcomes with semaglutide by baseline age:

- post hoc analysis of SUSTAIN 6 and PIONEER 6. *Diabetes Ther* 16(1):15–28. <https://doi.org/10.1007/s13300-024-01659-7>
375. Rasouli N, Wilding JPH, Kwan AYM, Paik JS, Sharma P, Peleshok J (2025) Tirzepatide for older adults with type 2 diabetes and without obesity: a post hoc analysis of the SURPASS clinical trials. *Diabetes Ther* 16(4):701–715. <https://doi.org/10.1007/s13300-025-01711-0>
 376. Bansal S, Canziani MEF, Birne R et al (2024) Finerenone cardiovascular and kidney outcomes by age and sex: FIDELITY post hoc analysis of two phase 3, multicentre, double-blind trials. *BMJ Open* 14(3):e076444. <https://doi.org/10.1136/bmjopen-2023-076444>
 377. Pan SY, Su EL, Huang CJ et al (2024) Evaluation of glucose-lowering medications in older people: a comprehensive systematic review and network meta-analysis of randomized controlled trials. *Age Ageing* 53(8):afae175. <https://doi.org/10.1093/ageing/afae175>
 378. Liu Y, An C, Liu P, Yang F, Zhao Q (2023) Comparative safety of sodium-glucose co-transporter 2 inhibitors in elderly patients with type 2 diabetes mellitus and diabetic kidney disease: a systematic review and meta-analysis. *Ren Fail* 45(1):2217287. <https://doi.org/10.1080/0886022x.2023.2217287>
 379. Mickute M, Henson J, Rowlands AV et al (2021) Device-measured physical activity and its association with physical function in adults with type 2 diabetes mellitus. *Diabet Med* 38(6):e14393. <https://doi.org/10.1111/dme.14393>
 380. Nguyen TN, Harris K, Woodward M et al (2021) The impact of frailty on the effectiveness and safety of intensive glucose control and blood pressure-lowering therapy for people with type 2 diabetes: results from the ADVANCE trial. *Diabetes Care* 44(7):1622–1629. <https://doi.org/10.2337/dc20-2664>
 381. Wightman H, Butterly E, Wei L et al (2025) Frailty in randomized controlled trials of glucose-lowering therapies for type 2 diabetes: an individual participant data meta-analysis of frailty prevalence, treatment efficacy, and adverse events. *PLoS Med* 22(4):e1004553. <https://doi.org/10.1371/journal.pmed.1004553>
 382. Rossing P, Birkenfeld AL, Fioretto P et al (2025) Finerenone and clinical outcomes in CKD and type 2 diabetes by frailty index: FIDELITY post hoc analysis. *Clin J Am Soc Nephrol* 20(7):968–977. <https://doi.org/10.2215/cjn.0000000700>
 383. Nguyen TN, Yu J, Perkovic V et al (2025) The efficacy and safety of canagliflozin by frailty status in participants of the CANVAS and CREDENCE trials. *J Am Geriatr Soc* 73(6):1787–1796. <https://doi.org/10.1111/jgs.19444>
 384. Bhattarai M, Salih M, Regmi M et al (2022) Association of sodium-glucose cotransporter 2 inhibitors with cardiovascular outcomes in patients with type 2 diabetes and other risk factors for cardiovascular disease: a meta-analysis. *JAMA Netw Open* 5(1):e2142078. <https://doi.org/10.1001/jamanetworkopen.2021.42078>
 385. Cardoza K, Kang A, Smyth B et al (2024) Geographic and racial variability in kidney, cardiovascular and safety outcomes with canagliflozin: a secondary analysis of the CREDENCE randomized trial. *Diabetes Obes Metab* 26(9):3530–3540. <https://doi.org/10.1111/dom.15685>
 386. Zhang J, Van Spall HG, Li L et al (2023) Effects of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors on cardiovascular and kidney outcomes in Asian versus White patients with type 2 diabetes mellitus. *Diabetes Metab Syndr* 17(7):102804. <https://doi.org/10.1016/j.dsx.2023.102804>
 387. Koya D, Anker SD, Ruilope LM et al (2023) Cardiorenal outcomes with finerenone in Asian patients with chronic kidney disease and type 2 diabetes: a FIDELIO-DKD post hoc analysis. *Am J Nephrol* 54(9–10):370–378. <https://doi.org/10.1159/000532102>
 388. Wada T, Anker SD, Liu Z et al (2025) Efficacy and safety of finerenone in Asian patients with type 2 diabetes and chronic kidney disease: a FIDELITY analysis. *Kidney Dis (Basel)* 11(1):402–415. <https://doi.org/10.1159/000545415>
 389. Flack JM, Agarwal R, Anker SD et al (2023) Finerenone in black patients with type 2 diabetes and CKD: a post hoc analysis of the pooled FIDELIO-DKD and FIGARO-DKD trials. *Kidney Med* 5(12):100730. <https://doi.org/10.1016/j.xkme.2023.100730>
 390. Mishriky BM, Powell JR, Wittwer JA et al (2019) Do GLP-1RAs and SGLT-2is reduce cardiovascular events in black patients with type 2 diabetes? A systematic review and meta-analysis. *Diabetes Obes Metab* 21(10):2274–2283. <https://doi.org/10.1111/dom.13805>
 391. US Food & Drug Administration (2024) Diversity action plans to improve enrollment of participants from underrepresented populations in clinical studies: draft guidance for industry. Available from <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/diversity-action-plans-improve-enrollment-participants-underrepresented-populations-clinical-studies>. Accessed 30 April 2026
 392. Morrish NJ, Wang SL, Stevens LK, Fuller JH, Keen H (2001) Mortality and causes of death in the WHO multinational study of vascular disease in diabetes. *Diabetologia* 44(Suppl 2):S14–21. <https://doi.org/10.1007/pl00002934>
 393. Regensteiner JG, Golden S, Huebschmann AG et al (2015) Sex differences in the cardiovascular consequences of diabetes mellitus: a scientific statement from the American Heart Association. *Circulation* 132(25):2424–2447. <https://doi.org/10.1161/cir.0000000000000343>
 394. Kannel WB, Wilson PW (1995) Risk factors that attenuate the female coronary disease advantage. *Arch Intern Med* 155(1):57–61
 395. Hu G, Jousilahti P, Qiao Q, Katoh S, Tuomilehto J (2005) Sex differences in cardiovascular and total mortality among diabetic and non-diabetic individuals with or without history of myocardial infarction. *Diabetologia* 48(5):856–861. <https://doi.org/10.1007/s00125-005-1730-6>
 396. Peters SA, Huxley RR, Woodward M (2014) Diabetes as a risk factor for stroke in women compared with men: a systematic review and meta-analysis of 64 cohorts, including 775,385 individuals and 12,539 strokes. *Lancet* 383(9933):1973–1980. [https://doi.org/10.1016/s0140-6736\(14\)60040-4](https://doi.org/10.1016/s0140-6736(14)60040-4)
 397. Peters SA, Huxley RR, Woodward M (2014) Diabetes as risk factor for incident coronary heart disease in women compared with men: a systematic review and meta-analysis of 64 cohorts including 858,507 individuals and 28,203 coronary events. *Diabetologia* 57(8):1542–1551. <https://doi.org/10.1007/s00125-014-3260-6>
 398. Peters SAE, Woodward M (2018) Sex differences in the burden and complications of diabetes. *Curr Diab Rep* 18(6):33. <https://doi.org/10.1007/s11892-018-1005-5>
 399. Clemens KK, Woodward M, Neal B, Zinman B (2020) Sex disparities in cardiovascular outcome trials of populations with diabetes: a systematic review and meta-analysis. *Diabetes Care* 43(5):1157–1163. <https://doi.org/10.2337/dc19-2257>
 400. Green JB, Merrill P, Lokhnygina Y, Mentz RJ, Alfredsson J, Holman RR (2023) Sex differences in the complications, care and clinical outcomes of patients with type 2 diabetes in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL). *Diabetes Obes Metab* 25(6):1473–1484. <https://doi.org/10.1111/dom.14993>
 401. Singh AK, Singh R (2020) Gender difference in cardiovascular outcomes with SGLT-2 inhibitors and GLP-1 receptor agonist in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. *Diabetes Metab Syndr* 14(3):181–187. <https://doi.org/10.1016/j.dsx.2020.02.012>
 402. Rådholm K, Zhou Z, Clemens K, Neal B, Woodward M (2020) Effects of sodium-glucose co-transporter-2 inhibitors in type 2

- diabetes in women versus men. *Diabetes Obes Metab* 22(2):263–266. <https://doi.org/10.1111/dom.13876>
403. Cusi K, Abdelmalek MF, Apovian CM et al (2025) Metabolic dysfunction-associated steatotic liver disease (MASLD) in people with diabetes: the need for screening and early intervention a consensus report of the American Diabetes Association. *Diabetes Care* 48(7):1057–1082. <https://doi.org/10.2337/dci24-0094>
 404. European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO) (2024) EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). *J Hepatol* 81(3):492–542. <https://doi.org/10.1016/j.jhep.2024.04.031>
 405. Koutoukidis DA, Koshariis C, Henry JA et al (2021) The effect of the magnitude of weight loss on non-alcoholic fatty liver disease: a systematic review and meta-analysis. *Metabolism* 115:154455. <https://doi.org/10.1016/j.metabol.2020.154455>
 406. Arita VA, Cabezas MC, Hernández Vargas JA et al (2025) Effects of Mediterranean diet, exercise, and their combination on body composition and liver outcomes in metabolic dysfunction-associated steatotic liver disease: a systematic review and meta-analysis of randomized controlled trials. *BMC Med* 23(1):502. <https://doi.org/10.1186/s12916-025-04320-7>
 407. Hashida R, Kawaguchi T, Bekki M et al (2017) Aerobic vs resistance exercise in non-alcoholic fatty liver disease: a systematic review. *J Hepatol* 66(1):142–152. <https://doi.org/10.1016/j.jhep.2016.08.023>
 408. Sabag A, Barr L, Armour M et al (2022) The effect of high-intensity interval training vs moderate-intensity continuous training on liver fat: a systematic review and meta-analysis. *J Clin Endocrinol Metab* 107(3):862–881. <https://doi.org/10.1210/clinem/dgab795>
 409. Zeng Y, Zhang X, Luo W, Sheng Y (2024) Effect of exercise intervention on clinical parameters in patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus: a meta-analysis of randomized controlled trials. *Eur J Gastroenterol Hepatol* 36(1):1–12. <https://doi.org/10.1097/meg.0000000000002662>
 410. Jara M, Norlin J, Kjær MS et al (2025) Modulation of metabolic, inflammatory and fibrotic pathways by semaglutide in metabolic dysfunction-associated steatohepatitis. *Nat Med* 31(9):3128–3140. <https://doi.org/10.1038/s41591-025-03799-0>
 411. Loomba R, Abdelmalek MF, Armstrong MJ et al (2023) Semaglutide 2.4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial. *Lancet Gastroenterol Hepatol* 8(6):511–522. [https://doi.org/10.1016/s2468-1253\(23\)00068-7](https://doi.org/10.1016/s2468-1253(23)00068-7)
 412. Armstrong MJ, Gaunt P, Aithal GP et al (2016) Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. *Lancet* 387(10019):679–690. [https://doi.org/10.1016/s0140-6736\(15\)00803-x](https://doi.org/10.1016/s0140-6736(15)00803-x)
 413. Kuchay MS, Krishan S, Mishra SK et al (2020) Effect of dulaglutide on liver fat in patients with type 2 diabetes and NAFLD: randomised controlled trial (D-LIFT trial). *Diabetologia* 63(11):2434–2445. <https://doi.org/10.1007/s00125-020-05265-7>
 414. Dutour A, Abdesselam I, Ancel P et al (2016) Exenatide decreases liver fat content and epicardial adipose tissue in patients with obesity and type 2 diabetes: a prospective randomized clinical trial using magnetic resonance imaging and spectroscopy. *Diabetes Obes Metab* 18(9):882–891. <https://doi.org/10.1111/dom.12680>
 415. Loomba R, Hartman ML, Lawitz EJ et al (2024) Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis. *N Engl J Med* 391(4):299–310. <https://doi.org/10.1056/NEJMoa2401943>
 416. Belfort R, Harrison SA, Brown K et al (2006) A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. *N Engl J Med* 355(22):2297–2307. <https://doi.org/10.1056/NEJMoa060326>
 417. Musso G, Cassader M, Paschetta E, Gambino R (2017) Thiazolidinediones and advanced liver fibrosis in nonalcoholic steatohepatitis: a meta-analysis. *JAMA Intern Med* 177(5):633–640. <https://doi.org/10.1001/jamainternmed.2016.9607>
 418. Wang Z, Du H, Zhao Y et al (2023) Response to pioglitazone in non-alcoholic fatty liver disease patients with vs without type 2 diabetes: a meta-analysis of randomized controlled trials. *Front Endocrinol (Lausanne)* 14:1111430. <https://doi.org/10.3389/fendo.2023.1111430>
 419. Majzoub AM, Nayfeh T, Barnard A et al (2021) Systematic review with network meta-analysis: comparative efficacy of pharmacologic therapies for fibrosis improvement and resolution of NASH. *Aliment Pharmacol Ther* 54(7):880–889. <https://doi.org/10.1111/apt.16583>
 420. Souza M, Al-Sharif L, Antunes VLJ, Huang DQ, Loomba R (2025) Comparison of pharmacological therapies in metabolic dysfunction-associated steatohepatitis for fibrosis regression and MASH resolution: systematic review and network meta-analysis. *Hepatology* 82(6):1523–1533. <https://doi.org/10.1097/hep.0000000000001254>
 421. Malandris K, Papandreou S, Avgerinos I et al (2023) Comparative efficacy of glucose-lowering drugs on liver steatosis as assessed by means of magnetic resonance imaging in patients with type 2 diabetes mellitus: systematic review and network meta-analysis. *Hormones (Athens)* 22(4):655–664. <https://doi.org/10.1007/s42000-023-00493-z>
 422. Sathyanarayana P, Jogi M, Muthupillai R, Krishnamurthy R, Samson SL, Bajaj M (2011) Effects of combined exenatide and pioglitazone therapy on hepatic fat content in type 2 diabetes. *Obesity (Silver Spring)* 19(12):2310–2315. <https://doi.org/10.1038/oby.2011.152>
 423. Lavynenko O, Abdul-Ghani M, Alatrach M et al (2022) Combination therapy with pioglitazone/exenatide/metformin reduces the prevalence of hepatic fibrosis and steatosis: the efficacy and durability of initial combination therapy for type 2 diabetes (EDICT). *Diabetes Obes Metab* 24(5):899–907. <https://doi.org/10.1111/dom.14650>
 424. Yoneda M, Kobayashi T, Honda Y et al (2022) Combination of tofogliflozin and pioglitazone for NAFLD: extension to the ToPiND randomized controlled trial. *Hepatol Commun* 6(9):2273–2285. <https://doi.org/10.1002/hep4.1993>
 425. Kahl S, Gancheva S, Straßburger K et al (2020) Empagliflozin effectively lowers liver fat content in well-controlled type 2 diabetes: a randomized, double-blind, phase 4, placebo-controlled trial. *Diabetes Care* 43(2):298–305. <https://doi.org/10.2337/dc19-0641>
 426. Takeshita Y, Honda M, Harada K et al (2022) Comparison of tofogliflozin and glimepiride effects on nonalcoholic fatty liver disease in participants with type 2 diabetes: a randomized, 48-week, open-label, active-controlled trial. *Diabetes Care* 45(9):2064–2075. <https://doi.org/10.2337/dc21-2049>
 427. Takahashi H, Kessoku T, Kawanaka M et al (2022) Ipragliflozin improves the hepatic outcomes of patients with diabetes with NAFLD. *Hepatol Commun* 6(1):120–132. <https://doi.org/10.1002/hep4.1696>
 428. Lin J, Huang Y, Xu B et al (2025) Effect of dapagliflozin on metabolic dysfunction-associated steatohepatitis: multicentre, double blind, randomised, placebo controlled trial. *BMJ* 389:e083735. <https://doi.org/10.1136/bmj-2024-083735>
 429. Joy TR, McKenzie CA, Tirona RG et al (2017) Sitagliptin in patients with non-alcoholic steatohepatitis: a randomized,

- placebo-controlled trial. *World J Gastroenterol* 23(1):141–150. <https://doi.org/10.3748/wjg.v23.i1.141>
430. Harrison SA, Bedossa P, Guy CD et al (2024) A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis. *N Engl J Med* 390(6):497–509. <https://doi.org/10.1056/NEJMoa2309000>
 431. Blackman A, Foster GD, Zammit G et al (2016) Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial. *Int J Obes (Lond)* 40(8):1310–1319. <https://doi.org/10.1038/ijo.2016.52>
 432. Jiang W, Li W, Cheng J, Li W, Cheng F (2023) Efficacy and safety of liraglutide in patients with type 2 diabetes mellitus and severe obstructive sleep apnea. *Sleep Breath* 27(5):1687–1694. <https://doi.org/10.1007/s11325-022-02768-y>
 433. Yang R, Zhang L, Guo J et al (2025) Glucagon-like peptide-1 receptor agonists for obstructive sleep apnea in patients with obesity and type 2 diabetes mellitus: a systematic review and meta-analysis. *J Transl Med* 23(1):389. <https://doi.org/10.1186/s12967-025-06302-y>
 434. Xie L, Li S, Yu X, Wei Q, Yu F, Tong J (2024) DAHOS study: efficacy of dapagliflozin in treating heart failure with reduced ejection fraction and obstructive sleep apnea syndrome - a 3-month, multicenter, randomized controlled clinical trial. *Eur J Clin Pharmacol* 80(5):771–780. <https://doi.org/10.1007/s00228-024-03643-3>
 435. Neeland IJ, Eliasson B, Kasai T et al (2020) The impact of empagliflozin on obstructive sleep apnea and cardiovascular and renal outcomes: an exploratory analysis of the EMPA-REG OUTCOME trial. *Diabetes Care* 43(12):3007–3015. <https://doi.org/10.2337/dc20-1096>
 436. Wojeck BS, Inzucchi SE, Neeland IJ et al (2023) Ertugliflozin and incident obstructive sleep apnea: an analysis from the VER-TIS CV trial. *Sleep Breath* 27(2):669–672. <https://doi.org/10.1007/s11325-022-02594-2>
 437. Pan F, Wang Y, Lim YZ et al (2025) Metformin for knee osteoarthritis in patients with overweight or obesity: a randomized clinical trial. *JAMA* 333(20):1804–1812. <https://doi.org/10.1001/jama.2025.3471>
 438. Jiang G, Yang X, Zhu G, Liu T (2025) Comparative efficacy and safety of antidiabetic drugs for obese patients with knee osteoarthritis: a network meta-analysis of randomized controlled trials. *Aging Clin Exp Res* 37(1):142. <https://doi.org/10.1007/s40520-025-03017-4>
 439. Gudbergson H, Overgaard A, Henriksen M et al (2021) Liraglutide after diet-induced weight loss for pain and weight control in knee osteoarthritis: a randomized controlled trial. *Am J Clin Nutr* 113(2):314–323. <https://doi.org/10.1093/ajcn/nqaa328>
 440. Bliddal H, Bays H, Czernichow S et al (2024) Once-weekly semaglutide in persons with obesity and knee osteoarthritis. *N Engl J Med* 391(17):1573–1583. <https://doi.org/10.1056/NEJMoa2403664>
 441. Luchsinger JA, Rosin SP, Kazemi EJ et al (2025) Glucose-lowering medications, glycemia, and cognitive outcomes: the GRADE randomized clinical trial. *JAMA Intern Med* 185(7):778–787. <https://doi.org/10.1001/jamainternmed.2025.1189>
 442. Seminer A, Mulihano A, O'Brien C et al (2025) Cardioprotective glucose-lowering agents and dementia risk: a systematic review and meta-analysis. *JAMA Neurol* 82(5):450–460. <https://doi.org/10.1001/jamaneurol.2025.0360>
 443. Pierret ACS, Mizuno Y, Saunders P et al (2025) Glucagon-like peptide 1 receptor agonists and mental health: a systematic review and meta-analysis. *JAMA Psychiatry* 82(7):643–653. <https://doi.org/10.1001/jamapsychiatry.2025.0679>
 444. Edison P, Femminella GD, Ritchie C et al (2026) Liraglutide in mild to moderate Alzheimer's disease: a phase 2b clinical trial. *Nat Med* 32(1):353–361. <https://doi.org/10.1038/s41591-025-04106-7>
 445. Cummings JL, Atri A, Sano M et al (2026) Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evolve and evolve+): two phase 3, randomised, placebo-controlled trials. *Lancet* 407(10544):2167–2179. [https://doi.org/10.1016/s0140-6736\(26\)00459-9](https://doi.org/10.1016/s0140-6736(26)00459-9)
 446. Lu HH, Zhou Y, Chen C, Gu ZJ (2024) Meta-analysis of the effect of exercise intervention on cognitive function in elderly patients with type 2 diabetes mellitus. *BMC Geriatr* 24(1):770. <https://doi.org/10.1186/s12877-024-05352-z>
 447. Zhang J, Tam WWS, Hounsri K, Kusuyama J, Wu VX (2024) Effectiveness of combined aerobic and resistance exercise on cognition, metabolic health, physical function, and health-related quality of life in middle-aged and older adults with type 2 diabetes mellitus: a systematic review and meta-analysis. *Arch Phys Med Rehabil* 105(8):1585–1599. <https://doi.org/10.1016/j.apmr.2023.10.005>
 448. Chen X, Huang Y, Xiong X (2025) Mechanisms underlying cognitive impairment and management strategies in type 2 diabetes. *Front Endocrinol (Lausanne)* 16:1655768. <https://doi.org/10.3389/fendo.2025.1655768>
 449. Lim LL, Jones S, Cikomola JC, Hivert MF, Misra S (2025) Understanding the drivers and consequences of early-onset type 2 diabetes. *Lancet* 405(10497):2327–2340. [https://doi.org/10.1016/s0140-6736\(25\)01012-8](https://doi.org/10.1016/s0140-6736(25)01012-8)
 450. Wojutari Ajele K, Sunday Idemudia E (2025) The role of depression and diabetes distress in glycemic control: a meta-analysis. *Diabetes Res Clin Pract* 221:112014. <https://doi.org/10.1016/j.diabres.2025.112014>
 451. Dickinson JK, Guzman SJ, Maryniuk MD et al (2017) The use of language in diabetes care and education. *Diabetes Care* 40(12):1790–1799. <https://doi.org/10.2337/dci17-0041>
 452. Litterbach E, Holmes-Truscott E, Gray S et al (2024) “I feel like I’m being talked to like an equal”: diabetes language matters to adults with diabetes, a mixed-methods study. *Diabet Med* 41(12):e15424. <https://doi.org/10.1111/dme.15424>
 453. Spreckley M, Ruggiero CF, Brown A (2026) Nutrition strategies for next-generation incretin therapies: a systematic scoping review of the current evidence. *Obes Rev* 27:e70079. <https://doi.org/10.1111/obr.70079>
 454. US Department of Health and Human Services, Centers for Disease Control and Prevention (2018) Writing SMART Objectives. Available from <https://www.cdc.gov/healthy-youth/funded-programs/pdf/brief3b.pdf>. Accessed 30 April 2026
 455. Wing RR, Bolin P, Brancati FL et al (2013) Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. *N Engl J Med* 369(2):145–154. <https://doi.org/10.1056/NEJMoa1212914>
 456. Pi-Sunyer X (2014) The look AHEAD trial: a review and discussion of its outcomes. *Curr Nutr Rep* 3(4):387–391. <https://doi.org/10.1007/s13668-014-0099-x>
 457. Romadlon DS, Tu YK, Chen YC, Hasan F, Kurniawan R, Chiu HY (2024) Comparative effects of diabetes self-management programs on type 2 diabetes clinical outcomes: a systematic review and network meta-analysis. *Diabetes Metab Res Rev* 40(6):e3840. <https://doi.org/10.1002/dmrr.3840>
 458. Powers MA, Bardsley J, Cypress M et al (2015) Diabetes self-management education and support in type 2 diabetes: a joint position statement of the American Diabetes Association, the American Association of Diabetes Educators, and the Academy

- of Nutrition and Dietetics. *Diabetes Care* 38(7):1372–1382. <https://doi.org/10.2337/dc15-0730>
459. American Diabetes Association Professional Practice Committee (2022) 5. Facilitating behavior change and well-being to improve health outcomes: standards of medical care in diabetes-2022. *Diabetes Care* 45(Suppl 1):S60–S82. <https://doi.org/10.2337/dc22-S005>
 460. Chrvala CA, Sherr D, Lipman RD (2016) Diabetes self-management education for adults with type 2 diabetes mellitus: a systematic review of the effect on glycemic control. *Patient Educ Couns* 99(6):926–943. <https://doi.org/10.1016/j.pec.2015.11.003>
 461. Pillay J, Armstrong MJ, Butalia S et al (2015) Behavioral programs for type 2 diabetes mellitus: a systematic review and network meta-analysis. *Ann Intern Med* 163(11):848–860. <https://doi.org/10.7326/m15-1400>
 462. Zhao FF, Suhonen R, Koskinen S, Leino-Kilpi H (2017) Theory-based self-management educational interventions on patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. *J Adv Nurs* 73(4):812–833. <https://doi.org/10.1111/jan.13163>
 463. Odgers-Jewell K, Ball LE, Kelly JT, Isenring EA, Reidlinger DP, Thomas R (2017) Effectiveness of group-based self-management education for individuals with type 2 diabetes: a systematic review with meta-analyses and meta-regression. *Diabet Med* 34(8):1027–1039. <https://doi.org/10.1111/dme.13340>
 464. He X, Li J, Wang B et al (2017) Diabetes self-management education reduces risk of all-cause mortality in type 2 diabetes patients: a systematic review and meta-analysis. *Endocrine* 55(3):712–731. <https://doi.org/10.1007/s12020-016-1168-2>
 465. Chatterjee S, Davies MJ, Heller S, Speight J, Snoek FJ, Khunti K (2018) Diabetes structured self-management education programmes: a narrative review and current innovations. *Lancet Diabetes Endocrinol* 6(2):130–142. [https://doi.org/10.1016/s2213-8587\(17\)30239-5](https://doi.org/10.1016/s2213-8587(17)30239-5)
 466. Atac O, Bryant GC, Burrows WB et al (2025) Referrals and utilization of diabetes self-management education and support (DSMES) among patients with type 1 and type 2 diabetes at a regional medical center in Kentucky. *BMC Public Health* 25(1):3880. <https://doi.org/10.1186/s12889-025-25014-y>
 467. Arena L, Austin R, Esquivel N, Vigil T, Kaelin-Kee J, Millstein S (2024) Understanding barriers and facilitators to participating in diabetes self-management education and support services from multiple perspectives: results of a mixed-methods study of medicaid members, medicaid managed care organizations, and providers in New York State. *Clin Diabetes* 42(4):505–514. <https://doi.org/10.2337/cd23-0082>
 468. Tharakan A, McPeck Hinz E, Zhu E et al (2024) Accessibility of diabetes education in the United States: barriers, policy implications, and the road ahead. *Health Aff Sch* 2(8):qxae097. <https://doi.org/10.1093/haschl/qxae097>
 469. Lindekilde N, Scheuer SH, Rutters F et al (2022) Prevalence of type 2 diabetes in psychiatric disorders: an umbrella review with meta-analysis of 245 observational studies from 32 systematic reviews. *Diabetologia* 65(3):440–456. <https://doi.org/10.1007/s00125-021-05609-x>
 470. Versluis A, Boels AM, Huijden MCG, Mijnsbergen MD, Rutten G, Vos RC (2025) Diabetes self-management education and support delivered by mobile health (mHealth) interventions for adults with type 2 diabetes-A systematic review and meta-analysis. *Diabet Med* 42(5):e70002. <https://doi.org/10.1111/dme.70002>
 471. Alonso-Carril N, Rodríguez-Rodríguez S, Quirós C et al (2024) Could online education replace face-to-face education in diabetes? A systematic review. *Diabetes Ther* 15(7):1513–1524. <https://doi.org/10.1007/s13300-024-01595-6>
 472. Khunti K, Cheng AYY (2023) Therapeutic inertia in type 2 diabetes mellitus: a fine line between advancing and de-intensifying. *Nat Rev Endocrinol* 19(8):437–438. <https://doi.org/10.1038/s41574-023-00857-w>
 473. Khunti K, Davies MJ (2017) Clinical inertia-time to reappraise the terminology? *Prim Care Diabetes* 11(2):105–106. <https://doi.org/10.1016/j.pcd.2017.01.007>
 474. Evans M, Engberg S, Faurby M, Fernandes J, Hudson P, Polonsky W (2022) Adherence to and persistence with antidiabetic medications and associations with clinical and economic outcomes in people with type 2 diabetes mellitus: a systematic literature review. *Diabetes Obes Metab* 24(3):377–390. <https://doi.org/10.1111/dom.14603>
 475. Polonsky WH, Henry RR (2016) Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors. *Patient Prefer Adherence* 10:1299–1307. <https://doi.org/10.2147/ppa.S106821>
 476. Konstantinou P, Kassianos AP, Georgiou G et al (2020) Barriers, facilitators, and interventions for medication adherence across chronic conditions with the highest non-adherence rates: a scoping review with recommendations for intervention development. *Transl Behav Med* 10(6):1390–1398. <https://doi.org/10.1093/tbm/ibaa118>
 477. Lasalvia P, Barahona-Correa JE, Romero-Alvernia DM et al (2016) Pen devices for insulin self-administration compared with needle and vial: systematic review of the literature and meta-analysis. *J Diabetes Sci Technol* 10(4):959–966. <https://doi.org/10.1177/1932296816633721>
 478. Davies M, Færch L, Jeppesen OK et al (2021) Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. *Lancet* 397(10278):971–984. [https://doi.org/10.1016/s0140-6736\(21\)00213-0](https://doi.org/10.1016/s0140-6736(21)00213-0)
 479. Giorgino F, Lingvay I, Van Gaal LF et al (2025) Early fasting serum glucose or weight reduction with tirzepatide and metabolic outcomes in people with type 2 diabetes: a post hoc analysis of the SURPASS trials. *Diabetes Care* 48(5):790–798. <https://doi.org/10.2337/dc24-2790>
 480. Quarengi M, Capelli S, Galligani G, Giana A, Preatoni G, Turri Quarengi R (2025) Weight regain after liraglutide, semaglutide or tirzepatide interruption: a narrative review of randomized studies. *J Clin Med* 14(11):3791. <https://doi.org/10.3390/jcm14113791>
 481. Yates T, Biddle GJH, Henson J et al (2024) Impact of weight loss and weight gain trajectories on body composition in a population at high risk of type 2 diabetes: a prospective cohort analysis. *Diabetes Obes Metab* 26(3):1008–1015. <https://doi.org/10.1111/dom.15400>
 482. Wang R, Luo S, Xiao Z, Zhou Z (2024) Efficacy and safety of fixed-ratio combination insulin degludec/liraglutide in type 2 diabetes: a systematic review and meta-analysis of randomised controlled trials. *Diabetes Metab Res Rev* 40(3):e3752. <https://doi.org/10.1002/dmrr.3752>
 483. Bertuol VC Jr, Iorra F, Vieceli T et al (2026) Effects of insulin regimens for type 2 diabetes mellitus: a systematic review and network meta-analysis. *Diabetologia* 69(5):1150–1163. <https://doi.org/10.1007/s00125-025-06633-x>
 484. Anderson SL, Trujillo JM (2016) Basal insulin use with GLP-1 receptor agonists. *Diabetes Spectr* 29(3):152–160. <https://doi.org/10.2337/diaspect.29.3.152>
 485. Rosenstock J, Frías JP, Rodbard HW et al (2023) Tirzepatide vs insulin lispro added to basal insulin in type 2 diabetes: the SURPASS-6 randomized clinical trial. *JAMA* 330(17):1631–1640. <https://doi.org/10.1001/jama.2023.20294>
 486. Davis G, Bailey R, Calhoun P, Price D, Beck RW (2022) Magnitude of glycemic improvement in patients with type 2 diabetes treated with basal insulin: subgroup analyses from the MOBILE

- study. *Diabetes Technol Ther* 24(5):324–331. <https://doi.org/10.1089/dia.2021.0489>
487. Wilmot EG, Moore P, Sathyapalan T et al (2026) Continuous glucose monitoring versus self-monitoring of blood glucose in individuals with type 2 diabetes: a randomised, multicentre, open-label, superiority trial. *Lancet Diabetes Endocrinol* 14(6):463–474. [https://doi.org/10.1016/s2213-8587\(26\)00076-8](https://doi.org/10.1016/s2213-8587(26)00076-8)
 488. Uhl S, Choure A, Rouse B, Loblack A, Reaven P (2024) Effectiveness of continuous glucose monitoring on metrics of glycemic control in type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials. *J Clin Endocrinol Metab* 109(4):1119–1131. <https://doi.org/10.1210/clinem/dgad652>
 489. Kudva YC, Raghinaru D, Lum JW et al (2025) A randomized trial of automated insulin delivery in type 2 diabetes. *N Engl J Med* 392(18):1801–1812. <https://doi.org/10.1056/NEJMoa2415948>
 490. Hespanhol LC, Agarwal S, Carvalhal G et al (2026) Automated insulin delivery systems in type 2 diabetes mellitus: a systematic review and meta-analysis. *Diabetes Care* 49(6):1134–1143. <https://doi.org/10.2337/dc25-2435>
 491. Di Molfetta S, Di Gioia L, Caruso I et al (2026) Efficacy and safety of automated insulin delivery in people with type 2 diabetes: a systematic review and meta-analysis. *Diabetes Obes Metab* 28(6):5091–5100. <https://doi.org/10.1111/dom.70708>
 492. Amer BE, Yaquout YE, Abozaid AM, Afifi E, Aboelkhier MM (2024) Does fully closed-loop automated insulin delivery improve glycaemic control in patients with type 2 diabetes? A meta-analysis of randomized controlled trials. *Diabet Med* 41(1):e15196. <https://doi.org/10.1111/dme.15196>
 493. Hinton W, Ansari AS, Whyte MB et al (2023) Sodium-glucose co-transporter-2 inhibitors in type 2 diabetes: are clinical trial benefits for heart failure reflected in real-world clinical practice? A systematic review and meta-analysis of observational studies. *Diabetes Obes Metab* 25(2):501–515. <https://doi.org/10.1111/dom.14893>
 494. Glover S, Borrego ME, Ray GM, Roberts MH (2022) Sodium-glucose cotransporter 2 inhibitor use among individuals age <65 with type 2 diabetes and heart failure with reduced ejection fraction: a cost-benefit analysis. *Clinicoecon Outcomes Res* 14:465–477. <https://doi.org/10.2147/ceor.S361886>
 495. Connolly D, Collins E, Ren H, Wan Yau Ming S, Davidson J, Bain S (2025) Real-world comparisons between glucagon-like peptide-1 receptor agonists and other glucose-lowering agents in type 2 diabetes: retrospective analyses of cardiovascular and economic outcomes in England. *Diabetes Ther* 16(5):955–975. <https://doi.org/10.1007/s13300-025-01715-w>
 496. Dunn TJ, Cao Y, Xie L, Guevarra M, Mitri J (2025) Comparing demographic/clinical characteristics, health care resource utilization, and costs among patients with type 2 diabetes and established atherosclerotic cardiovascular disease with and without the use of cardioprotective medications. *J Manag Care Spec Pharm* 31(2):117–126. <https://doi.org/10.18553/jmcp.2025.24251>
 497. White GE, Shu I, Rometo D, Arnold J, Korytkowski M, Luo J (2023) Real-world weight-loss effectiveness of glucagon-like peptide-1 agonists among patients with type 2 diabetes: a retrospective cohort study. *Obesity (Silver Spring)* 31(2):537–544. <https://doi.org/10.1002/oby.23622>
 498. Mayer CS, Fontelo P (2024) Semaglutide use in people with obesity and type 2 diabetes from real-world utilization data: an analysis of the All of US program. *Diabetes Obes Metab* 26(11):4989–4995. <https://doi.org/10.1111/dom.15911>
 499. Neugebauer R, An J, Dombrowski SK et al (2025) Glucose-lowering medication classes and cardiovascular outcomes in patients with type 2 diabetes. *JAMA Netw Open* 8(10):e2536100. <https://doi.org/10.1001/jamanetworkopen.2025.36100>
 500. Malik ME, Falkentoft AC, Jensen J et al (2023) Discontinuation and reinitiation of SGLT-2 inhibitors and GLP-1R agonists in patients with type 2 diabetes: a nationwide study from 2013 to 2021. *Lancet Reg Health Eur* 29:100617. <https://doi.org/10.1016/j.lanepe.2023.100617>
 501. Boonpatharatthiti K, Songkla PN, Chantara J et al (2024) Prevalence of adherence to oral antidiabetic drugs in patients with type 2 diabetes: a systematic review and meta-analysis. *J Diabetes Investig* 15(11):1614–1625. <https://doi.org/10.1111/jdi.14285>
 502. Rodriguez P, San Martin VT, Pantalone KM (2024) Therapeutic inertia in the management of type 2 diabetes: a narrative review. *Diabetes Ther* 15(3):567–583. <https://doi.org/10.1007/s13300-024-01530-9>
 503. Powell RE, Zaccardi F, Beebe C et al (2021) Strategies for overcoming therapeutic inertia in type 2 diabetes: a systematic review and meta-analysis. *Diabetes Obes Metab* 23(9):2137–2154. <https://doi.org/10.1111/dom.14455>
 504. Chen Y, Zhou T, Su L, Guo Y, Ke X (2025) Effects of nurse-led telephone interventions on HbA1c levels in patients with type 2 diabetes: a meta-analysis-based evaluation of follow-up protocols. *BMC Nurs* 24(1):284. <https://doi.org/10.1186/s12912-025-02782-x>
 505. Levensgood TW, Peng Y, Xiong KZ et al (2019) Team-based care to improve diabetes management: a community guide meta-analysis. *Am J Prev Med* 57(1):e17–e26. <https://doi.org/10.1016/j.amepre.2019.02.005>
 506. Abdulrhim S, Sankaralingam S, Ibrahim MIM, Awaisu A (2020) The impact of pharmacist care on diabetes outcomes in primary care settings: an umbrella review of published systematic reviews. *Prim Care Diabetes* 14(5):393–400. <https://doi.org/10.1016/j.pcd.2019.12.007>
 507. Moschonis G, Siopis G, Jung J et al (2023) Effectiveness, reach, uptake, and feasibility of digital health interventions for adults with type 2 diabetes: a systematic review and meta-analysis of randomised controlled trials. *Lancet Digit Health* 5(3):e125–e143. [https://doi.org/10.1016/s2589-7500\(22\)00233-3](https://doi.org/10.1016/s2589-7500(22)00233-3)
 508. Gomez-Garcia C, Maher CA, Sañudo B, Jurado-Castro JM (2025) Mobile health interventions for individuals with type 2 diabetes and overweight or obesity-a systematic review and meta-analysis. *J Funct Morphol Kinesiol* 10(3):292. <https://doi.org/10.3390/jfkm10030292>
 509. Santos DS, Batistelli CRS, Lara M, Ferreira ES, Moreira TR, Cotta RMM (2022) The effectiveness of the use of telehealth programs in the care of individuals with hypertension and or diabetes mellitus: systematic review and meta-analysis. *Diabetol Metab Syndr* 14(1):76. <https://doi.org/10.1186/s13098-022-00846-5>
 510. Mueller S, Dinges SMT, Gass F et al (2025) Telemedicine-supported lifestyle intervention for glycemic control in patients with CHD and T2DM: multicenter, randomized controlled trial. *Nat Med* 31(4):1203–1213. <https://doi.org/10.1038/s41591-025-03498-w>
 511. Christy A, Fernanda F, Insani WN, Abdulah R (2025) Pharmacist-led digital health interventions for patients with diabetes: a systematic review. *J Multidiscip Healthc* 18:101–112. <https://doi.org/10.2147/jmdh.S494584>
 512. Wang L, Li J, Zhang M, Chan MMK, Ho MH (2025) Effectiveness of transtheoretical model-based motivational interviewing on glycemic control among adults with type 2 diabetes: a systematic review and meta-analysis of randomized control trials. *Worldviews Evid Based Nurs* 22(3):e70041. <https://doi.org/10.1111/wvn.70041>
 513. Finkelstein EA, Gardner DS, Tham KW et al (2025) Effectiveness and cost-effectiveness of an app and rewards-based intervention

- in type 2 diabetes: a randomised controlled trial. *Diabetes Obes Metab* 27(2):729–739. <https://doi.org/10.1111/dom.16067>
514. Goh LH, Siah CJR, Tam WWS, Tai ES, Young DYL (2022) Effectiveness of the chronic care model for adults with type 2 diabetes in primary care: a systematic review and meta-analysis. *Syst Rev* 11(1):273. <https://doi.org/10.1186/s13643-022-02117-w>
 515. Grant RW, Peterson I, McCloskey JM et al (2025) Diabetes deprescribing in older adults: a randomized clinical trial. *JAMA Intern Med* 185(8):926–935. <https://doi.org/10.1001/jamainternmed.2025.2015>
 516. Rezaeiahari M, Acharya M, Henske J, Owsley K, Bodenhamer J (2024) Utilization of diabetes self-management education and support among medicare beneficiaries newly diagnosed with diabetes in Arkansas, 12 months postdiagnosis (2015–2018). *Sci Diabetes Self Manag Care* 50(6):510–519. <https://doi.org/10.1177/26350106241285827>
 517. Rodriguez LA, Finertie H, Neugebauer RS et al (2024) Race and ethnicity and pharmacy dispensing of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes. *Lancet Reg Health Am* 34:100759. <https://doi.org/10.1016/j.lana.2024.100759>
 518. Wallia A, Agarwal S, Owen AL et al (2024) Disparities in continuous glucose monitoring among patients receiving care in federally qualified health centers. *JAMA Netw Open* 7(11):e2445316. <https://doi.org/10.1001/jamanetworkopen.2024.45316>
 519. Dennis JM, Young KG, Cardoso P et al (2025) A five-drug class model using routinely available clinical features to optimise prescribing in type 2 diabetes: a prediction model development and validation study. *Lancet* 405(10480):701–714. [https://doi.org/10.1016/s0140-6736\(24\)02617-5](https://doi.org/10.1016/s0140-6736(24)02617-5)
 520. Tsapas A, Avgerinos I, Karagiannis T et al (2020) Comparative effectiveness of glucose-lowering drugs for type 2 diabetes: a systematic review and network meta-analysis. *Ann Intern Med* 173(4):278–286. <https://doi.org/10.7326/m20-0864>
 521. Tsapas A, Karagiannis T, Kakotrichi P et al (2021) Comparative efficacy of glucose-lowering medications on body weight and blood pressure in patients with type 2 diabetes: a systematic review and network meta-analysis. *Diabetes Obes Metab* 23(9):2116–2124. <https://doi.org/10.1111/dom.14451>

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Authors and Affiliations

Melanie J. Davies^{1,2}  · Vanita R. Aroda³  · Mandeep Bajaj⁴  · Nuha A. ElSayed^{5,6}  · Francesco Giorgino⁷  · Jennifer Green⁸  · Rita R. Kalyani^{9,10}  · Nisa M. Maruthur^{11,12}  · Chantal Mathieu¹³  · Sylvia E. Rosas¹⁴  · Peter Rossing^{15,16}  · Tommy Slater^{1,2}  · Tsvetelina Tankova¹⁷  · Pinar Topsever¹⁸  · Apostolos Tsapas^{19,20}  · John B. Buse²¹ 

✉ Melanie J. Davies
melanie.davies39@nhs.net

✉ John B. Buse
jbuse@med.unc.edu

¹ Diabetes Research Centre, College of Life Sciences, University of Leicester, Leicester General Hospital, Leicester, UK

² NIHR Leicester Biomedical Research Centre, University Hospitals of Leicester NHS Trust, Leicester, UK

³ Division of Endocrinology, Diabetes and Hypertension, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA

⁴ Department of Medicine, Section of Endocrinology, Diabetes and Metabolism, Baylor College of Medicine, Houston, TX, USA

⁵ Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA

⁶ Diabetes Education for All Foundation, New York, NY, USA

⁷ Department of Precision and Regenerative Medicine and Ionian Area, Section of Internal Medicine, Endocrinology, Andrology and Metabolic Diseases, University of Bari Aldo Moro, Bari, Italy

⁸ Division of Endocrinology, Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC, USA

⁹ Division of Endocrinology, Diabetes, and Metabolism, Johns Hopkins University School of Medicine, Baltimore, MD, USA

¹⁰ American Diabetes Association, Arlington, VA, USA

¹¹ Division of Hospitalist and General Internal Medicine, University of Maryland School of Medicine, Baltimore, MD, USA

¹² Division of General Internal Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA

¹³ Department of Endocrinology, UZ Gasthuisberg, KU Leuven, Leuven, Belgium

¹⁴ Kidney and Hypertension Unit, Joslin Diabetes Center and Harvard Medical School, Boston, MA, USA

¹⁵ Steno Diabetes Center Copenhagen, Herlev, Denmark

¹⁶ Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark

¹⁷ Department of Endocrinology, Medical University - Sofia, Sofia, Bulgaria

¹⁸ Department of Family Medicine, Acıbadem Mehmet Ali Aydınlar University, School of Medicine, Istanbul, Türkiye

¹⁹ Clinical Research and Evidence-Based Medicine Unit, Second Medical Department, Aristotle University of Thessaloniki, Thessaloniki, Greece

²⁰ Diabetes Centre, Hippokration Hospital, Thessaloniki, Greece

²¹ University of North Carolina School of Medicine, Chapel Hill, NC, USA